Dapagliflozin Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Dapagliflozin comprises 1,315 peer-reviewed publications across 15 journals, 103 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Diabetes Mellitus, Type 2, Heart Failure, Diabetes Mellitus, and Renal Insufficiency, Chronic. Most recent publication: Baseline, Early Changes, and Residual Albuminuria: Post Hoc Analysis of a Randomized Clinical Trial of Dapagliflozin in Chronic Kidney Disease., Clin J Am Soc Nephrol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, et al. · Lancet · 2020
    PubMed: PMID 32877652 · NCT05424315 (DACAMI) · Heart Failure
  2. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    Solomon SD, McMurray JJV, Claggett B, et al. · N Engl J Med · 2022
    PubMed: PMID 36027570 · NCT05759000 · Heart Failure
  3. Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial.
    Reddy YNV, Carter RE, Sorimachi H, et al. · JAMA Cardiol · 2024
    PubMed: PMID 39046727 · NCT06612086 · Hypertension, Pulmonary
  4. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
    Nassif ME, Windsor SL, Borlaug BA, et al. · Nat Med · 2021
    PubMed: PMID 34711976 · NCT03030235 (PRESERVED-HF) · Heart Failure
  5. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N, Greene T, Chertow GM, et al. · Lancet Diabetes Endocrinol · 2021
    PubMed: PMID 34619106 · NCT06890143 · Proteinuria
  6. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL, Jongs N, Chertow GM, et al. · Lancet Diabetes Endocrinol · 2021
    PubMed: PMID 34619108 · NCT06890143 · Proteinuria
  7. Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure.
    Chen K, Nie Z, Shi R, et al. · JAMA Netw Open · 2023
    PubMed: PMID 37615988 · NCT06668389 (STEPS) · Heart Defects, Congenital
  8. Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    Anker SD, Butler J, Filippatos G, et al. · N Engl J Med · 2021
    PubMed: PMID 34449189 · NCT06612086 · Hypertension, Pulmonary

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00357370Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2
From Baseline to Week 12
Dapagliflozin 10 mg-0.61 % of hemoglobin (±0.1276 Standard Error)
Dapagliflozin 20 mg-0.69 % of hemoglobin (±0.1278 Standard Error)
Placebo0.09 % of hemoglobin (±0.1406 Standard Error)
NCT00528372Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1C (HbA1c) (Last Observation Carried Forward [LOCF]): Group 1
Baseline to Week 24 (end of Short-term Period)
Group 1: Dapagliflozin Placebo AM & PM-0.23 Percent (±0.1044 Standard Error)
Group 1: Dapagliflozin, 10 mg AM-0.89 Percent (±0.1099 Standard Error)
Group 1: Dapagliflozin, 10 mg PM-0.79 Percent (±0.1037 Standard Error)
Group 1: Dapagliflozin, 2.5 mg AM-0.58 Percent (±0.1107 Standard Error)
Group 1: Dapagliflozin, 2.5 mg PM-0.83 Percent (±0.1125 Standard Error)
Group 1: Dapagliflozin, 5 mg AM-0.77 Percent (±0.1134 Standard Error)
Group 1: Dapagliflozin, 5 mg PM-0.79 Percent (±0.1117 Standard Error)
NCT00528372Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (Last Observation Carried Forward [LOCF]): Group 2
Baseline to Week 24 (end of Short-term Period)
Group 2: Dapagliflozin, 10 mg AM-2.66 Percent (±1.261 Standard Deviation)
Group 2: Dapagliflozin, 5 mg AM-2.88 Percent (±1.406 Standard Deviation)
NCT00528879Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])
From Baseline to Week 24
Dapagliflozin, 10 mg + Metformin-0.84 Percent (±0.0724 Standard Error)
Dapagliflozin, 2.5 mg + Metformin-0.67 Percent (±0.0715 Standard Error)
Dapagliflozin, 5 mg + Metformin-0.70 Percent (±0.0722 Standard Error)
Placebo + Metformin-0.30 Percent (±0.0718 Standard Error)
NCT00643851Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])
From Baseline to Week 24
Dapagliflozin 5 mg-1.19 % of hemoglobin (±0.0866 Standard Error)
Dapagliflozin 5 mg + Metformin XR-2.05 % of hemoglobin (±0.0892 Standard Error)
Metformin XR-1.35 % of hemoglobin (±0.0868 Standard Error)
NCT00660907Diabetes Mellitus, Type 2Adjusted Mean Change in HbA1c Levels
Baseline to Week 52
Dapagliflozin Plus Metformin-0.52 percent
Glipizide Plus Metformin-0.52 percent
NCT00663260Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]
From Baseline to Week 24
Dapagliflozin 10 mg-0.44 % of hemoglobin (±0.1708 Standard Error)
Dapagliflozin 5 mg-0.41 % of hemoglobin (±0.1701 Standard Error)
Placebo-0.32 % of hemoglobin (±0.1701 Standard Error)
NCT00673231Diabetes Mellitus, Type 2Adjusted Mean Change in HbA1c Levels
Baseline to Week 24
Dapagliflozin 10mg-0.90 Percent
Dapagliflozin 2.5mg-0.75 Percent
Dapagliflozin 5mg-0.82 Percent
Placebo-0.30 Percent
NCT00680745Diabetes Mellitus, Type 2Adjusted Mean Change in HbA1c Levels
Baseline to Week 24
Dapagliflozin 10mg + Glimepiride-0.82 Percent
Dapagliflozin 2.5mg + Glimepiride-0.58 Percent
Dapagliflozin 5mg + Glimepiride-0.63 Percent
Placebo + Glimepiride-0.13 Percent
NCT00683878Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])
From Baseline to Week 24
Dapagliflozin 10MG + Pioglitazone-0.97 % of hemoglobin (±0.0828 Standard Error)
Dapagliflozin 5MG + Pioglitazone-0.82 % of hemoglobin (±0.0828 Standard Error)
PLACEBO + Pioglitazone-0.42 % of hemoglobin (±0.0834 Standard Error)
NCT00736879Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants
Baseline (Day 1), Week 24
Dapagliflozin 1mg-0.68 Percent Hemoglobin (±0.1166 Standard Error)
Dapagliflozin 2.5 mg-0.72 Percent Hemoglobin (±0.1169 Standard Error)
Dapagliflozin 5 mg-0.82 Percent Hemoglobin (±0.1217 Standard Error)
Placebo0.02 Percent Hemoglobin (±0.1200 Standard Error)
NCT00855166Diabetes Mellitus, Type 2Adjusted Mean Change in Total Body Weight
Baseline to Week 24
Dapagliflozin Plus Metformin-2.96 kg (±0.2766 95% Confidence Interval)
Placebo Plus Metformin-0.88 kg (±0.2746 95% Confidence Interval)
NCT00859898Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants
Week 24
Dapagliflozin-1.45 Percent of hemoglobin (±0.0734 Standard Error)
Dapagliflozin + Metformin XR-1.98 Percent of hemoglobin (±0.0759 Standard Error)
Metformin XR-1.44 Percent of hemoglobin (±0.0757 Standard Error)
NCT00984867Diabetes Mellitus, Type 2Adjusted Mean Change in HbA1c Levels
Baseline to Week 24
Dapagliflozin-0.45 Percent (±0.0509 95% Confidence Interval)
Placebo0.04 Percent (±0.0509 95% Confidence Interval)
NCT01031680Diabetes Mellitus, Type 2Adjusted Mean Change in HbA1c Levels
Baseline to Week 24
Experimental-0.38 Percent
Placebo Comparator0.08 Percent
NCT01031680Diabetes Mellitus, Type 2Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit
Baseline to week 24
Experimental11.7 Percentage of participants
Placebo Comparator0.9 Percentage of participants
NCT01042977Diabetes Mellitus, Type 2Adjusted Mean Change in HbA1c Levels
Baseline to Week 24
Dapagliflozin-0.33 Percent (±0.0434 95% Confidence Interval)
Placebo0.07 Percent
NCT01042977Diabetes Mellitus, Type 2Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit
Baseline to Week 24
Dapagliflozin10.0 Percentage of participants (±0.7 95% Confidence Interval)
Placebo1.9 Percentage of participants (±7.3 95% Confidence Interval)
NCT01095653Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])
From Baseline to Week 24
Dapagliflozin 10 mg-1.11 % of hemoglobin (±0.0680 Standard Error)
Dapagliflozin 5 mg-1.04 % of hemoglobin (±0.0695 Standard Error)
Placebo-0.29 % of hemoglobin (±0.0681 Standard Error)
NCT01095666Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])
From Baseline to Week 24
Dapagliflozin 10 mg + Metformin-0.85 % of hemoglobin (±0.0601 Standard Error)
Dapagliflozin 5 mg + Metformin-0.82 % of hemoglobin (±0.0607 Standard Error)
Placebo + Metformin-0.23 % of hemoglobin (±0.0622 Standard Error)
NCT01137474Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin (HbA1c) at Week 12
From Baseline to Week 12
Dapagliflozin 10 mg-0.56 Percent (±0.0633 Standard Error)
Placebo-0.10 Percent (±0.0631 Standard Error)
NCT01137474Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12
From Baseline to Week 12
Dapagliflozin 10 mg-10.40 mm Hg (±0.8822 Standard Error)
Placebo-7.34 mm Hg (±0.8812 Standard Error)
NCT01195662Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants
Baseline to Week 12
Dapagliflozin 10 mg-0.41 Percent of Hemoglobin (±0.0496 Standard Error)
Dapagliflozin 10 mg-0.58 Percent of Hemoglobin (±0.0602 Standard Error)
Dapagliflozin 10 mg-0.63 Percent of Hemoglobin (±0.0668 Standard Error)
Placebo Matching Dapagliflozin-0.06 Percent of Hemoglobin (±0.0498 Standard Error)
Placebo Matching Dapagliflozin-0.07 Percent of Hemoglobin (±0.0606 Standard Error)
Placebo Matching Dapagliflozin-0.02 Percent of Hemoglobin (±0.0673 Standard Error)
NCT01195662Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants
Baseline to Week 12
Dapagliflozin 10 mg-9.69 mmHg (±1.0097 Standard Error)
Dapagliflozin 10 mg-11.38 mmHg (±1.0251 Standard Error)
Dapagliflozin 10 mg-7.93 mmHg (±0.9357 Standard Error)
Dapagliflozin 10 mg-11.90 mmHg (±1.0585 Standard Error)
Placebo Matching Dapagliflozin-6.05 mmHg (±1.0232 Standard Error)
Placebo Matching Dapagliflozin-6.80 mmHg (±1.0374 Standard Error)
Placebo Matching Dapagliflozin-7.62 mmHg (±1.0701 Standard Error)
Placebo Matching Dapagliflozin-5.13 mmHg (±0.9489 Standard Error)
NCT01217892Diabetes Mellitus, Type 2Adjusted Mean Change in HbA1c Levels
Baseline to Week 16
Dapagliflozin 10mg OD Plus Metformin-0.59 Percent (±0.0598 Standard Error)
Dapagliflozin 2.5mg BID Plus Metformin-0.52 Percent (±0.0594 Standard Error)
Dapagliflozin 5mg BID Plus Metformin-0.65 Percent (±0.0600 Standard Error)
Placebo Plus Metformin-0.30 Percent (±0.0593 Standard Error)
NCT01294423Diabetes Mellitus, Type 2Adjusted Mean Change in HbA1c Levels
From Baseline to Week 24
Dapagliflozin 10 mg-0.45 Percent
Dapagliflozin 5 mg-0.41 Percent
Placebo-0.06 Percent
NCT01294436Diabetes Mellitus, Type 2Mean Change in Alanine Aminotransferase (ALT)
Baseline to Week 52
All Combination Therapies-5.4 U/L (±0.622 Standard Error)
Monotherapy-7.1 U/L (±0.955 Standard Error)
NCT01294436Diabetes Mellitus, Type 2Mean Change in Aspartate Aminotransferase (AST)
Baseline to Week 52
All Combination Therapies-2.6 U/L (±0.410 Standard Error)
Monotherapy-3.9 U/L (±0.695 Standard Error)
NCT01294436Diabetes Mellitus, Type 2Mean Change in Blood Urea Nitrogen (BUN)
Baseline to Week 52
All Combination Therapies2.3 mg/dL (±0.168 Standard Error)
Monotherapy2.4 mg/dL (±0.250 Standard Error)
NCT01294436Diabetes Mellitus, Type 2Mean Change in Hematocrit
Baseline to Week 52
All Combination Therapies2.00 Percent (±0.1115 Standard Error)
Monotherapy2.17 Percent (±0.1396 Standard Error)
NCT01294436Diabetes Mellitus, Type 2Mean Change in Magnesium
Baseline to Week 52
All Combination Therapies0.05 mEq/L (±0.0064 Standard Error)
Monotherapy0.05 mEq/L (±0.0074 Standard Error)
NCT01294436Diabetes Mellitus, Type 2Mean Change in Seated Diastolic Blood Pressure
Baseline to Week 52
All Combination Therapies-2.1 mmHg (±8.73 Standard Deviation)
Monotherapy-2.9 mmHg (±8.16 Standard Deviation)
NCT01294436Diabetes Mellitus, Type 2Mean Change in Seated Heart Rate
Baseline to Week 52
All Combination Therapies0.2 beats per minute (bpm) (±7.95 Standard Deviation)
Monotherapy-0.4 beats per minute (bpm) (±7.52 Standard Deviation)
NCT01294436Diabetes Mellitus, Type 2Mean Change in Seated Systolic Blood Pressure
Baseline to Week 52
All Combination Therapies-3.9 mmHg (±13.03 Standard Deviation)
Monotherapy-5.2 mmHg (±11.68 Standard Deviation)
NCT01294436Diabetes Mellitus, Type 2Mean Change in Serum Uric Acid
Baseline to Week 52
All Combination Therapies-0.50 mg/dL (±0.0374 Standard Error)
Monotherapy-0.61 mg/dL (±0.0578 Standard Error)
NCT01294436Diabetes Mellitus, Type 2Proportion of Participants With Adverse Events
Long-term treatment up to 52 weeks
All Combination Therapies72.4 Percentage of participants
Monotherapy79.1 Percentage of participants
NCT01294436Diabetes Mellitus, Type 2Proportion of Participants With At Least One Episode of Hypoglycemia
Long-term treatment up to 52 weeks
All Combination Therapies4.0 Percentage of participants
Monotherapy2.4 Percentage of participants
NCT01294436Diabetes Mellitus, Type 2Proportion of Participants With Serious Adverse Events
Long-term treatment up to 52 weeks
All Combination Therapies3.1 Percentage of participants
Monotherapy5.6 Percentage of participants
NCT01392677Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in HbA1c Levels
Baseline to week 24
Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea-0.86 Percent
Placebo Plus Metformin Plus Sulfonylurea-0.17 Percent
NCT01606007Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24
Baseline (Week 0) and at Week 24
Arm 1: Saxagliptin+Metformin XR+Placebo-0.88 % HbA1c
Arm 2: Dapagliflozin+Metformin XR+Placebo-1.20 % HbA1c
Arm 3: Saxagliptin+Dapagliflozin+Metformin XR-1.47 % HbA1c
NCT01619059Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24
From Baseline to Week 24
Placebo + Dapagliflozin 10mg + Metformin-0.16 Percent of glycosylated haemoglobin (±0.0605 Standard Error)
Saxagliptin 5mg + Dapagliflozin 10mg + Metformin-0.51 Percent of glycosylated haemoglobin (±0.0624 Standard Error)
NCT01646320Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24
From Baseline to Week 24
Dapa+Saxa+Met-0.82 Percentage of glycosylated hemoglobin (±0.0686 Standard Error)
Pla+Saxa+Met-0.1 Percentage of glycosylated hemoglobin (±0.0704 Standard Error)
NCT01730534
DECLARE-TIMI58
Diabetes Mellitus, Type 2Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.
up to 5.2 years
Dapa 10 mg417 Participants
Placebo496 Participants
NCT01730534
DECLARE-TIMI58
Diabetes Mellitus, Type 2Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke
up to 5.2 years
Dapa 10 mg756 Participants
Placebo803 Participants
NCT02096705Diabetes MellitusAdjusted Mean Change in HbA1c From Baseline to Week 24
Baseline (Day 1) and 24 weeks
Dapagliflozin-0.87 percentage of hemoglobin (±0.0666 Standard Error)
Placebo0.03 percentage of hemoglobin (±0.0707 Standard Error)
NCT02113241Insulin ResistanceDiastolic Blood Pressure at Week 12.
Week 12
Dapagliflozin76 mmHg (±8 Standard Deviation)
Placebo79 mmHg (±10 Standard Deviation)
NCT02113241Insulin ResistanceGlucose Levels at Minute 0 at Week 12.
Week 12
Dapagliflozin5.7 mmol/L (±1.1 Standard Deviation)
Placebo5.8 mmol/L (±0.7 Standard Deviation)
NCT02113241Insulin ResistanceHigh Density Lipoprotein (c-HDL) Levels at Week 12.
Week 12
Dapagliflozin1.3 mmol/L (±0.2 Standard Deviation)
Placebo1.3 mmol/L (±0.2 Standard Deviation)
NCT02113241Insulin ResistanceInsulinogenic Index (Total Insulin Secretion) at Week 12.
Week 12
Dapagliflozin0.35 index (±0.11 Standard Deviation)
Placebo0.99 index (±0.38 Standard Deviation)
NCT02113241Insulin ResistanceMatsuda Index (Total Insulin Sensitivity) at Week 12.
Week 12
Dapagliflozin2.7 index (±1.4 Standard Deviation)
Placebo1.6 index (±0.8 Standard Deviation)
NCT02113241Insulin ResistanceStumvoll Index (First Phase of Insulin Secretion) at Week 12.
Week 12
Dapagliflozin1463 index (±879 Standard Deviation)
Placebo2198 index (±996 Standard Deviation)
NCT02113241Insulin ResistanceSystolic Blood Pressure at Week 12.
Week 12
Dapagliflozin117 mmHg (±10 Standard Deviation)
Placebo121 mmHg (±13 Standard Deviation)
NCT02113241Insulin ResistanceTriglycerides Levels at Week 12.
Week 12
Dapagliflozin1.7 mmol/L (±0.8 Standard Deviation)
Placebo1.7 mmol/L (±0.6 Standard Deviation)
NCT02113241Insulin ResistanceWaist Circumference at Week 12.
Week 12
Dapagliflozin97.6 centimeters (±8.9 Standard Deviation)
Placebo97.2 centimeters (±6.9 Standard Deviation)
NCT02229396Diabetes MellitusChange in HbA1c From Baseline to Week 28
Baseline to Week 28
Dapagliflozin + Placebo-1.39 % HbA1c
Exenatide + Dapagliflozin-1.98 % HbA1c
Exenatide + Placebo-1.60 % HbA1c
NCT02268214
DEPICT 1
Diabetes Mellitus, Type 1Adjusted Mean Change in HbA1c From Baseline at Week 24
From Baseline to Week 24
Dapagliflozin 10 mg + Insulin-0.47 Percentage of hemoglobin (±0.0538 Standard Error)
Dapagliflozin 5 mg + Insulin-0.45 Percentage of hemoglobin (±0.0537 Standard Error)
Placebo + Insulin-0.03 Percentage of hemoglobin (±0.0540 Standard Error)
NCT02284893Diabetes Mellitus, Type 2Mean Change in HbA1c
Baseline (randomization) to Week 26
Saxagliptin + Dapagliflozin + Metformin Group-1.41 percentage (%) (±0.0696 Standard Error)
SITA + MET-1.07 percentage (%) (±0.0719 Standard Error)
NCT02413398
DERIVE
Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24
Baseline, Week 24
Dapagliflozin-0.37 percent (±0.10 Standard Error)
Placebo-0.03 percent (±0.10 Standard Error)
NCT02419612Diabetes MellitusChange From Baseline in Hemoglobin A1c (HbA1c) at Week 52
Baseline and Week 52
Dapagliflozin 10mg and Saxagliptin 5mg-1.35 % HbA1c
Titrated Glimepiride-0.98 % HbA1c
NCT02460978
DEPICT 2
Diabetes Mellitus, Type 1Adjusted Mean Change From Baseline in HbA1c at Week 24
Baseline and 24 weeks
DAPA 10 MG + INS-0.39 HbA1c (%)
DAPA 5 MG + INS-0.34 HbA1c (%)
PLA + INS0.03 HbA1c (%)
NCT02518945Diabetes Mellitus, Type 1Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo.
12 weeks
Active Drugs-0.66 % HbA1c (±0.1 Standard Error)
Placebo0 % HbA1c (±0.2 Standard Error)
NCT02532855Diabetes Mellitus, Type 2Change From Baseline in A1C at Week 24
Baseline and Week 24
Dapagliflozin-0.36 Percent A1C
Sitagliptin-0.51 Percent A1C
NCT02532855Diabetes Mellitus, Type 2Percentage of Participants Who Discontinued Study Drug Due to an AE
Up to 24 weeks
Dapagliflozin3.3 Percentage of participants
Sitagliptin3.3 Percentage of participants
NCT02532855Diabetes Mellitus, Type 2Percentage of Participants Who Experienced One or More Adverse Events
Up to 26 weeks
Dapagliflozin51.6 Percentage of participants
Sitagliptin48.9 Percentage of participants
NCT02547935Diabetes Mellitus, Type 2Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24
Baseline and Week 24
Dapagliflozin 10 mg + Saxagliptin 2.5 mg-0.85 Percentage of Glycoslyated HbA1c (±0.09 Standard Error)
Placebo-0.27 Percentage of Glycoslyated HbA1c (±0.09 Standard Error)
NCT02547935Diabetes Mellitus, Type 2Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24
Baseline and Week 24
Dapagliflozin 10 mg-22.4 Percent change (±6.6 Standard Error)
Dapagliflozin 10 mg + Saxagliptin 2.5 mg-39.1 Percent change (±5.1 Standard Error)
Placebo-1.8 Percent change (±8.3 Standard Error)
NCT02551874Diabetes Mellitus, Type 2Mean Change From Baseline in HbA1c at Week 24
Baseline and Week 24
Dapagliflozin + Saxagliptin + Metformin-1.67 % HbA1c
Titrated Insulin + Metformin-1.54 % HbA1c
NCT02582814Diabetes Mellitus, Type 1Clinical Laboratory Measures, Urine Test Results (Any Marked Abnormality)
From baseline to 52 weeks
Dapagliflozin 10mg + Insulin1 Participants
Dapagliflozin 10mg + Insulin1 Participants
Dapagliflozin 10mg + Insulin0 Participants
Dapagliflozin 10mg + Insulin1 Participants
Dapagliflozin 10mg + Insulin1 Participants
Dapagliflozin 10mg + Insulin0 Participants
Dapagliflozin 10mg + Insulin1 Participants
Dapagliflozin 5mg + Insulin1 Participants
Dapagliflozin 5mg + Insulin1 Participants
Dapagliflozin 5mg + Insulin2 Participants
Dapagliflozin 5mg + Insulin0 Participants
Dapagliflozin 5mg + Insulin1 Participants
Dapagliflozin 5mg + Insulin1 Participants
Dapagliflozin 5mg + Insulin0 Participants
NCT02582814Diabetes Mellitus, Type 1Diabetic Ketoacidosis (DKA)
From baseline to 52 weeks
Dapagliflozin 10mg + Insulin0 Participants
Dapagliflozin 10mg + Insulin0 Participants
Dapagliflozin 10mg + Insulin1 Participants
Dapagliflozin 5mg + Insulin2 Participants
Dapagliflozin 5mg + Insulin1 Participants
Dapagliflozin 5mg + Insulin0 Participants
NCT02582814Diabetes Mellitus, Type 1ECGs
From baseline to 52 weeks
Dapagliflozin 10mg + Insulin8 Participants
Dapagliflozin 10mg + Insulin67 Participants
Dapagliflozin 10mg + Insulin0 Participants
Dapagliflozin 10mg + Insulin0 Participants
Dapagliflozin 10mg + Insulin8 Participants
Dapagliflozin 10mg + Insulin67 Participants
Dapagliflozin 5mg + Insulin2 Participants
Dapagliflozin 5mg + Insulin69 Participants
Dapagliflozin 5mg + Insulin0 Participants
Dapagliflozin 5mg + Insulin5 Participants
Dapagliflozin 5mg + Insulin65 Participants
Dapagliflozin 5mg + Insulin11 Participants
NCT02582814Diabetes Mellitus, Type 1Hypoglycemia
From baseline to 52 weeks
Dapagliflozin 10mg + Insulin11 Participants
Dapagliflozin 10mg + Insulin75 Participants
Dapagliflozin 10mg + Insulin5 Participants
Dapagliflozin 10mg + Insulin73 Participants
Dapagliflozin 10mg + Insulin64 Participants
Dapagliflozin 10mg + Insulin14 Participants
Dapagliflozin 5mg + Insulin2 Participants
Dapagliflozin 5mg + Insulin67 Participants
Dapagliflozin 5mg + Insulin60 Participants
Dapagliflozin 5mg + Insulin13 Participants
Dapagliflozin 5mg + Insulin14 Participants
Dapagliflozin 5mg + Insulin75 Participants
NCT02582814Diabetes Mellitus, Type 1Overall Adverse Event Summary
From baseline to 52 weeks
Dapagliflozin 10mg + Insulin0 Participants
Dapagliflozin 10mg + Insulin22 Participants
Dapagliflozin 10mg + Insulin3 Participants
Dapagliflozin 10mg + Insulin55 Participants
Dapagliflozin 10mg + Insulin4 Participants
Dapagliflozin 5mg + Insulin4 Participants
Dapagliflozin 5mg + Insulin23 Participants
Dapagliflozin 5mg + Insulin67 Participants
Dapagliflozin 5mg + Insulin0 Participants
Dapagliflozin 5mg + Insulin7 Participants
NCT02582814Diabetes Mellitus, Type 1Vital Signs (Blood Pressure)
From baseline to 52 weeks
Dapagliflozin 10mg + Insulin-2.9 mmHg (±12.55 Standard Deviation)
Dapagliflozin 10mg + Insulin-1.0 mmHg (±7.89 Standard Deviation)
Dapagliflozin 5mg + Insulin-3.4 mmHg (±11.41 Standard Deviation)
Dapagliflozin 5mg + Insulin-0.6 mmHg (±8.21 Standard Deviation)
NCT02582814Diabetes Mellitus, Type 1Vital Signs (Heart Rate)
From baseline to 52 weeks
Dapagliflozin 10mg + Insulin0.4 bpm (±8.89 Standard Deviation)
Dapagliflozin 5mg + Insulin-0.3 bpm (±10.07 Standard Deviation)
NCT02592421Diabetes Mellitus, Type 2Change in Endogenous Glucose Production (EGP)
Baseline to 240-300 minutes
Dapagliflozin0.1 mg/kg.min (±0.1 Standard Deviation)
Dapagliflozin-0.23 mg/kg.min (±0.09 Standard Deviation)
Dapagliflozin-0.57 mg/kg.min (±0.12 Standard Deviation)
Placebo-1.28 mg/kg.min (±0.17 Standard Deviation)
Placebo-0.56 mg/kg.min (±0.1 Standard Deviation)
Placebo-0.48 mg/kg.min (±0.05 Standard Deviation)
NCT02592421Diabetes Mellitus, Type 2Change in Plasma Glucose Concentration
Baseline to 240-300 minutes
Dapagliflozin-29.7 mg/dl (±3 Standard Deviation)
Dapagliflozin3.1 mg/dl (±0.9 Standard Deviation)
Dapagliflozin-30.3 mg/dl (±3.5 Standard Deviation)
Placebo-17.2 mg/dl (±2.9 Standard Deviation)
Placebo-2.3 mg/dl (±6.1 Standard Deviation)
Placebo0.9 mg/dl (±1.1 Standard Deviation)
NCT02635386ObesityOral Disposition (Insulin Sensitivity-insulin Secretion) Index
24 weeks of treatment
Dapagliflozin (DAPA)311 index score (±90 Standard Error)
Dapagliflozin Plus Glucophage (MET ER)395 index score (±85 Standard Error)
EQW Plus DAPA503 index score (±80 Standard Error)
Exenatide Once Weekly (EQW )471 index score (±83 Standard Error)
Phentermine /Topiramate (PHEN/ TPM) ER545 index score (±93 Standard Error)
NCT02681094Diabetes Mellitus, Type 2Change From Baseline in HbA1c at Week 24
Baseline and week 24
Dapagliflozin + Metformin-0.63 Percentage (%) (±0.0560 Standard Error)
Dapagliflozin + Saxagliptin + Metformin-1.03 Percentage (%) (±0.0558 Standard Error)
Saxagliptin + Metformin-0.69 Percentage (%) (±0.0551 Standard Error)
NCT02725593Diabetes Mellitus, Type 2Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24
Baseline to Week 24
Dapagliflozin 10mg/ Dapagliflozin 10mg-0.25 Percentage of HbA1c (±0.30 Standard Error)
Placebo/ Dapagliflozin 10mg0.50 Percentage of HbA1c (±0.34 Standard Error)
NCT02984644
AZ11040
Diabetes Mellitus, Type 2Change in EGP With Glucose Clamp: Study 2
Baseline to 240-300 minutes
Dapagliflozin 10mg-0.57 mg/kg.min (±0.12 Standard Deviation)
Placebo-1.28 mg/kg.min (±0.172 Standard Deviation)
NCT02984644
AZ11040
Diabetes Mellitus, Type 2Change in EGP With Pancreatic Clamp: Study 3
Baseline to 240-300 minutes
Dapagliflozin 10mg-0.23 mg/kg.min (±0.09 Standard Deviation)
Placebo-0.48 mg/kg.min (±0.05 Standard Deviation)
NCT02984644
AZ11040
Diabetes Mellitus, Type 2Change in EGP: Study 1
Baseline to 240-300 minutes
Dapagliflozin0.10 mg/kg.min (±0.1 Standard Deviation)
Placebo-0.56 mg/kg.min (±0.11 Standard Deviation)
NCT02984644
AZ11040
Diabetes Mellitus, Type 2Change in Plasma Glucose Measurement Using a Glucose Clamp: Study 2
Baseline to 240-300 minutes
Dapagliflozin 10mg3 mg/dl (±1 Standard Deviation)
Placebo1 mg/dl (±1 Standard Deviation)
NCT02984644
AZ11040
Diabetes Mellitus, Type 2Change in Plasma Glucose Using a Pancreatic Clamp: Study 3
Baseline to 240-300 minutes
Dapagliflozin 10mg-30 mg/dl (±4 Standard Deviation)
Placebo-7 mg/dl (±5 Standard Deviation)
NCT02984644
AZ11040
Diabetes Mellitus, Type 2Measurement of the Change in Plasma Glucose (mg/dL): Study 1
Baseline to 240-300 minutes
Dapagliflozin 10mg-29 mg/dl (±4 Standard Deviation)
Placebo-17 mg/dl (±3 Standard Deviation)
NCT03036124
DAPA-HF
Heart FailureSubjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.
Up to 27.8 months.
Dapa 10 mg386 Participants
Placebo502 Participants
NCT03036150
Dapa-CKD
Renal Insufficiency, ChronicTime to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death.
Up to 38.2 months
Dapagliflozin197 Participants
Placebo312 Participants
NCT03199053Diabetes Mellitus, Type 2Dapagliflozin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26
Baseline and Week 26
Dapagliflozin-0.62 Percentage HbA1c (±0.218 Standard Error)
Placebo0.41 Percentage HbA1c (±0.218 Standard Error)
NCT03199053Diabetes Mellitus, Type 2Saxagliptin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26
Baseline and Week 26
Placebo0.50 Percentage HbA1c (±0.202 Standard Error)
Saxagliptin0.06 Percentage HbA1c (±0.198 Standard Error)
NCT03619213
DELIVER
—Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation
Up to 42.1 months
Dapa 10 mg381 Participants
Placebo440 Participants
NCT03619213
DELIVER
—Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.
Up to 42.1 months
Dapa 10 mg512 Participants
Placebo610 Participants
NCT03762850
PROTECT
Glomerulonephritis, IGAPercent Change From Baseline in the Urine Protein/Creatinine (UP/C) at Week 36
Baseline (Day 1) and at Week 36
Irbesartan-15.05 Percent change
Sparsentan-49.77 Percent change
NCT03877224—Change From Baseline in 6-minute Walk Distance (6MWD) at Week 16 (Larger Distances Represent Better Functional Capacity)
At baseline and at week 16 or death before week 16
Dapa 10mg9.0 meters
Placebo8.5 meters
NCT03877224—Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS) at Week 16 (Higher Scores Represent Less Physical Limitation Due to HF)
At baseline and at week 16 or death before week 16
Dapa 10mg0.00 Score on a scale
Placebo0.00 Score on a scale
NCT03877224—Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)
At baseline and at week 16 or death before week 16
Dapa 10mg5.21 Score on a scale
Placebo1.04 Score on a scale
NCT03877237—Change From Baseline in 6-minute Walk Distance (6MWD) at Week 16 (Larger Distances Represent Better Functional Capacity).
At baseline and at week 16 or death prior to week 16
Dapa 10mg20.0 meters
Placebo13.5 meters
NCT03877237—Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS) at Week 16 (Higher Scores Represent Less Physical Limitation Due to HF)
At baseline and at week 16 or death before week 16
Dapa 10mg4.17 Score on a scale
Placebo0.00 Score on a scale
NCT03877237—Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden).
At baseline and at week 16 or death before week 16
Dapa 10mg2.08 Score on a scale
Placebo0.00 Score on a scale
NCT03968224Diabetes Mellitus, Type 2Change in Weight
12 months
Metformin115 kg (±20.18 Standard Deviation)
Metformin118.4 kg (±21.4 Standard Deviation)
Metformin119.9 kg (±22.4 Standard Deviation)
Metformin120 kg (±20.58 Standard Deviation)
Metformin123.7 kg (±21.8 Standard Deviation)
Metformin125.9 kg (±23.9 Standard Deviation)
Metformin/Dapagliflozin115.4 kg (±17.9 Standard Deviation)
Metformin/Dapagliflozin116.3 kg (±20.11 Standard Deviation)
Metformin/Dapagliflozin114.4 kg (±17.8 Standard Deviation)
Metformin/Dapagliflozin116 kg (±19 Standard Deviation)
Metformin/Dapagliflozin121.5 kg (±21.1 Standard Deviation)
Metformin/Dapagliflozin118 kg (±20.8 Standard Deviation)
NCT04298229
DICTATE-AHF
Diabetes Mellitus, Type 2Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight
Baseline to Day 5 or discharge if earlier
Dapagliflozin Plus Structured Usual Care-0.42 kg/40mg IV furosemide
Structured Usual Care-0.31 kg/40mg IV furosemide
NCT04350593
DARE-19
COVID-19Improving Clinical Recovery: Hierarchical Composite Outcome Measure Including Death From Any Cause Through Day 30, New/Worsened Organ Dysfunction, Clinical Status at Day 30 and Hospital Discharge Before Day 30 and Alive at Day 30.
Randomization through Day 30
Dapagliflozin 10mg547 participants
Placebo532 participants
NCT04350593
DARE-19
COVID-19Prevention of COVID-19 Complications or Death: During the 30-day Treatment Period, Time to First Occurrence of New/Worsened Organ Dysfunction During Index Hospitalization or Death From Any Cause.
Randomization through Day 30
Dapagliflozin 10mg12.4 Patients with events/100 pt-mos at risk
Placebo15.6 Patients with events/100 pt-mos at risk
NCT04564742
DAPA-MI
Heart FailureAnalysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set)
29 months
Dapa 10 mg40 Participants
Dapa 10 mg41 Participants
Dapa 10 mg8 Participants
Dapa 10 mg32 Participants
Dapa 10 mg29 Participants
Dapa 10 mg1990 Participants
Dapa 10 mg1839 Participants
Dapa 10 mg684 Participants
Placebo41 Participants
Placebo32 Participants
Placebo74 Participants
Placebo468 Participants
Placebo33 Participants
Placebo15 Participants
Placebo1970 Participants
Placebo1773 Participants

Publications by year

1967–2026: 1,315 publications.

1967
1
1970
1
1974
1
1981
4
1982
1
1985
1
1986
4
1988
3
1989
1
1990
5
1991
1
1992
1
1993
7
1994
3
1995
7
1996
4
1997
3
1998
4
1999
8
2000
5
2001
16
2002
8
2003
8
2004
13
2005
12
2006
10
2007
18
2008
25
2009
24
2010
25
2011
40
2012
60
2013
41
2014
57
2015
68
2016
60
2017
63
2018
53
2019
88
2020
86
2021
131
2022
95
2023
96
2024
75
2025
54
2026
24

Publications by indication

Diabetes Mellitus, Type 2 (499)

  • Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Clin J Am Soc Nephrol · 2026 · PMID 41385300 · NCT04965935
  • Dapagliflozin Mitigates Medullary Hypoxia in CKD Patients: Analysis of Blood Oxygenation Level-Dependent Magnetic Resonance Imaging Renal Data from the Randomized Glucose Transport and Renal Protection in CKD Trial.
    Kidney360 · 2026 · PMID 41223002 · NCT05998837
  • Dapagliflozin Reduces Ambulatory Arterial Stiffness Index in CKD Patients with and Without Diabetes Independently of Blood Pressure Control: Results from the GLUcose Transport and Renal PROtection in Chronic Kidney Disease (GLUTREPRO) Trial.
    High Blood Press Cardiovasc Prev · 2026 · PMID 41366613 · NCT05998837
  • Dapagliflozin-Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes.
    Obesity (Silver Spring) · 2026 · PMID 41629250 · NCT03782259
  • Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial.
    Cardiovasc Diabetol · 2026 · PMID 41888924 · NCT02919345

Heart Failure (198)

  • Cardiac impact of dapagliflozin in advanced chronic kidney disease: rationale and design of the Renal Lifecycle Trial cardiac imaging sub-studies.
    Clin Kidney J · 2026 · PMID 41551843 · NCT05374291
  • Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.
    J Am Soc Nephrol · 2026 · PMID 40913594 · NCT06677060
  • Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU).
    BMJ Open · 2026 · PMID 41991273 · NCT07025629
  • Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.
    Circ Heart Fail · 2025 · PMID 41170566 · NCT03036124
  • Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical Trial.
    JAMA Cardiol · 2025 · PMID 40465275 · NCT03036124

Diabetes Mellitus (115)

  • Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.
    J Magn Reson Imaging · 2025 · PMID 22025886 · NCT05042505
  • Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial.
    J Cardiovasc Dev Dis · 2025 · PMID 40558655 · NCT06619600
  • Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus.
    J Diabetes Metab Disord · 2025 · PMID 39697865 · NCT02798757
  • Effect of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on ventricular repolarization electrocardiographic parameters in type 2 diabetes patients: DAPA - ECG study.
    Front Clin Diabetes Healthc · 2025 · PMID 40230406 · NCT06721442
  • Dapagliflozin for Small Nerve Fibre Regeneration in Diabetic Peripheral Neuropathy: A Randomised Controlled Study (DINE).
    J Peripher Nerv Syst · 2025 · PMID 40044634 · NCT05162690

Renal Insufficiency, Chronic (60)

  • Baseline, Early Changes, and Residual Albuminuria: Post Hoc Analysis of a Randomized Clinical Trial of Dapagliflozin in Chronic Kidney Disease.
    Clin J Am Soc Nephrol · 2026 · PMID 39475817 · NCT03036150
  • Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition.
    J Am Soc Nephrol · 2026 · PMID 41926219 · NCT03036150
  • Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.
    J Am Soc Nephrol · 2026 · PMID 40526444 · NCT03036150
  • Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease.
    Clin J Am Soc Nephrol · 2026 · PMID 41805697 · NCT05570305
  • Effects of Dapagliflozin on Progression of CKD According to Different Rates of Pretrial eGFR Loss.
    Clin J Am Soc Nephrol · 2026 · PMID 41128261 · NCT03036150

Atrial Fibrillation (50)

  • Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.
    Circulation · 2026 · PMID 41206792 · NCT06433479
  • Efficacy of sodium-glucose cotransporter 2 inhibitors in preventing atrial fibrillation recurrence after catheter ablation.
    Hellenic J Cardiol · 2024 · PMID 38484841 · NCT06759909
  • Effect of Dapagliflozin on the Outcome of Radiofrequency Catheter Ablation in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation.
    Cardiovasc Drugs Ther · 2024 · PMID 35962156 · NCT06759909
  • Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review.
    JACC Basic Transl Sci · 2023 · PMID 32613148 · NCT04780438
  • SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Cardiovasc Diabetol · 2021 · PMID 32847602 · NCT04780438

Proteinuria (31)

  • Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD).
    BMJ Open · 2025 · PMID 41397763 · NCT06890143
  • The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
    Clin Kidney J · 2025 · PMID 30524708 · NCT06890143
  • Global case studies for chronic kidney disease/end-stage kidney disease care.
    Kidney Int Suppl (2011) · 2024 · PMID 32149007 · NCT06890143
  • The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
    Am J Nephrol · 2024 · PMID 29253846 · NCT06890143
  • Safety Profile and Effectiveness of Dapagliflozin in Pediatric Patients with Chronic Kidney Disease.
    Am J Nephrol · 2024 · PMID 38735286 · NCT07204743

Publications by journal

Trial-results highlights

Clinical trials investigated the effects of Dapagliflozin on Hemoglobin A1C (HbA1c) levels in patients with Type 2 Diabetes Mellitus. In NCT00357370, at Week 12, the Dapagliflozin 10 mg arm reported a mean change from baseline of -0.61 % of hemoglobin, and the Dapagliflozin 20 mg arm reported -0.69 %, while the placebo arm reported 0.09 %. In NCT00528372, Group 1, at Week 24, the Dapagliflozin, 10 mg AM arm showed a mean change of -0.89 Percent in HbA1c, and the Dapagliflozin, 2.5 mg PM arm showed -0.83 Percent. In Group 2 of the same study, the Dapagliflozin, 5 mg AM arm showed a mean change of -2.88 Percent, and the Dapagliflozin, 10 mg AM arm showed -2.66 Percent. Another study, NCT00673231, reported at Week 24 a mean change of -0.90 Percent for the Dapagliflozin 10mg arm, -0.82 Percent for the Dapagliflozin 5mg arm, and -0.75 Percent for the Dapagliflozin 2.5mg arm, compared to -0.30 Percent for the placebo arm.

Studies also assessed Dapagliflozin in combination with metformin. In NCT00528879, at Week 24, the Dapagliflozin, 10 mg + Metformin arm showed a mean change of -0.84 Percent in HbA1c, while the Dapagliflozin, 5 mg + Metformin arm showed -0.70 Percent, and the Dapagliflozin, 2.5 mg + Metformin arm showed -0.67 Percent. The Placebo + Metformin arm reported -0.30 Percent. In NCT00643851, at Week 24, the Dapagliflozin 5 mg + Metformin XR arm showed a mean change of -2.05 % in HbA1c. The Dapagliflozin 5 mg arm showed -1.19 %, and the Metformin XR arm showed -1.35 %. A longer study, NCT00660907, found that at Week 52, the Dapagliflozin Plus Metformin arm had a mean change of -0.52 percent in HbA1c, which was the same as the Glipizide Plus Metformin arm.

In NCT00663260, at Week 24, the Dapagliflozin 10 mg arm showed a mean change of -0.44 % of hemoglobin, and the Dapagliflozin 5 mg arm showed -0.41 %. The placebo arm in this study showed -0.32 %.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Dapagliflozin publications (1,315)

2026 (24 papers)

  1. Baseline, Early Changes, and Residual Albuminuria: Post Hoc Analysis of a Randomized Clinical Trial of Dapagliflozin in Chronic Kidney Disease.
    van Mil D, Vart P, Chertow GM, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 39475817 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  2. Dapagliflozin in Acute Cardiovascular Conditions: Insights From the DEFENDER Trial.
    Tavares CAM, Azevedo LCP, Guimarães PO, et al. · JACC Adv · 2026 · Derived
    PubMed: PMID 41421016 · NCT05558098 (DEFENDER) · Critical Illness
  3. Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Sridhar VS, Kugathasan L, Lytvyn Y, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41385300 · NCT04965935 (INFINITI2019) · Diabetes Mellitus, Type 2
  4. Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Sridhar VS, Kugathasan L, Lytvyn Y, et al. · Hypertension · 2026 · Derived
    PubMed: PMID 41347301 · NCT04258371 (DAPA-SWEET)
  5. Targeting epicardial adipose tissue in heart failure with preserved ejection fraction: exploring the dapagliflozin connection.
    Soliman AM, Ghaleb R, Mahmoud AH, et al. · BMC Cardiovasc Disord · 2026 · Derived
    PubMed: PMID 42021144 · NCT06510270
  6. Dapagliflozin Mitigates Medullary Hypoxia in CKD Patients: Analysis of Blood Oxygenation Level-Dependent Magnetic Resonance Imaging Renal Data from the Randomized Glucose Transport and Renal Protection in CKD Trial.
    Russo E, Venturelli E, Di Vincenzo J, et al. · Kidney360 · 2026 · Derived
    PubMed: PMID 41223002 · NCT05998837 (GLUTREPRO) · Diabetes Mellitus, Type 2
  7. Dapagliflozin Reduces Ambulatory Arterial Stiffness Index in CKD Patients with and Without Diabetes Independently of Blood Pressure Control: Results from the GLUcose Transport and Renal PROtection in Chronic Kidney Disease (GLUTREPRO) Trial.
    Russo E, Cappadona F, Macciò L, et al. · High Blood Press Cardiovasc Prev · 2026 · Derived
    PubMed: PMID 41366613 · NCT05998837 (GLUTREPRO) · Diabetes Mellitus, Type 2
  8. Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk.
    Nyein PP, Haskelberg H, Martinello M, et al. · Trials · 2026 · Derived
    PubMed: PMID 42050587 · NCT06317051 (OPTIMAR) · HIV Infections
  9. Dapagliflozin-Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes.
    Naumova AV, Cunha GM, Kim NJ, et al. · Obesity (Silver Spring) · 2026 · Derived
    PubMed: PMID 41629250 · NCT03782259 · Diabetes Mellitus, Type 2
  10. Modeling Cardiorenal Protection with Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and DEPICT-2.
    Nardone M, Kugathasan L, Sridhar VS, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 39918875 · NCT02460978 (DEPICT 2) · Diabetes Mellitus, Type 1
  11. Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition.
    Moedt E, Koshino A, Jongs N, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41926219 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  12. Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial.
    Kimura-Medorima ST, Oliveira DC, Breder I, et al. · Cardiovasc Diabetol · 2026 · Derived
    PubMed: PMID 41888924 · NCT02919345 (ADDENDA) · Diabetes Mellitus, Type 2
  13. Cardiac impact of dapagliflozin in advanced chronic kidney disease: rationale and design of the Renal Lifecycle Trial cardiac imaging sub-studies.
    Karsten M, Badve SV, Gansevoort RT, et al. · Clin Kidney J · 2026 · Derived
    PubMed: PMID 41551843 · NCT05374291 · Heart Failure
  14. Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.
    Jongs N, Gasparyan SB, Frison L, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 40526444 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  15. Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.
    Jiang C, Zhao Z, Yang Z, et al. · Circulation · 2026 · Derived
    PubMed: PMID 41206792 · NCT06433479 (DARE-AF) · Atrial Fibrillation
  16. Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease.
    Hu S, Lee K, He JC, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41805697 · NCT05570305 (ZODIAC) · Renal Insufficiency, Chronic
  17. Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial.
    Hofherr A, Mäki-Petäjä K, Selvarajah V, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41563367 · NCT04170543 · Diabetic Nephropathies
  18. Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.
    Heerspink HJL, Rovin BH, Komers R, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41428405 · NCT03762850 (PROTECT) · Glomerulonephritis, IGA
  19. Effects of Dapagliflozin on Progression of CKD According to Different Rates of Pretrial eGFR Loss.
    Heerspink HJL, Chertow GM, Rossing P, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41128261 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  20. SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications.
    Eriksson JW, Fanni G, Lundqvist MH, et al. · Diabetes Obes Metab · 2026 · Derived
    PubMed: PMID 41311237 · NCT03982381 (SMARTEST) · Diabetes Mellitus, Type 2
  21. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Dwyer JP, Maklad N, Vedin O, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 40913594 · NCT06677060 (Prevent-HF) · Heart Failure
  22. Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU).
    Dépret F, Chousterman B, Roger C, et al. · BMJ Open · 2026 · Derived
    PubMed: PMID 41991273 · NCT07025629 (DAPA-ICU) · Heart Failure
  23. Interaction of Kidney Function and Dapagliflozin in Patients With Acute Heart Failure: A Pre-Specified Analysis of DICTATE-AHF.
    Brademeyer A, Jenkins CA, Kampe C, et al. · Am J Cardiol · 2026 · Derived
    PubMed: PMID 42013970 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  24. Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD.
    Bakker WM, Heerspink HJL, Jongs N, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 40679863 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic

2025 (54 papers)

  1. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.
    Reeder SB, Cruite I, Hamilton G, et al. · J Magn Reson Imaging · 2025 · Trial result
    PubMed: PMID 22025886 · NCT05042505 (Dapa-LiT) · Diabetes Mellitus
  2. Sodium-glucose co-transporter-2 inhibitor treatmentassociated changes in hemoglobin level in anemic patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
    Alsugair A, Fathima S, Aperna F, et al. · Haematologica · 2025 · Trial result
    PubMed: PMID 39844769 · NCT07516847 (DAPA-MDS1) · Anemia
  3. Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD).
    Zhang W, Dou Y, Liu J, et al. · BMJ Open · 2025 · Derived
    PubMed: PMID 41397763 · NCT06890143 · Proteinuria
  4. EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER.
    Yang M, Kondo T, Talebi A, et al. · JACC Heart Fail · 2025 · Derived
    PubMed: PMID 39909641 · NCT03619213 (DELIVER)
  5. Dapagliflozin Reduces Systemic Inflammation in Patients with Type 2 Diabetes Without Known Heart Failure.
    Wang D, Naumova A, Isquith D, et al. · Res Sq · 2025 · Derived
    PubMed: PMID 38585865 · NCT03782259 · Diabetes Mellitus, Type 2
  6. The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: An open-label randomized pilot study.
    Snel LIP, Oosterom-Eijmael MJP, Rampanelli E, et al. · J Clin Anesth · 2025 · Derived
    PubMed: PMID 40153894 · NCT05590143 (MERCURI-2) · Acute Kidney Injury
  7. Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction.
    Siqueira SRO, Pabon MA, Vaduganathan M, et al. · JACC Heart Fail · 2025 · Derived
    PubMed: PMID 40834567 · NCT03619213 (DELIVER)
  8. Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study.
    Singh V, De A, Aggrawal R, et al. · Dig Dis Sci · 2025 · Derived
    PubMed: PMID 39384712 · NCT05014594 · Fibrosis
  9. Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.
    Raposeiras-Roubin S, Amat-Santos IJ, Rossello X, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40162639 · NCT04696185 (DapaTAVI) · Aortic Valve Stenosis
  10. Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study.
    Park LK, Lim KH, Volkman J, et al. · Cancer Metab · 2025 · Derived
    PubMed: PMID 37202813 · NCT04542291 · Pancreatic Neoplasms
  11. Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
    Ostrominski JW, Neuen BL, Claggett BL, et al. · J Am Coll Cardiol · 2025 · Derived
    PubMed: PMID 40892613 · NCT03619213 (DELIVER)
  12. Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials.
    Oshima M, Buizen L, Jongs N, et al. · Clin J Am Soc Nephrol · 2025 · Derived
    PubMed: PMID 40658498 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  13. Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial.
    Ortega-Paz L, Laudani C, Sionis A, et al. · J Cardiovasc Dev Dis · 2025 · Derived
    PubMed: PMID 40558655 · NCT06619600 (DAPA-STEMI) · Diabetes Mellitus
  14. Study protocol of the multicentre, randomised, triple-blind, placebo-controlled MERCURI-2 trial: promoting effective renoprotection in cardiac surgery patients by inhibition of sodium glucose cotransporter (SGLT)-2.
    Oosterom-Eijmael M, Monteiro de Oliveira NP, Niesten ED, et al. · BMJ Open · 2025 · Derived
    PubMed: PMID 40379310 · NCT05590143 (MERCURI-2) · Acute Kidney Injury
  15. Cardio-renal effect of dapagliflozin and dapagliflozin- saxagliptin combination on CD34 + ve hematopoietic stem cells (HSCs) and podocyte specific markers in type 2 diabetes (T2DM) subjects: a randomized trial.
    Nandula SR, Jain A, Sen S, et al. · Stem Cell Res Ther · 2025 · Derived
    PubMed: PMID 39865301 · NCT03660683 · Diabetes Mellitus, Type 2
  16. Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.
    Myte R, Mattsson A, Poole M, et al. · Circ Heart Fail · 2025 · Derived
    PubMed: PMID 41170566 · NCT03036124 (DAPA-HF) · Heart Failure
  17. Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical Trial.
    McDowell K, Welsh P, Docherty KF, et al. · JAMA Cardiol · 2025 · Derived
    PubMed: PMID 40465275 · NCT03036124 (DAPA-HF) · Heart Failure
  18. Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial.
    Mark PB, De Sousa-Amorim E, Eriksson AL, et al. · Nephrol Dial Transplant · 2025 · Derived
    PubMed: PMID 40623005 · NCT06350123 (MIRO-CKD) · Renal Insufficiency, Chronic
  19. Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial.
    Mahmud FH, Bjornstad P, Clarson C, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 40481206 · NCT04333823 (ATTEMPT) · Diabetes Mellitus, Type 1
  20. Dapagliflozin prevents vascular ischemia-reperfusion injury in healthy young males: a randomized, placebo-controlled, double-blinded trial.
    Lutnik M, Weisshaar S, Litschauer B, et al. · Sci Rep · 2025 · Derived
    PubMed: PMID 40360700 · NCT05217654 · Reperfusion Injury
  21. Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials.
    Lu H, Kondo T, Claggett BL, et al. · J Am Coll Cardiol · 2025 · Derived
    PubMed: PMID 39745404 · NCT03619213 (DELIVER)
  22. Unveiling the benefits of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients.
    Loh HH, Tay SP, Koa AJ, et al. · J Transl Med · 2025 · Derived
    PubMed: PMID 40055713 · NCT06690723 (D3DOSA) · Hypertension
  23. Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.
    Liu Y, Chen Y, Ma J, et al. · BMJ · 2025 · Derived
    PubMed: PMID 39843169 · NCT04004793 (READ) · Diabetes Mellitus, Type 2
  24. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial.
    Lin J, Huang Y, Xu B, et al. · BMJ · 2025 · Derived
    PubMed: PMID 40467095 · NCT03723252 (DEAN) · Non-alcoholic Fatty Liver Disease
  25. Severe Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum: DAPA-HF and DELIVER.
    Inciardi RM, Lu H, Claggett BL, et al. · JACC Heart Fail · 2025 · Derived
    PubMed: PMID 40047763 · NCT03619213 (DELIVER)
  26. DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial.
    Holmen S, Manintveld O, Damman K, et al. · Am Heart J · 2025 · Derived
    PubMed: PMID 40840822 · NCT05321706 (DAPARHT) · Renal Insufficiency
  27. Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
    Heerspink HJL, Cardona JF, Jolly S, et al. · Lancet · 2025 · Derived
    PubMed: PMID 41218621 · NCT06350123 (MIRO-CKD) · Renal Insufficiency, Chronic
  28. Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58.
    Haller PM, Wiviott SD, Berg DD, et al. · ESC Heart Fail · 2025 · Derived
    PubMed: PMID 40952180 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  29. SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial.
    Greco A, Quagliariello V, Rizzo G, et al. · Cardiooncology · 2025 · Derived
    PubMed: PMID 40890873 · NCT06341842 (PROTECT) · Breast Neoplasms
  30. Management of Kidney Disease in Heart Transplant Patients: A National Delphi Survey-based Consensus Expert Paper.
    García-Cosío Carmena MD, Farrero M, Blasco Peiró MT, et al. · Transplantation · 2025 · Derived
    PubMed: PMID 39928546 · NCT05374291 · Heart Failure
  31. Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus.
    Filippas-Ntekouan S, Dimou A, Dafopoulos P, et al. · J Diabetes Metab Disord · 2025 · Derived
    PubMed: PMID 39697865 · NCT02798757 · Diabetes Mellitus
  32. Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction: The SOGALDI-PEF Trial.
    Ferreira JP, Vasques-Nóvoa F, Saraiva F, et al. · J Am Coll Cardiol · 2025 · Derived
    PubMed: PMID 40738559 · NCT05676684 (SOGALDI-PEF)
  33. Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
    Docherty KF, McDowell K, Welsh P, et al. · JACC Heart Fail · 2025 · Derived
    PubMed: PMID 40088234 · NCT03036124 (DAPA-HF) · Heart Failure
  34. Wearable Accelerometer-Derived Measures of Physical Activity in Heart Failure: Insights From the DETERMINE trials.
    Docherty KF, Buendia Lopez R, Folkvaljon F, et al. · J Card Fail · 2025 · Derived
    PubMed: PMID 39603408 · NCT03877237
  35. Effect of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on ventricular repolarization electrocardiographic parameters in type 2 diabetes patients: DAPA - ECG study.
    Campos RN, Moreira DAR, Fonseca GM, et al. · Front Clin Diabetes Healthc · 2025 · Derived
    PubMed: PMID 40230406 · NCT06721442 (DAPA-ECG) · Diabetes Mellitus
  36. Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
    Bonanad-Lozano C, García Blas S, Amat-Santos I, et al. · J Am Coll Cardiol · 2025 · Derived
    PubMed: PMID 41062227 · NCT04696185 (DapaTAVI) · Aortic Valve Stenosis
  37. Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial.
    Bitos K, Laptseva N, Haider T, et al. · PLoS One · 2025 · Derived
    PubMed: PMID 40601599 · NCT04869124 (DAPA-VOLVO) · Heart Failure
  38. The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone.
    Bhattacharya CS, Ericsson H, Johansson S, et al. · Br J Clin Pharmacol · 2025 · Derived
    PubMed: PMID 39962632 · NCT06350123 (MIRO-CKD) · Renal Insufficiency, Chronic
  39. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.
    Berg DD, Patel SM, Haller PM, et al. · Circulation · 2025 · Derived
    PubMed: PMID 40884036 · NCT04363697 · Heart Failure
  40. Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial.
    Berg DD, Patel SM, Haller PM, et al. · JACC Heart Fail · 2025 · Derived
    PubMed: PMID 40335233 · NCT04363697 · Heart Failure
  41. Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease.
    Bartholdy KV, Johansen ND, Skaarup KG, et al. · NEJM Evid · 2025 · Derived
    PubMed: PMID 41147829 · NCT05359263 (DECODE-CKD) · Renal Insufficiency, Chronic
  42. Dapagliflozin for Small Nerve Fibre Regeneration in Diabetic Peripheral Neuropathy: A Randomised Controlled Study (DINE).
    Adhikari U, Gad H, Chatterjee D, et al. · J Peripher Nerv Syst · 2025 · Derived
    PubMed: PMID 40044634 · NCT05162690 (DINE) · Diabetes Mellitus
  43. Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers, Combined with Dapagliflozin as Type 2 Diabetes Mellitus Routine Treatment: A Controlled Randomized, Double-blind Trial.
    Aburayyan W, Zakaraya Z, Hamad M, et al. · Iran J Med Sci · 2025 · Derived
    PubMed: PMID 40433181 · NCT06241638 · Diabetes Mellitus
  44. Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial.
    Abdel Monem MS, Adel A, Abbassi MM, et al. · Clin Res Hepatol Gastroenterol · 2025 · Derived
    PubMed: PMID 39884573 · NCT05254626 · Non-alcoholic Fatty Liver Disease
  45. Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial.
    Abdel Jawad M, Furtado RHM, Esterline R, et al. · Cardiovasc Diabetol · 2025 · Derived
    PubMed: PMID 40739638 · NCT04350593 (DARE-19) · COVID-19
  46. Experience with sodium glucose cotransporter-2 inhibitors in adult patients with Fontan circulation.
    Skorek P, Frączek-Jucha MM, Sarnecka A, et al. · Adv Clin Exp Med · 2025 · Background
    PubMed: PMID 39807605 · NCT07482943 · Heart Failure
  47. Efficacy and Safety of Sglt-2 Inhibitors In Renal Allograft Recipients: an Open-Label, Single-Center Prospective Study.
    Novikova MS, Minushkina LO, Allazova SS, et al. · Kardiologiia · 2025 · Background
    PubMed: PMID 41129246 · NCT07555106 (DAPA-GRAFT)
  48. SGLT2 inhibition for patients with ADPKD - closing the evidence gap.
    Müller RU, Guerrot D, Chonchol M, et al. · Nephrol Dial Transplant · 2025 · Background
    PubMed: PMID 40199734 · NCT07280585 (STOP-PKD) · Polycystic Kidney Diseases
  49. Experience with SGLT2 Inhibitors in Patients with Single Ventricle Congenital Heart Disease and Fontan Circulatory Failure.
    Konduri A, West C, Lowery R, et al. · Pediatr Cardiol · 2025 · Background
    PubMed: PMID 37919530 · NCT07482943 · Heart Failure
  50. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.
    Joshi SS, Singh T, Newby DE, et al. · Heart · 2025 · Background
    PubMed: PMID 33637556 · NCT06012266 · Heart Failure
  51. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
    Herrington WG, Preiss D, Haynes R, et al. · Clin Kidney J · 2025 · Background
    PubMed: PMID 30524708 · NCT06890143 · Proteinuria
  52. Empagliflozin to Prevent Doxorubicin Cardiotoxicity.
    Guo Z, Javaheri A · JACC CardioOncol · 2025 · Background
    PubMed: PMID 39967205 · NCT07174687 · Eye Diseases
  53. Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport.
    Gross O, Boeckhaus J, Weber LT, et al. · Nephrol Dial Transplant · 2025 · Background
    PubMed: PMID 39122650 · NCT05944016 (DOUBLE_PROTECT) · Nephritis, Hereditary
  54. Potential Role of SGLT-2 Inhibitors in Improving Allograft Function and Reducing Rejection in Kidney Transplantation.
    Demir ME, Helvacı Ö, Yıldırım T, et al. · Clin Transplant · 2025 · Background
    PubMed: PMID 40892675 · NCT07555106 (DAPA-GRAFT)

2024 (75 papers)

  1. Global case studies for chronic kidney disease/end-stage kidney disease care.
    Yang CW, Harris DCH, Luyckx VA, et al. · Kidney Int Suppl (2011) · 2024 · Trial result
    PubMed: PMID 32149007 · NCT06890143 · Proteinuria
  2. Glioma.
    Weller M, Wen PY, Chang SM, et al. · Nat Rev Dis Primers · 2024 · Trial result
    PubMed: PMID 38724526 · NCT06750458 · Glioma
  3. Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial.
    Reddy YNV, Carter RE, Sorimachi H, et al. · JAMA Cardiol · 2024 · Trial result
    PubMed: PMID 39046727 · NCT06612086 · Hypertension, Pulmonary
  4. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
    Pamporis K, Karakasis P, Sagris M, et al. · Curr Probl Cardiol · 2024 · Trial result
    PubMed: PMID 38692445 · NCT07351864 (FIN-SGLT2-HF) · Heart Failure
  5. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
    Jardine MJ, Mahaffey KW, Neal B, et al. · Am J Nephrol · 2024 · Trial result
    PubMed: PMID 29253846 · NCT06890143 · Proteinuria
  6. Dapagliflozin in Patients With a Failing Systemic Right Ventricle: Results From the DAPA-SERVE Trial.
    Fusco F, Scognamiglio G, Abbate M, et al. · JACC Heart Fail · 2024 · Trial result
    PubMed: PMID 38430085 · NCT06668389 (STEPS) · Heart Defects, Congenital
  7. Effects of empagliflozin on right ventricular adaptation to pressure overload.
    Axelsen JS, Nielsen-Kudsk AH, Schwab J, et al. · Front Cardiovasc Med · 2024 · Trial result
    PubMed: PMID 38162132 · NCT06668389 (STEPS) · Heart Defects, Congenital
  8. Evaluating the Safety and Efficacy of Sodium-Glucose Co-transporter 2 Inhibitors in Subjects with Prediabetes: A Protocol for a Randomized Controlled Trial.
    Zhu X, Xia L, Yin D, et al. · Diabetes Ther · 2024 · Derived
    PubMed: PMID 38494571 · NCT05914857 · Prediabetic State
  9. Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial.
    Zhang Z, Heerspink HJL, Chertow GM, et al. · Lancet Planet Health · 2024 · Derived
    PubMed: PMID 38580424 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  10. Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial.
    Yuan T, Liu S, Dong Y, et al. · Diabetol Metab Syndr · 2024 · Derived
    PubMed: PMID 33117454 · NCT04014192 · Diabetes Mellitus, Type 2
  11. Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.
    Yu MK, Vart P, Jongs N, et al. · J Gen Intern Med · 2024 · Derived
    PubMed: PMID 38097862 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  12. Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure.
    Wang DD, Naumova AV, Isquith D, et al. · Cardiovasc Diabetol · 2024 · Derived
    PubMed: PMID 38849829 · NCT03782259 · Diabetes Mellitus, Type 2
  13. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial.
    Vardeny O, Desai AS, Jhund PS, et al. · JAMA Cardiol · 2024 · Derived
    PubMed: PMID 38265835 · NCT03619213 (DELIVER)
  14. Non-immunosuppressive treatment for IgA nephropathy.
    Tunnicliffe DJ, Reid S, Craig JC, et al. · Cochrane Database Syst Rev · 2024 · Derived
    PubMed: PMID 38299639 · NCT03762850 (PROTECT) · Glomerulonephritis, IGA
  15. Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial.
    Tavares CAM, Azevedo LCP, Rea-Neto Á, et al. · JAMA · 2024 · Derived
    PubMed: PMID 38873723 · NCT05558098 (DEFENDER) · Critical Illness
  16. Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial.
    Tada A, Burkhoff D, Naser JA, et al. · Circulation · 2024 · Derived
    PubMed: PMID 39101201 · NCT04730947
  17. Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.
    Smeijer JD, Wasehuus VS, Dhaun N, et al. · J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 39352861 · NCT06087835 · Kidney Diseases
  18. Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes.
    Shehadeh N, Barrett T, Galassetti P, et al. · NEJM Evid · 2024 · Derived
    PubMed: PMID 38320500 · NCT03199053 · Diabetes Mellitus, Type 2
  19. Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF Trial.
    Selvaraj S, Patel S, Sauer AJ, et al. · JACC Heart Fail · 2024 · Derived
    PubMed: PMID 38639697 · NCT03030235 (PRESERVED-HF) · Heart Failure
  20. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.
    Selvaraj S, Patel S, Sauer AJ, et al. · Circ Heart Fail · 2024 · Derived
    PubMed: PMID 39421941 · NCT02653482 (DEFINE-HF) · Heart Failure
  21. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial.
    Peikert A, Bart BA, Vaduganathan M, et al. · JACC Heart Fail · 2024 · Derived
    PubMed: PMID 37767674 · NCT03619213 (DELIVER)
  22. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
    Natale P, Tunnicliffe DJ, Toyama T, et al. · Cochrane Database Syst Rev · 2024 · Derived
    PubMed: PMID 38770818 · NCT03036124 (DAPA-HF) · Heart Failure
  23. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
    McMurray JJV, Docherty KF, de Boer RA, et al. · Circulation · 2024 · Derived
    PubMed: PMID 38059368 · NCT03877237
  24. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
    Mc Causland FR, Claggett BL, Vaduganathan M, et al. · JAMA Cardiol · 2024 · Derived
    PubMed: PMID 37952176 · NCT03619213 (DELIVER)
  25. Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.
    Marton A, Saffari SE, Rauh M, et al. · J Am Coll Cardiol · 2024 · Derived
    PubMed: PMID 38599715 · NCT04080518 (DAPA-Shuttle1) · Diabetes Mellitus
  26. Effect of dapagliflozin on epicardial fat volume in patients with acute coronary syndrome assessed by computed tomography.
    Macías-Cervantes HE, Martínez-Ramírez DB, Hinojosa-Gutiérrez LR, et al. · Curr Probl Cardiol · 2024 · Derived
    PubMed: PMID 38000564 · NCT05998525 · Diabetes Mellitus, Type 2
  27. Racial Comparison of the Pharmacokinetics and Safety of Fixed-dose Combination of Dapagliflozin/Sitagliptin in Western and Korean Healthy Adults.
    Lukka PB, Tang W, Hammarstedt A, et al. · Clin Ther · 2024 · Derived
    PubMed: PMID 39179458 · NCT05266404
  28. ELUCIDATE Trial: A Single-Center Randomized Controlled Study.
    Lin JL, Liu SC, Liu TF, et al. · J Am Heart Assoc · 2024 · Derived
    PubMed: PMID 38639353 · NCT03871621 (ELUCIDATE) · Diabetes Mellitus, Type 2
  29. A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.
    Lapuerta P, Urbina S, He J, et al. · Clin Pharmacol Ther · 2024 · Derived
    PubMed: PMID 38456487 · NCT04956263 · Diabetes Mellitus
  30. Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.
    Koshino A, Schechter M, Chertow GM, et al. · NEJM Evid · 2024 · Derived
    PubMed: PMID 38320128 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  31. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.
    Kondo T, Mogensen UM, Talebi A, et al. · J Am Coll Cardiol · 2024 · Derived
    PubMed: PMID 38537918 · NCT03036124 (DAPA-HF) · Heart Failure
  32. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials.
    Kondo T, Gasparyan SB, Jhund PS, et al. · NEJM Evid · 2024 · Derived
    PubMed: PMID 38320525 · NCT03036124 (DAPA-HF) · Heart Failure
  33. Impact of Acute Insulin Resistance on Myocardial Blush in Non-Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention.
    Kasem SM, Saied GM, Hegazy ANM, et al. · Front Cardiovasc Med · 2024 · Derived
    PubMed: PMID 34041280 · NCT04385589 · Heart Failure
  34. Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study.
    Jeong IK, Choi KM, Han KA, et al. · Diabetes Obes Metab · 2024 · Derived
    PubMed: PMID 39223856 · NCT04356742 · Diabetes Mellitus, Type 2
  35. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.
    James S, Erlinge D, Storey RF, et al. · NEJM Evid · 2024 · Derived
    PubMed: PMID 38320489 · NCT04564742 (DAPA-MI) · Heart Failure
  36. Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction.
    Ibrahim A, Ghaleb R, Mansour H, et al. · Front Cardiovasc Med · 2024 · Derived
    PubMed: PMID 33426003 · NCT04385589 · Heart Failure
  37. Inhibition of Interleukin-33 to Reduce Glomerular Endothelial Inflammation in Diabetic Kidney Disease.
    Hofherr A, Liarte Marin E, Musial B, et al. · Kidney Int Rep · 2024 · Derived
    PubMed: PMID 38899206 · NCT04170543 · Diabetic Nephropathies
  38. Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial.
    Heerspink HJL, Stack AG, Terkeltaub R, et al. · J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 38564654 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  39. Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
    Heerspink HJL, Greasley PJ, Ahlström C, et al. · Nephrol Dial Transplant · 2024 · Derived
    PubMed: PMID 37632201 · NCT04724837 (ZENITH-CKD) · Renal Insufficiency, Chronic
  40. Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function.
    Hamdan Z, Abdel-Hafez Y, Enaya A, et al. · BMC Nephrol · 2024 · Derived
    PubMed: PMID 38279109 · NCT04923295
  41. The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF).
    Emara AN, Wadie M, Mansour NO, et al. · Eur J Pharmacol · 2024 · Derived
    PubMed: PMID 37923161 · NCT05406505
  42. Metformin for preventing the progression of chronic kidney disease.
    El-Damanawi R, Stanley IK, Staatz C, et al. · Cochrane Database Syst Rev · 2024 · Derived
    PubMed: PMID 38837240 · NCT03982381 (SMARTEST) · Diabetes Mellitus, Type 2
  43. Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.
    Dwibedi C, Ekström O, Brandt J, et al. · Nat Metab · 2024 · Derived
    PubMed: PMID 38177805 · NCT04451837
  44. Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials.
    Docherty KF, Buendia Lopez R, Folkvaljon F, et al. · Circ Heart Fail · 2024 · Derived
    PubMed: PMID 39212948 · NCT03877237
  45. Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy.
    Dihoum A, Brown AJ, McCrimmon RJ, et al. · BMC Cardiovasc Disord · 2024 · Derived
    PubMed: PMID 38997620 · NCT02956811 (DAPA-LVH) · Diabetes Mellitus, Type 2
  46. New guidelines and therapeutic updates for the management of lupus nephritis.
    Desai SB, Ahdoot R, Malik F, et al. · Curr Opin Nephrol Hypertens · 2024 · Derived
    PubMed: PMID 38334499 · NCT06113900 · Lupus Nephritis
  47. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure.
    Cox ZL, Collins SP, Hernandez GA, et al. · J Am Coll Cardiol · 2024 · Derived
    PubMed: PMID 38569758 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  48. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes.
    Cinti F, Leccisotti L, Sorice GP, et al. · Cardiovasc Diabetol · 2024 · Derived
    PubMed: PMID 38115004 · NCT03313752 (DapaHeart) · Diabetes Mellitus
  49. Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study.
    Cho YK, Kim KS, Lee BW, et al. · Clin Ther · 2024 · Derived
    PubMed: PMID 39068060 · NCT04885712
  50. Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production.
    Capece U, Pavanello C, Cinti F, et al. · Diabetes Ther · 2024 · Derived
    PubMed: PMID 37883003 · NCT03313752 (DapaHeart) · Diabetes Mellitus
  51. Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial.
    Bhatt AS, Kosiborod MN, Claggett BL, et al. · Eur J Heart Fail · 2024 · Derived
    PubMed: PMID 37771274 · NCT03619213 (DELIVER)
  52. Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study.
    Aldossary KM, Ali LS, Abdallah MS, et al. · Front Pharmacol · 2024 · Derived
    PubMed: PMID 38855751 · NCT05792540 · Depressive Disorder
  53. Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).
    Al-Ozairi E, Narula K, Miras AD, et al. · Trials · 2024 · Derived
    PubMed: PMID 38365744 · NCT05390307 (OTID) · Renal Insufficiency, Chronic
  54. Reducing chemical exposures at home: opportunities for action.
    Zota AR, Singla V, Adamkiewicz G, et al. · J Epidemiol Community Health · 2024 · Background
    PubMed: PMID 28756396 · NCT04242758 (PURITY) · Glucose Metabolism Disorders
  55. Safety Profile and Effectiveness of Dapagliflozin in Pediatric Patients with Chronic Kidney Disease.
    Van Reeth O, Caliment A, de la Fuente Garcia I, et al. · Am J Nephrol · 2024 · Background
    PubMed: PMID 38735286 · NCT07204743 · Proteinuria
  56. SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
    Ul Amin N, Sabir F, Amin T, et al. · Healthcare (Basel) · 2024 · Background
    PubMed: PMID 36553880 · NCT06012279
  57. Chinese expert consensus on the clinical application of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease.
    The Expert Group of Chinese Expert Consensus on the Clinical Application of Sodium-glucose Cotransporter 2 Inhibitors in Patients with Chronic Kidney Disease · Chin Med J (Engl) · 2024 · Background
    PubMed: PMID 38738698 · NCT06890143 · Proteinuria
  58. Efficacy of sodium-glucose cotransporter 2 inhibitors in preventing atrial fibrillation recurrence after catheter ablation.
    Stachteas P, Karakasis P, Karagiannidis E, et al. · Hellenic J Cardiol · 2024 · Background
    PubMed: PMID 38484841 · NCT06759909 · Atrial Fibrillation
  59. Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
    Siddiqui R, Obi Y, Dossabhoy NR, et al. · Curr Hypertens Rep · 2024 · Background
    PubMed: PMID 38913113 · NCT06759077 · Kidney Diseases
  60. Acetazolamide as an Adjunctive Diuretic Therapy for Patients with Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.
    Siddiqi AK, Maniya MT, Alam MT, et al. · Am J Cardiovasc Drugs · 2024 · Background
    PubMed: PMID 38416359 · NCT06535529
  61. Unlocking the Potential of Acetazolamide: A Literature Review of an Adjunctive Approach in Heart Failure Management.
    Sabina M, Barakat Z, Feliciano A, et al. · J Clin Med · 2024 · Background
    PubMed: PMID 38202295 · NCT06535529
  62. Trends in mortality related to kidney failure and diabetes mellitus in the United States: a 1999-2020 analysis.
    Rashid AM, Jamil A, Khan Z, et al. · J Nephrol · 2024 · Background
    PubMed: PMID 38916852 · NCT06759077 · Kidney Diseases
  63. Applications of SGLT2 inhibitors beyond glycaemic control.
    O'Hara DV, Lam CSP, McMurray JJV, et al. · Nat Rev Nephrol · 2024 · Background
    PubMed: PMID 38671190 · NCT06890143 · Proteinuria
  64. Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic and Non-Diabetic Patients with Advanced Chronic Kidney Disease in Peritoneal Dialysis on Residual Kidney Function: In Real-World Data.
    Moral Berrio E, De La Flor JC, Arambarri Segura M, et al. · Medicina (Kaunas) · 2024 · Background
    PubMed: PMID 39202480 · NCT06982079 · Renal Insufficiency, Chronic
  65. Effect of Acetazolamide as Add-On Diuretic Therapy in Patients With Heart Failure: A Meta-Analysis.
    Malik BA, Nnodebe I, Fayaz A, et al. · Cureus · 2024 · Background
    PubMed: PMID 37213994 · NCT06535529
  66. Effect of Dapagliflozin on the Outcome of Radiofrequency Catheter Ablation in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation.
    Luo F, Sun L, Wang Z, et al. · Cardiovasc Drugs Ther · 2024 · Background
    PubMed: PMID 35962156 · NCT06759909 · Atrial Fibrillation
  67. CKD-Associated Cardiovascular Mortality in the United States: Temporal Trends From 1999 to 2020.
    Kobo O, Abramov D, Davies S, et al. · Kidney Med · 2024 · Background
    PubMed: PMID 36814454 · NCT06759077 · Kidney Diseases
  68. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group · Kidney Int · 2024 · Background
    PubMed: PMID 38490803 · NCT06982079 · Renal Insufficiency, Chronic
  69. Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis.
    Hegde NC, Mishra A, Maiti R, et al. · Gen Hosp Psychiatry · 2024 · Background
    PubMed: PMID 38878592 · NCT07342764 · Psychotic Disorders
  70. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.
    Handelsman Y, Henry RR, Bloomgarden ZT, et al. · Endocr Pract · 2024 · Background
    PubMed: PMID 27082665 · NCT03968224 · Diabetes Mellitus, Type 2
  71. Apolipoprotein M Attenuates Anthracycline Cardiotoxicity and Lysosomal Injury.
    Guo Z, Valenzuela Ripoll C, Picataggi A, et al. · JACC Basic Transl Sci · 2024 · Background
    PubMed: PMID 37034289 · NCT07174687 · Eye Diseases
  72. SGLT2 inhibitors: approved for adults and cats but not for children with CKD.
    Gross O, Haffner D, Schaefer F, et al. · Nephrol Dial Transplant · 2024 · Background
    PubMed: PMID 38308509 · NCT05944016 (DOUBLE_PROTECT) · Nephritis, Hereditary
  73. Renal Function Tests
    Renal Function Tests · 2024 · Background
    PubMed: PMID 29939598 · NCT06113900 · Lupus Nephritis
  74. Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis.
    Chewcharat A, Prasitlumkum N, Thongprayoon C, et al. · Med Sci (Basel) · 2024 · Background
    PubMed: PMID 33213078 · NCT05374291 · Heart Failure
  75. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.
    Avula V, Sharma G, Kosiborod MN, et al. · JACC Heart Fail · 2024 · Background
    PubMed: PMID 37897456 · NCT06427226 · Breast Neoplasms

2023 (96 papers)

  1. Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value.
    Xie Y, Wei Y, Li D, et al. · J Cardiovasc Pharmacol · 2023 · Trial result
    PubMed: PMID 36607775 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  2. Canagliflozin, an Inhibitor of the Na+-Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia.
    Shim B, Stokum JA, Moyer M, et al. · Cells · 2023 · Trial result
    PubMed: PMID 37759444 · NCT06750458 · Glioma
  3. MRI-based brain tumor detection using convolutional deep learning methods and chosen machine learning techniques.
    Saeedi S, Rezayi S, Keshavarz H, et al. · BMC Med Inform Decis Mak · 2023 · Trial result
    PubMed: PMID 36691030 · NCT06750458 · Glioma
  4. The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease.
    Neijenhuis RML, Nederend M, Jongbloed MRM, et al. · Front Cardiovasc Med · 2023 · Trial result
    PubMed: PMID 37435053 · NCT06668389 (STEPS) · Heart Defects, Congenital
  5. Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction.
    Mustapic I, Bakovic D, Susilovic Grabovac Z, et al. · J Clin Med · 2023 · Trial result
    PubMed: PMID 36614843 · NCT06612086 · Hypertension, Pulmonary
  6. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    McDonagh TA, Metra M, Adamo M, et al. · Eur Heart J · 2023 · Trial result
    PubMed: PMID 37622666 · NCT06668389 (STEPS) · Heart Defects, Congenital
  7. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review.
    Lopaschuk GD, Verma S · JACC Basic Transl Sci · 2023 · Trial result
    PubMed: PMID 32613148 · NCT04780438 · Atrial Fibrillation
  8. Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
    Koshino A, Neuen BL, Jongs N, et al. · Cardiovasc Diabetol · 2023 · Trial result
    PubMed: PMID 38017482 · NCT06820567 · Diabetes Mellitus, Type 2
  9. Prognostic value of N-terminal pro-form B-type natriuretic peptide (NT-proBNP) in patients with congenital heart disease undergoing cardiac surgery: a systematic review and meta-analysis of cohort studies.
    Gong Z, Xing D, Wu R, et al. · Cardiovasc Diagn Ther · 2023 · Trial result
    PubMed: PMID 36605072 · NCT06668389 (STEPS) · Heart Defects, Congenital
  10. The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell-mediated graft-versus-host disease.
    Cheng Q, Wang D, Lai X, et al. · Blood · 2023 · Trial result
    PubMed: PMID 36574342 · NCT06626737 (DAPALAG-01) · Graft vs Host Disease
  11. Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure.
    Chen K, Nie Z, Shi R, et al. · JAMA Netw Open · 2023 · Trial result
    PubMed: PMID 37615988 · NCT06668389 (STEPS) · Heart Defects, Congenital
  12. Pharmacokinetic Properties of Dapagliflozin in Hemodialysis and Peritoneal Dialysis Patients.
    Barreto J, Borges C, Rodrigues TB, et al. · Clin J Am Soc Nephrol · 2023 · Trial result
    PubMed: PMID 37227937 · NCT06398977
  13. Pharmacokinetic Variables of Dapagliflozin/Metformin Extended-release Fixed-dose Combination in Healthy Chinese Volunteers and Regional Comparison.
    Zhao X, Ning R, Hui A, et al. · Clin Ther · 2023 · Derived
    PubMed: PMID 37442656 · NCT04856007
  14. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.
    Zelniker TA, Wiviott SD, Mosenzon O, et al. · JAMA Cardiol · 2023 · Derived
    PubMed: PMID 36857035 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  15. Comparative study of Dapagliflozin versus Glimepiride effect on insulin regulated aminopeptidase (IRAP) and interleukin-34 (IL-34) in patient with type 2 diabetes mellitus.
    Zekry R, Omran GA, El-Gharbawy NM, et al. · Sci Rep · 2023 · Derived
    PubMed: PMID 37072577 · NCT04240171 · Diabetes Mellitus, Type 2
  16. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics.
    Yeoh SE, Osmanska J, Petrie MC, et al. · Eur Heart J · 2023 · Derived
    PubMed: PMID 37210742 · NCT04860011 (DAPARESIST) · Heart Failure
  17. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
    Yeoh SE, Docherty KF, Campbell RT, et al. · Circulation · 2023 · Derived
    PubMed: PMID 37039015 · NCT03036124 (DAPA-HF) · Heart Failure
  18. The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial.
    Willigers BJA, Ouwens M, Briggs A, et al. · Adv Ther · 2023 · Derived
    PubMed: PMID 37071317 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  19. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial.
    Veelen A, Andriessen C, Op den Kamp Y, et al. · Metabolism · 2023 · Derived
    PubMed: PMID 36592688 · NCT03721874 (MaasFlex) · Prediabetic State
  20. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
    Vart P, Vaduganathan M, Jongs N, et al. · Clin J Am Soc Nephrol · 2023 · Derived
    PubMed: PMID 36414316 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  21. Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial.
    Vart P, Jongs N, Wheeler DC, et al. · JAMA Netw Open · 2023 · Derived
    PubMed: PMID 37103935 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  22. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.
    Vardeny O, Fang JC, Desai AS, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 36522606 · NCT03619213 (DELIVER)
  23. Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction.
    Vaduganathan M, Claggett BL, Jhund P, et al. · J Am Coll Cardiol · 2023 · Derived
    PubMed: PMID 36889870 · NCT03619213 (DELIVER)
  24. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure.
    Vaduganathan M, Claggett BL, Jhund P, et al. · J Am Coll Cardiol · 2023 · Derived
    PubMed: PMID 36041669 · NCT03619213 (DELIVER)
  25. Dapagliflozin in patients with critical illness: rationale and design of the DEFENDER study.
    Tavares CAM, Azevedo LCP, Rea-Neto Á, et al. · Crit Care Sci · 2023 · Derived
    PubMed: PMID 38133155 · NCT05558098 (DEFENDER) · Critical Illness
  26. Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis.
    Staef M, Ott C, Kannenkeril D, et al. · Sci Rep · 2023 · Derived
    PubMed: PMID 37268640 · NCT02383238 (Dapa) · Diabetes Mellitus, Type 2
  27. Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.
    Sorice GP, Cinti F, Leccisotti L, et al. · Diabetes Ther · 2023 · Derived
    PubMed: PMID 34037951 · NCT03313752 (DapaHeart) · Diabetes Mellitus
  28. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER.
    Selvaraj S, Vaduganathan M, Claggett BL, et al. · JACC Heart Fail · 2023 · Derived
    PubMed: PMID 36599553 · NCT03619213 (DELIVER)
  29. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
    Selvaraj S, Fu Z, Jones P, et al. · Circulation · 2023 · Derived
    PubMed: PMID 35603596 · NCT02653482 (DEFINE-HF) · Heart Failure
  30. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
    Schechter M, Wiviott SD, Raz I, et al. · Lancet Diabetes Endocrinol · 2023 · Derived
    PubMed: PMID 36878239 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  31. Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.
    Schechter M, Jongs N, Chertow GM, et al. · Ann Intern Med · 2023 · Derived
    PubMed: PMID 36469914 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  32. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Rovin BH, Barratt J, Heerspink HJL, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37931634 · NCT03762850 (PROTECT) · Glomerulonephritis, IGA
  33. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status.
    Peikert A, Goyal P, Vaduganathan M, et al. · JACC Heart Fail · 2023 · Derived
    PubMed: PMID 37294244 · NCT03619213 (DELIVER)
  34. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial.
    Peikert A, Chandra A, Kosiborod MN, et al. · JAMA Cardiol · 2023 · Derived
    PubMed: PMID 37208998 · NCT03619213 (DELIVER)
  35. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study.
    Pascual-Figal DA, Zamorano JL, Domingo M, et al. · Eur J Heart Fail · 2023 · Derived
    PubMed: PMID 37211950 · NCT04707352 (MODA) · Heart Failure
  36. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
    Ostrominski JW, Vaduganathan M, Selvaraj S, et al. · Circulation · 2023 · Derived
    PubMed: PMID 37830208 · NCT03619213 (DELIVER)
  37. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
    Ostrominski JW, Thierer J, Claggett BL, et al. · JACC Heart Fail · 2023 · Derived
    PubMed: PMID 37226448 · NCT03619213 (DELIVER)
  38. Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations.
    Obadina M, Wilson S, Derebail VK, et al. · Kidney360 · 2023 · Derived
    PubMed: PMID 37254256 · NCT03762850 (PROTECT) · Glomerulonephritis, IGA
  39. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
    Nassif ME, Windsor SL, Gosch K, et al. · Circ Heart Fail · 2023 · Derived
    PubMed: PMID 37203441 · NCT02653482 (DEFINE-HF) · Heart Failure
  40. Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension.
    Moon JS, Park IR, Kim HJ, et al. · Diabetes Metab J · 2023 · Derived
    PubMed: PMID 37750183 · NCT04170998
  41. Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.
    McEwan P, Darlington O, Miller R, et al. · Clin J Am Soc Nephrol · 2023 · Derived
    PubMed: PMID 36323444 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  42. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.
    Mc Causland FR, Claggett BL, Vaduganathan M, et al. · JAMA Cardiol · 2023 · Derived
    PubMed: PMID 36326604 · NCT03619213 (DELIVER)
  43. Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes.
    Mathieu C, Catrinoiu D, Ranetti AE, et al. · Diabetes Ther · 2023 · Derived
    PubMed: PMID 29802530 · NCT01646320 · Diabetes Mellitus, Type 2
  44. Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF.
    Lewis GD, Gosch K, Cohen LP, et al. · Circ Heart Fail · 2023 · Derived
    PubMed: PMID 37869881 · NCT03030235 (PRESERVED-HF) · Heart Failure
  45. Effects of two- and twelve-weeks sodium-glucose cotransporter 2 inhibition on DNA and RNA oxidation: two randomized, placebo-controlled trials.
    Larsen EL, Andersen A, Kjær LK, et al. · Free Radic Res · 2023 · Derived
    PubMed: PMID 37171199 · NCT02914691 (DapKid) · Diabetes Mellitus, Type 2
  46. Dapagliflozin for inpatient hyperglycemia in cardiac surgery patients with type 2 diabetes: randomised controlled trial (Dapa-Hospital trial).
    Kuchay MS, Khatana P, Mishra M, et al. · Acta Diabetol · 2023 · Derived
    PubMed: PMID 37380728 · NCT05457933 · Coronary Artery Disease
  47. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
    Kosiborod MN, Bhatt AS, Claggett BL, et al. · J Am Coll Cardiol · 2023 · Derived
    PubMed: PMID 36526515 · NCT03619213 (DELIVER)
  48. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.
    Kondo T, Jering KS, Borleffs CJW, et al. · Circulation · 2023 · Derived
    PubMed: PMID 36876483 · NCT03619213 (DELIVER)
  49. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
    Kondo T, Butt JH, Curtain JP, et al. · Circ Heart Fail · 2023 · Derived
    PubMed: PMID 37886880 · NCT03619213 (DELIVER)
  50. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial.
    Jhund PS, Claggett BL, Talebi A, et al. · JAMA Cardiol · 2023 · Derived
    PubMed: PMID 37099283 · NCT03619213 (DELIVER)
  51. Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction.
    James S, Erlinge D, Storey RF, et al. · Am Heart J · 2023 · Derived
    PubMed: PMID 37648579 · NCT04564742 (DAPA-MI) · Heart Failure
  52. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
    Heerspink HJL, Radhakrishnan J, Alpers CE, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37015244 · NCT03762850 (PROTECT) · Glomerulonephritis, IGA
  53. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
    Heerspink HJL, Kiyosue A, Wheeler DC, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37931629 · NCT04724837 (ZENITH-CKD) · Renal Insufficiency, Chronic
  54. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
    Heerspink HJL, Jongs N, Schloemer P, et al. · J Am Soc Nephrol · 2023 · Derived
    PubMed: PMID 37872654 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  55. Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial.
    Han KA, Kim YH, Kim DM, et al. · Diabetes Metab J · 2023 · Derived
    PubMed: PMID 36756676 · NCT04634500 (ENHANCE-M) · Diabetes Mellitus, Type 2
  56. Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport-2 inhibitor.
    Gill M, Leung M, Luo CY, et al. · Clin Transplant · 2023 · Derived
    PubMed: PMID 37170711 · NCT05374291 · Heart Failure
  57. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
    Fletcher RA, Jongs N, Chertow GM, et al. · J Am Soc Nephrol · 2023 · Derived
    PubMed: PMID 37876229 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  58. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure.
    Docherty KF, McDowell K, Welsh P, et al. · J Am Coll Cardiol · 2023 · Derived
    PubMed: PMID 37407113 · NCT03036124 (DAPA-HF) · Heart Failure
  59. Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial).
    Dayem KA, Younis O, Zarif B, et al. · Int J Cardiol · 2023 · Derived
    PubMed: PMID 36889650 · NCT05424315 (DACAMI) · Heart Failure
  60. Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial.
    Chertow GM, Correa-Rotter R, Vart P, et al. · J Am Heart Assoc · 2023 · Derived
    PubMed: PMID 37119064 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  61. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.
    Chatur S, Vaduganathan M, Claggett BL, et al. · J Am Coll Cardiol · 2023 · Derived
    PubMed: PMID 37634707 · NCT03619213 (DELIVER)
  62. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
    Chatur S, Vaduganathan M, Claggett BL, et al. · Circulation · 2023 · Derived
    PubMed: PMID 37632455 · NCT03619213 (DELIVER)
  63. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
    Chatur S, Vaduganathan M, Claggett B, et al. · Eur Heart J · 2023 · Derived
    PubMed: PMID 37220093 · NCT03619213 (DELIVER)
  64. Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF.
    Chatur S, Kondo T, Claggett BL, et al. · Eur J Heart Fail · 2023 · Derived
    PubMed: PMID 37210608 · NCT03619213 (DELIVER)
  65. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial.
    Chatur S, Cunningham JW, Vaduganathan M, et al. · Eur J Heart Fail · 2023 · Derived
    PubMed: PMID 37212168 · NCT03619213 (DELIVER)
  66. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER.
    Butt JH, Lu H, Kondo T, et al. · Eur J Heart Fail · 2023 · Derived
    PubMed: PMID 37634087 · NCT03619213 (DELIVER)
  67. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Butt JH, Kondo T, Yang M, et al. · Eur Heart J · 2023 · Derived
    PubMed: PMID 37220172 · NCT03036124 (DAPA-HF) · Heart Failure
  68. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction.
    Butt JH, Docherty KF, Kosiborod MN, et al. · JACC Heart Fail · 2023 · Derived
    PubMed: PMID 37318419 · NCT03036124 (DAPA-HF) · Heart Failure
  69. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.
    Butt JH, Docherty KF, Claggett BL, et al. · JAMA Cardiol · 2023 · Derived
    PubMed: PMID 36811901 · NCT03036124 (DAPA-HF) · Heart Failure
  70. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum.
    Butt JH, Docherty KF, Claggett BL, et al. · JACC Heart Fail · 2023 · Derived
    PubMed: PMID 36881399 · NCT03619213 (DELIVER)
  71. Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
    Borlaug BA, Reddy YNV, Braun A, et al. · Circulation · 2023 · Derived
    PubMed: PMID 37534453 · NCT04730947
  72. Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVER.
    Bhatt AS, Lindholm D, Nilsson A, et al. · Am Heart J · 2023 · Derived
    PubMed: PMID 37220822 · NCT03619213 (DELIVER)
  73. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
    Bhatt AS, Kosiborod MN, Vaduganathan M, et al. · Eur J Heart Fail · 2023 · Derived
    PubMed: PMID 37211977 · NCT03036124 (DAPA-HF) · Heart Failure
  74. Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial.
    Bartholdy KV, Johansen ND, Landler N, et al. · Kidney360 · 2023 · Derived
    PubMed: PMID 36649484 · NCT05359263 (DECODE-CKD) · Renal Insufficiency, Chronic
  75. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF.
    Adamson C, Welsh P, Docherty KF, et al. · JACC Heart Fail · 2023 · Derived
    PubMed: PMID 36592046 · NCT03036124 (DAPA-HF) · Heart Failure
  76. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group.
    Wechalekar AD, Cibeira MT, Gibbs SD, et al. · Amyloid · 2023 · Background
    PubMed: PMID 35838162 · NCT06297681
  77. Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
    Verma S, Rawat S, Ho KL, et al. · JACC Basic Transl Sci · 2023 · Background
    PubMed: PMID 30456329 · NCT05719714 · Heart Failure
  78. Nephrotic Syndrome
    Nephrotic Syndrome · 2023 · Background
    PubMed: PMID 29262216 · NCT05966818 · Proteinuria
  79. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
    Suzuki K, Wechalekar AD, Kim K, et al. · Ann Hematol · 2023 · Background
    PubMed: PMID 36862168 · NCT06297681
  80. MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT.
    Sada K, Kurita N, Noma H, et al. · Lupus Sci Med · 2023 · Background
    PubMed: PMID 37017254 · NCT06113900 · Lupus Nephritis
  81. Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association.
    Rychik J, Atz AM, Celermajer DS, et al. · Circulation · 2023 · Background
    PubMed: PMID 31256636 · NCT05741658 (FonDap) · Heart Failure
  82. UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE.
    Roddick AJ, Wonnacott A, Webb D, et al. · BMC Nephrol · 2023 · Background
    PubMed: PMID 37880609 · NCT06982079 · Renal Insufficiency, Chronic
  83. Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction.
    Ortega-Paz L, Cristóbal H, Ortiz-Perez JT, et al. · ESC Heart Fail · 2023 · Background
    PubMed: PMID 36303443 · NCT06619600 (DAPA-STEMI) · Diabetes Mellitus
  84. Early Clinical Experience with Dapagliflozin in Children with Heart Failure.
    Newland DM, Law YM, Albers EL, et al. · Pediatr Cardiol · 2023 · Background
    PubMed: PMID 35948644 · NCT07482943 · Heart Failure
  85. Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice.
    Mullens W, Schulze PC, Westphal J, et al. · Eur Heart J · 2023 · Background
    PubMed: PMID 37207453 · NCT06535529
  86. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
    Minnema MC, Dispenzieri A, Merlini G, et al. · JACC CardioOncol · 2023 · Background
    PubMed: PMID 36444227 · NCT06297681
  87. SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies.
    Ma Y, Zhao Q, Peng H, et al. · Front Biosci (Landmark Ed) · 2023 · Background
    PubMed: PMID 37258468 · NCT06113900 · Lupus Nephritis
  88. Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond.
    Lahoti S, Nashawi M, Sheikh O, et al. · Cardiovasc Endocrinol Metab · 2023 · Background
    PubMed: PMID 33634250 · NCT05310916 · Diabetic Retinopathy
  89. Diuretic, natriuretic, and chloride-regaining effects of oral acetazolamide as an add-on therapy for acute heart failure with volume overload: a single-center, prospective, randomized study.
    Kosiorek A, Urban S, Detyna J, et al. · Pol Arch Intern Med · 2023 · Background
    PubMed: PMID 37415505 · NCT06535529
  90. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
    Fitchett D, Zinman B, Wanner C, et al. · Eur Heart J · 2023 · Background
    PubMed: PMID 26819227 · NCT06286878 · Diabetes Mellitus
  91. The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers.
    Demir ME, Özler TE, Merhametsiz Ö, et al. · Int Urol Nephrol · 2023 · Background
    PubMed: PMID 37289399 · NCT07555106 (DAPA-GRAFT)
  92. Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
    De La Flor JC, Villa D, Cruzado L, et al. · Biomedicines · 2023 · Background
    PubMed: PMID 37509547 · NCT06982079 · Renal Insufficiency, Chronic
  93. [Guidelines for the early evaluation and management of chronic kidney disease in China].
    Chinese Preventive Medicine Association for Kidney Disease · Zhonghua Nei Ke Za Zhi · 2023 · Background
    PubMed: PMID 37528029 · NCT06890143 · Proteinuria
  94. Cardio-protective effect of dapagliflozin against doxorubicin induced cardiomyopathy in rats.
    Belen E, Canbolat IP, Yigittürk G, et al. · Eur Rev Med Pharmacol Sci · 2023 · Background
    PubMed: PMID 35776041 · NCT06427226 · Breast Neoplasms
  95. Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial.
    Adamstein NH, Cornel JH, Davidson M, et al. · JAMA Cardiol · 2023 · Background
    PubMed: PMID 36449307 · NCT06364930 · Hepatitis B, Chronic
  96. A Clinical and Preclinical Assessment of Clinical Trials for Dry Age-Related Macular Degeneration.
    Abidi M, Karrer E, Csaky K, et al. · Ophthalmol Sci · 2023 · Background
    PubMed: PMID 36570624 · NCT07174687 · Eye Diseases

2022 (95 papers)

  1. Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling.
    Wu J, Liu T, Shi S, et al. · Cardiovasc Diabetol · 2022 · Trial result
    PubMed: PMID 36171554 · NCT06668389 (STEPS) · Heart Defects, Congenital
  2. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW, Vart P, Cherney DZI, et al. · Diabetologia · 2022 · Trial result
    PubMed: PMID 35445820 · NCT06890143 · Proteinuria
  3. The role of cardiopulmonary exercise testing in predicting mortality and morbidity in people with congenital heart disease: a systematic review and meta-analysis.
    Wadey CA, Weston ME, Dorobantu DM, et al. · Eur J Prev Cardiol · 2022 · Trial result
    PubMed: PMID 34405863 · NCT06668389 (STEPS) · Heart Defects, Congenital
  4. Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
    Verma S, Garg A, Yan AT, et al. · Diabetes Care · 2022 · Trial result
    PubMed: PMID 27679584 · NCT03658031 · Diabetes Mellitus, Type 2
  5. Associations between blood biomarkers, cardiac function and adverse outcome in a young tetralogy of Fallot cohort.
    van den Bosch E, van Genuchten WJ, Luijnenburg SE, et al. · Int J Cardiol · 2022 · Trial result
    PubMed: PMID 35487320 · NCT06668389 (STEPS) · Heart Defects, Congenital
  6. Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects.
    Takashima M, Nakamura K, Kiyohara T, et al. · Commun Biol · 2022 · Trial result
    PubMed: PMID 35780235 · NCT06750458 · Glioma
  7. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
    Solomon SD, Vaduganathan M, Claggett BL, et al. · JACC Heart Fail · 2022 · Trial result
    PubMed: PMID 35241246 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  8. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    Solomon SD, McMurray JJV, Claggett B, et al. · N Engl J Med · 2022 · Trial result
    PubMed: PMID 36027570 · NCT05759000 · Heart Failure
  9. Predicting Survival in Repaired Tetralogy of Fallot: A Lesion-Specific and Personalized Approach.
    Ghonim S, Gatzoulis MA, Ernst S, et al. · JACC Cardiovasc Imaging · 2022 · Trial result
    PubMed: PMID 34656466 · NCT06668389 (STEPS) · Heart Defects, Congenital
  10. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
    Filippatos G, Anker SD, Agarwal R, et al. · Circulation · 2022 · Trial result
    PubMed: PMID 34775784 · NCT07351864 (FIN-SGLT2-HF) · Heart Failure
  11. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control.
    Cowie MR, Fisher M · Nat Rev Cardiol · 2022 · Trial result
    PubMed: PMID 32665641 · NCT04717986 (DAPA-AMI) · Heart Failure
  12. Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification.
    Bjergfelt SS, Sørensen IMH, Hjortkjær HØ, et al. · PLoS One · 2022 · Trial result
    PubMed: PMID 34813630 · NCT05565976 (DECIST) · Cognitive Dysfunction
  13. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.
    Amat-Santos IJ, Sánchez-Luna JP, Abu-Assi E, et al. · Eur J Heart Fail · 2022 · Trial result
    PubMed: PMID 34693613 · NCT04696185 (DapaTAVI) · Aortic Valve Stenosis
  14. Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients.
    Zeng J, Zhu Y, Zhao W, et al. · Cardiovasc Drugs Ther · 2022 · Derived
    PubMed: PMID 33779938 · NCT04707261 (ADIDAS) · Heart Failure
  15. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA, Raz I, Mosenzon O, et al. · JAMA Cardiol · 2022 · Derived
    PubMed: PMID 33851953 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  16. Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.
    Yeoh SE, Docherty KF, Jhund PS, et al. · JACC Heart Fail · 2022 · Derived
    PubMed: PMID 35483792 · NCT03036124 (DAPA-HF) · Heart Failure
  17. Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.
    Vart P, Correa-Rotter R, Hou FF, et al. · Kidney Int Rep · 2022 · Derived
    PubMed: PMID 35497805 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  18. Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.
    van Ruiten CC, Veltman DJ, Schrantee A, et al. · J Clin Endocrinol Metab · 2022 · Derived
    PubMed: PMID 35134184 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  19. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
    van Ruiten CC, Smits MM, Kok MD, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 35484607 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  20. Whole-body insulin clearance in people with type 2 diabetes and normal kidney function: Relationship with glomerular filtration rate, renal plasma flow, and insulin sensitivity.
    van Baar MJB, van Bommel EJM, Smits MM, et al. · J Diabetes Complications · 2022 · Derived
    PubMed: PMID 35221224 · NCT02682563 (RED) · Diabetes Mellitus, Type 2
  21. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
    Vaduganathan M, Claggett BL, Jhund P, et al. · JAMA Cardiol · 2022 · Derived
    PubMed: PMID 36190011 · NCT03619213 (DELIVER)
  22. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.
    Tamborlane WV, Laffel LM, Shehadeh N, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 35378069 · NCT02725593 · Diabetes Mellitus, Type 2
  23. A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol.
    Sundström J, Kristófi R, Östlund O, et al. · J Diabetes Complications · 2022 · Derived
    PubMed: PMID 34389234 · NCT03982381 (SMARTEST) · Diabetes Mellitus, Type 2
  24. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.
    Suijk DLS, van Baar MJB, van Bommel EJM, et al. · Clin J Am Soc Nephrol · 2022 · Derived
    PubMed: PMID 35322793 · NCT02682563 (RED) · Diabetes Mellitus, Type 2
  25. The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet.
    Scholtes RA, Muskiet MHA, van Baar MJB, et al. · Kidney Int Rep · 2022 · Derived
    PubMed: PMID 35570989 · NCT03152084 (DAPASALT) · Diabetes Mellitus, Type 2
  26. Is the impact of add on heart failure therapy influenced by background therapy?
    Rydén L, Ferrannini G · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 34861151 · NCT03036124 (DAPA-HF) · Heart Failure
  27. A multicenter program for electronic health record screening for patients with heart failure with preserved ejection fraction: Lessons from the DELIVER-EHR initiative.
    Peters AE, Ogunniyi MO, Hegde SM, et al. · Contemp Clin Trials · 2022 · Derived
    PubMed: PMID 36100197 · NCT03619213 (DELIVER)
  28. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.
    Peikert A, Martinez FA, Vaduganathan M, et al. · Circ Heart Fail · 2022 · Derived
    PubMed: PMID 36029467 · NCT03619213 (DELIVER)
  29. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
    Oyama K, Raz I, Cahn A, et al. · Eur Heart J · 2022 · Derived
    PubMed: PMID 34427295 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  30. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Oyama K, Raz I, Cahn A, et al. · JAMA Cardiol · 2022 · Derived
    PubMed: PMID 35857296 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  31. Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism.
    Op den Kamp YJM, Gemmink A, de Ligt M, et al. · Mol Metab · 2022 · Derived
    PubMed: PMID 36280113 · NCT03338855 (DAPAMAAST) · Diabetes Mellitus, Type 2
  32. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
    O'Donoghue ML, Kato ET, Mosenzon O, et al. · Diabetologia · 2022 · Derived
    PubMed: PMID 33611623 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  33. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
    Myhre PL, Vaduganathan M, Claggett BL, et al. · JACC Heart Fail · 2022 · Derived
    PubMed: PMID 36114137 · NCT03619213 (DELIVER)
  34. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
    Mosenzon O, Raz I, Wiviott SD, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 35997319 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  35. Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.
    Melin J, Tang W, Rekić D, et al. · J Clin Pharmacol · 2022 · Derived
    PubMed: PMID 35403243 · NCT01498185 · Diabetes Mellitus, Type 1
  36. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.
    Leccisotti L, Cinti F, Sorice GP, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 36057768 · NCT03313752 (DapaHeart) · Diabetes Mellitus
  37. Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes.
    Kannenkeril D, Jung S, Harazny J, et al. · J Diabetes Complications · 2022 · Derived
    PubMed: PMID 34620556 · NCT02383238 (Dapa) · Diabetes Mellitus, Type 2
  38. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.
    Jongs N, Chertow GM, Greene T, et al. · J Am Soc Nephrol · 2022 · Derived
    PubMed: PMID 35977807 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  39. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial.
    Inzucchi SE, Claggett BL, Vaduganathan M, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 36372069 · NCT03619213 (DELIVER)
  40. Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD.
    Heerspink HJL, Law G, Psachoulia K, et al. · Kidney Int Rep · 2022 · Derived
    PubMed: PMID 34805632 · NCT04492722 · Diabetes Mellitus
  41. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
    Gessner A, Gemeinhardt A, Bosch A, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 34991562 · NCT02383238 (Dapa) · Diabetes Mellitus, Type 2
  42. Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial.
    Gasparyan SB, Buenconsejo J, Kowalewski EK, et al. · Ther Innov Regul Sci · 2022 · Derived
    PubMed: PMID 35699910 · NCT04350593 (DARE-19) · COVID-19
  43. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
    Furtado RHM, Raz I, Goodrich EL, et al. · Circulation · 2022 · Derived
    PubMed: PMID 35510542 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  44. The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial.
    Færch K, Blond MB, Bruhn L, et al. · Diabetologia · 2022 · Derived
    PubMed: PMID 33064182 · NCT02695810 · Obesity
  45. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
    Docherty KF, Welsh P, Verma S, et al. · Circulation · 2022 · Derived
    PubMed: PMID 35971840 · NCT03036124 (DAPA-HF) · Heart Failure
  46. Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.
    Docherty KF, Simpson J, Jhund PS, et al. · JACC Heart Fail · 2022 · Derived
    PubMed: PMID 35115084 · NCT03036124 (DAPA-HF) · Heart Failure
  47. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.
    Docherty KF, Ogunniyi MO, Anand IS, et al. · JACC Heart Fail · 2022 · Derived
    PubMed: PMID 34969498 · NCT03036124 (DAPA-HF) · Heart Failure
  48. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
    Docherty KF, Jhund PS, Claggett B, et al. · JAMA Cardiol · 2022 · Derived
    PubMed: PMID 34319398 · NCT03036124 (DAPA-HF) · Heart Failure
  49. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
    Docherty KF, Anand IS, Chiang CE, et al. · JACC Asia · 2022 · Derived
    PubMed: PMID 36339117 · NCT03036124 (DAPA-HF) · Heart Failure
  50. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER.
    Desai AS, Jhund PS, Claggett BL, et al. · JAMA Cardiol · 2022 · Derived
    PubMed: PMID 36189985 · NCT03619213 (DELIVER)
  51. Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial.
    Curovic VR, Eickhoff MK, Rönkkö T, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 35998283 · NCT02914691 (DapKid) · Diabetes Mellitus, Type 2
  52. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.
    Cunningham JW, Vaduganathan M, Claggett BL, et al. · J Am Coll Cardiol · 2022 · Derived
    PubMed: PMID 36041912 · NCT03619213 (DELIVER)
  53. Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial.
    Cintra RMR, Soares AAS, Breder I, et al. · Diabetol Metab Syndr · 2022 · Derived
    PubMed: PMID 31384310 · NCT02919345 (ADDENDA) · Diabetes Mellitus, Type 2
  54. Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
    Cheng H, Zhang Z, Zhang B, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 35263425 · NCT03961659 · Diabetes Mellitus, Type 2
  55. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58.
    Cahn A, Wiviott SD, Mosenzon O, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 35015847 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  56. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.
    Butt JH, Kondo T, Jhund PS, et al. · J Am Coll Cardiol · 2022 · Derived
    PubMed: PMID 36041668 · NCT03619213 (DELIVER)
  57. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.
    Butt JH, Jhund PS, Belohlávek J, et al. · Circulation · 2022 · Derived
    PubMed: PMID 36029465 · NCT03619213 (DELIVER)
  58. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
    Butt JH, Docherty KF, Petrie MC, et al. · JAMA Cardiol · 2022 · Derived
    PubMed: PMID 33787831 · NCT03036124 (DAPA-HF) · Heart Failure
  59. Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.
    Butt JH, Dewan P, Merkely B, et al. · Ann Intern Med · 2022 · Derived
    PubMed: PMID 35467935 · NCT03036124 (DAPA-HF) · Heart Failure
  60. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF.
    Butt JH, Dewan P, DeFilippis EM, et al. · JACC Heart Fail · 2022 · Derived
    PubMed: PMID 35902157 · NCT03036124 (DAPA-HF) · Heart Failure
  61. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
    Butt JH, Adamson C, Docherty KF, et al. · Circ Heart Fail · 2022 · Derived
    PubMed: PMID 34802253 · NCT03036124 (DAPA-HF) · Heart Failure
  62. SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes.
    Boeder SC, Gregory JM, Giovannetti ER, et al. · Diabetes · 2022 · Derived
    PubMed: PMID 34857545 · NCT03704818
  63. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
    Berg DD, Jhund PS, Docherty KF, et al. · JAMA Cardiol · 2022 · Derived
    PubMed: PMID 33595593 · NCT03036124 (DAPA-HF) · Heart Failure
  64. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
    Berg DD, Docherty KF, Sattar N, et al. · Circulation · 2022 · Derived
    PubMed: PMID 34743554 · NCT03036124 (DAPA-HF) · Heart Failure
  65. Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D).
    Ang L, Kidwell KM, Dillon B, et al. · J Diabetes Complications · 2022 · Derived
    PubMed: PMID 34024686 · NCT02973477 · Cardiovascular Diseases
  66. Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
    Alatrach M, Agyin C, Solis-Herrera C, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 35235659 · NCT03331289 · Diabetes Mellitus, Type 2
  67. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.
    Adamson C, Jhund PS, Docherty KF, et al. · Eur J Heart Fail · 2022 · Derived
    PubMed: PMID 34272791 · NCT03036124 (DAPA-HF) · Heart Failure
  68. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.
    Adamson C, Docherty KF, Heerspink HJL, et al. · Circulation · 2022 · Derived
    PubMed: PMID 35442064 · NCT03036124 (DAPA-HF) · Heart Failure
  69. Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF.
    Adamson C, Cowan LM, de Boer RA, et al. · Eur J Heart Fail · 2022 · Derived
    PubMed: PMID 36054568 · NCT03036124 (DAPA-HF) · Heart Failure
  70. Apolipoprotein M promotes cholesterol uptake and efflux from mouse macrophages.
    Yao S, Zheng F, Yu Y, et al. · FEBS Open Bio · 2022 · Background
    PubMed: PMID 33830664 · NCT07174687 · Eye Diseases
  71. Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model.
    Xu X, Sun Y, Cen X, et al. · Protein Cell · 2022 · Background
    PubMed: PMID 34291435 · NCT05262257
  72. Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study.
    Wilding J, Bailey C, Rigney U, et al. · Diabetes Ther · 2022 · Background
    PubMed: PMID 27585582 · NCT03968224 · Diabetes Mellitus, Type 2
  73. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
    Sanchorawala V, Palladini G, Minnema MC, et al. · Am J Hematol · 2022 · Background
    PubMed: PMID 35293006 · NCT06297681
  74. The Epidemiology of Persons Living with Fontan in 2020 and Projections for 2030: Development of an Epidemiology Model Providing Multinational Estimates.
    Plappert L, Edwards S, Senatore A, et al. · Adv Ther · 2022 · Background
    PubMed: PMID 34936056 · NCT07482943 · Heart Failure
  75. Comparison of Myocardial Deformation by Speckle-Tracking Echocardiography and Cardiac Magnetic Resonance in Patients with Fontan Circulation: Diagnostic Algorithm.
    Pascual ES, Zurita MB, Sebastián JD, et al. · J Cardiovasc Echogr · 2022 · Background
    PubMed: PMID 34900549 · NCT07482943 · Heart Failure
  76. B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab.
    Parodis I, Gomez A, Lindblom J, et al. · Int J Mol Sci · 2022 · Background
    PubMed: PMID 36430417 · NCT06113900 · Lupus Nephritis
  77. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease.
    Ohara K, Masuda T, Morinari M, et al. · Diabetol Metab Syndr · 2022 · Background
    PubMed: PMID 32377235 · NCT04385589 · Heart Failure
  78. Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice.
    Nguyen T, Wen S, Gong M, et al. · Diabetes Metab Syndr Obes · 2022 · Background
    PubMed: PMID 32848437 · NCT05262257
  79. Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure.
    Muneuchi J, Sugitani Y, Kobayashi M, et al. · Case Rep Cardiol · 2022 · Background
    PubMed: PMID 36530388 · NCT07482943 · Heart Failure
  80. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.
    Mullens W, Dauw J, Martens P, et al. · N Engl J Med · 2022 · Background
    PubMed: PMID 36027559 · NCT06535529
  81. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
    McGuire DK, Shih WJ, Cosentino F, et al. · JAMA Cardiol · 2022 · Background
    PubMed: PMID 33031522 · NCT06759077 · Kidney Diseases
  82. The role of metformin in treatment of weight gain associated with atypical antipsychotic treatment in children and adolescents: A systematic review and meta-analysis of randomized controlled trials.
    Mansuri Z, Makani R, Trivedi C, et al. · Front Psychiatry · 2022 · Background
    PubMed: PMID 36458118 · NCT07342764 · Psychotic Disorders
  83. Obesity: Epidemiology, Pathophysiology, and Therapeutics.
    Lin X, Li H · Front Endocrinol (Lausanne) · 2022 · Background
    PubMed: PMID 34552557 · NCT06000462 (DAPA-ANDO) · Obesity
  84. Prognostic value of plasma ST2 in patients with non-ST segment elevation acute coronary syndrome.
    Kokkoz Ç, Bilge A, Irik M, et al. · Turk J Emerg Med · 2022 · Background
    PubMed: PMID 29922732 · NCT05335629 · Diabetes Mellitus, Type 2
  85. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
    Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group · Kidney Int · 2022 · Background
    PubMed: PMID 36272764 · NCT06759077 · Kidney Diseases
  86. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Heidenreich PA, Bozkurt B, Aguilar D, et al. · J Am Coll Cardiol · 2022 · Background
    PubMed: PMID 35379503 · NCT07482943 · Heart Failure
  87. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
    Heerspink HJL, Cherney D, Postmus D, et al. · Kidney Int · 2022 · Background
    PubMed: PMID 34560136 · NCT06890143 · Proteinuria
  88. Prevalence, risk factors and microorganisms of urinary tract infections in patients with type 2 diabetes mellitus: a retrospective study in China.
    He K, Hu Y, Shi JC, et al. · Ther Clin Risk Manag · 2022 · Background
    PubMed: PMID 29520146 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  89. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy.
    Hansen L, Iqbal N, Ekholm E, et al. · Endocr Pract · 2022 · Background
    PubMed: PMID 25370334 · NCT02613897 · Diabetes Mellitus, Type 2
  90. Safety of SGLT2 Inhibitors in CKD: Walking the Fine Line.
    Dobre M · Clin J Am Soc Nephrol · 2022 · Background
    PubMed: PMID 35618341 · NCT06982079 · Renal Insufficiency, Chronic
  91. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence.
    Dayabandara M, Hanwella R, Ratnatunga S, et al. · Neuropsychiatr Dis Treat · 2022 · Background
    PubMed: PMID 28883731 · NCT07342764 · Psychotic Disorders
  92. Gliflozins in the Management of Cardiovascular Disease.
    Braunwald E · N Engl J Med · 2022 · Background
    PubMed: PMID 35613023 · NCT06113900 · Lupus Nephritis
  93. Epidemiology of peritoneal dialysis outcomes.
    Bello AK, Okpechi IG, Osman MA, et al. · Nat Rev Nephrol · 2022 · Background
    PubMed: PMID 36114414 · NCT06398977
  94. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.
    Authors/Task Force Members:, McDonagh TA, Metra M, et al. · Eur J Heart Fail · 2022 · Background
    PubMed: PMID 35083827 · NCT06012266 · Heart Failure
  95. Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages.
    Abdollahi E, Keyhanfar F, Delbandi AA, et al. · Eur J Pharmacol · 2022 · Background
    PubMed: PMID 35026193 · NCT06113900 · Lupus Nephritis

2021 (131 papers)

  1. Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop.
    Zlokovic BV, Gottesman RF, Bernstein KE, et al. · Alzheimers Dement · 2021 · Trial result
    PubMed: PMID 33030307 · NCT05565976 (DECIST) · Cognitive Dysfunction
  2. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.
    Writing Committee, Maddox TM, Januzzi JL, et al. · J Am Coll Cardiol · 2021 · Trial result
    PubMed: PMID 33446410 · NCT05759000 · Heart Failure
  3. The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial.
    Sato T, Aizawa Y, Yuasa S, et al. · J Atheroscler Thromb · 2021 · Trial result
    PubMed: PMID 32115470 · NCT05565976 (DECIST) · Cognitive Dysfunction
  4. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
    Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. · J Am Coll Cardiol · 2021 · Trial result
    PubMed: PMID 33197559 · NCT06668389 (STEPS) · Heart Defects, Congenital
  5. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.
    Ostermann M, Bellomo R, Burdmann EA, et al. · Kidney Int · 2021 · Trial result
    PubMed: PMID 32709292 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  6. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
    Nassif ME, Windsor SL, Borlaug BA, et al. · Nat Med · 2021 · Trial result
    PubMed: PMID 34711976 · NCT03030235 (PRESERVED-HF) · Heart Failure
  7. Impact of Plaque Burden Versus Stenosis on Ischemic Events in Patients With Coronary Atherosclerosis.
    Mortensen MB, Dzaye O, Steffensen FH, et al. · J Am Coll Cardiol · 2021 · Trial result
    PubMed: PMID 33303068 · NCT05998525 · Diabetes Mellitus, Type 2
  8. Frequency of Cognitive Impairment Among Malaysian Elderly Patients Following First Ischaemic Stroke-A Case Control Study.
    Mohamed Fuad Z, Mahadzir H, Syed Zakaria SZ, et al. · Front Public Health · 2021 · Trial result
    PubMed: PMID 33282811 · NCT05565976 (DECIST) · Cognitive Dysfunction
  9. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    McDonagh TA, Metra M, Adamo M, et al. · Eur Heart J · 2021 · Trial result
    PubMed: PMID 34447992 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  10. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Li WJ, Chen XQ, Xu LL, et al. · Cardiovasc Diabetol · 2021 · Trial result
    PubMed: PMID 32847602 · NCT04780438 · Atrial Fibrillation
  11. Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models.
    Li H, Zhang Y, Wang S, et al. · Front Pharmacol · 2021 · Trial result
    PubMed: PMID 34790128 · NCT06612086 · Hypertension, Pulmonary
  12. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
    Kuchay MS, Krishan S, Mishra SK, et al. · Diabetologia · 2021 · Trial result
    PubMed: PMID 32865597 · NCT05042505 (Dapa-LiT) · Diabetes Mellitus
  13. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
    Kuchay MS, Farooqui KJ, Mishra SK, et al. · Adv Exp Med Biol · 2021 · Trial result
    PubMed: PMID 32006266 · NCT05042505 (Dapa-LiT) · Diabetes Mellitus
  14. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
    Knuuti J, Wijns W, Saraste A, et al. · Eur Heart J · 2021 · Trial result
    PubMed: PMID 31504439 · NCT05998525 · Diabetes Mellitus, Type 2
  15. Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations.
    Klen J, Dolžan V · Int J Mol Sci · 2021 · Trial result
    PubMed: PMID 34575958 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  16. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N, Greene T, Chertow GM, et al. · Lancet Diabetes Endocrinol · 2021 · Trial result
    PubMed: PMID 34619106 · NCT06890143 · Proteinuria
  17. Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries.
    Johansson I, Joseph P, Balasubramanian K, et al. · Circulation · 2021 · Trial result
    PubMed: PMID 33906372 · NCT05759000 · Heart Failure
  18. Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.
    Ihara M, Saito S · J Alzheimers Dis · 2021 · Trial result
    PubMed: PMID 32144994 · NCT05565976 (DECIST) · Cognitive Dysfunction
  19. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL, Jongs N, Chertow GM, et al. · Lancet Diabetes Endocrinol · 2021 · Trial result
    PubMed: PMID 34619108 · NCT06890143 · Proteinuria
  20. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial.
    Harreiter J, Just I, Leutner M, et al. · Diabetes Obes Metab · 2021 · Trial result
    PubMed: PMID 33464703 · NCT03007329 (EXENDA) · Diabetes Mellitus, Type 2
  21. Circulatory markers of immunity and carotid atherosclerotic plaque.
    Fani L, van Dam-Nolen DHK, Vernooij M, et al. · Atherosclerosis · 2021 · Trial result
    PubMed: PMID 33894597 · NCT05565976 (DECIST) · Cognitive Dysfunction
  22. A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?
    Esterline R, Oscarsson J, Burns J, et al. · Int Rev Neurobiol · 2021 · Trial result
    PubMed: PMID 32854852 · NCT05565976 (DECIST) · Cognitive Dysfunction
  23. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
    Damman K, Beusekamp JC, Boorsma EM, et al. · Eur J Heart Fail · 2021 · Trial result
    PubMed: PMID 31912605 · NCT05457933 · Coronary Artery Disease
  24. Acute heart failure.
    Arrigo M, Jessup M, Mullens W, et al. · Nat Rev Dis Primers · 2021 · Trial result
    PubMed: PMID 32139695 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  25. Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    Anker SD, Butler J, Filippatos G, et al. · N Engl J Med · 2021 · Trial result
    PubMed: PMID 34449189 · NCT06612086 · Hypertension, Pulmonary
  26. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
    Zelniker TA, Bonaca MP, Furtado RHM, et al. · Circulation · 2021 · Derived
    PubMed: PMID 31983236 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  27. Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?
    Yeoh SE, Dewan P, Jhund PS, et al. · Circ Heart Fail · 2021 · Derived
    PubMed: PMID 33164553 · NCT03036124 (DAPA-HF) · Heart Failure
  28. Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition.
    Wolf P, Fellinger P, Pfleger L, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 33318126 · NCT02558270 · Diabetes Mellitus, Type 2
  29. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC, Stefánsson BV, Jongs N, et al. · Lancet Diabetes Endocrinol · 2021 · Derived
    PubMed: PMID 33338413 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  30. Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease.
    van der Aart-van der Beek AB, Koomen JV, Dekkers CCJ, et al. · Clin Pharmacokinet · 2021 · Derived
    PubMed: PMID 33587286 · NCT03190694 (DIAMOND) · Renal Insufficiency, Chronic
  31. Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes.
    van Bommel EJM, Smits MM, Ruiter D, et al. · J Hypertens · 2021 · Derived
    PubMed: PMID 32516291 · NCT02682563 (RED) · Diabetes Mellitus, Type 2
  32. Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.
    van Bommel EJM, Lytvyn Y, Perkins BA, et al. · Kidney Int · 2021 · Derived
    PubMed: PMID 32200854 · NCT02682563 (RED) · Diabetes Mellitus, Type 2
  33. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.
    van Bommel EJM, Herrema H, Davids M, et al. · Diabetes Metab · 2021 · Derived
    PubMed: PMID 31816432 · NCT02682563 (RED) · Diabetes Mellitus, Type 2
  34. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
    van Bommel EJM, Geurts F, Muskiet MHA, et al. · Clin Sci (Lond) · 2021 · Derived
    PubMed: PMID 33205810 · NCT02682563 (RED) · Diabetes Mellitus, Type 2
  35. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
    Stack AG, Han D, Goldwater R, et al. · J Clin Endocrinol Metab · 2021 · Derived
    PubMed: PMID 33075806 · NCT03316131 · Gout
  36. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
    Solomon SD, Jhund PS, Claggett BL, et al. · JACC Heart Fail · 2021 · Derived
    PubMed: PMID 32653447 · NCT03036124 (DAPA-HF) · Heart Failure
  37. Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion.
    Solis-Herrera C, Daniele G, Alatrach M, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 32144165 · NCT03168295 · Diabetes Mellitus, Type 2
  38. Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.
    Smeijer JD, Kohan DE, Webb DJ, et al. · Curr Opin Nephrol Hypertens · 2021 · Derived
    PubMed: PMID 33990507 · NCT04724837 (ZENITH-CKD) · Renal Insufficiency, Chronic
  39. Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
    Singh JSS, Mordi IR, Vickneson K, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 32245746 · NCT02397421 (REFORM) · Diabetes Mellitus
  40. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
    Shen L, Kristensen SL, Bengtsson O, et al. · JACC Heart Fail · 2021 · Derived
    PubMed: PMID 33549554 · NCT03036124 (DAPA-HF) · Heart Failure
  41. A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes.
    Shah M, Stolbov L, Yakovleva T, et al. · Diabetes Obes Metab · 2021 · Derived
    PubMed: PMID 33368935 · NCT00673231 · Diabetes Mellitus, Type 2
  42. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
    Serenelli M, Böhm M, Inzucchi SE, et al. · Eur Heart J · 2021 · Derived
    PubMed: PMID 32820334 · NCT03036124 (DAPA-HF) · Heart Failure
  43. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial.
    Scholtes RA, Muskiet MHA, van Baar MJB, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 33318125 · NCT03152084 (DAPASALT) · Diabetes Mellitus, Type 2
  44. Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Qin Y, Adams J, Solis-Herrera C, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 32694214 · NCT02613897 · Diabetes Mellitus, Type 2
  45. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.
    Piperidou A, Loutradis C, Sarafidis P, et al. · J Hum Hypertens · 2021 · Derived
    PubMed: PMID 32778748 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  46. Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
    Persson F, Rossing P, Vart P, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 34183431 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  47. Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus.
    Papadopoulou E, Theodorakopoulou MP, Loutradis C, et al. · Am J Hypertens · 2021 · Derived
    PubMed: PMID 33277990 · NCT02887677 · Diabetes Mellitus
  48. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial.
    Op den Kamp YJM, de Ligt M, Dautzenberg B, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 33858855 · NCT03338855 (DAPAMAAST) · Diabetes Mellitus, Type 2
  49. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
    Mosenzon O, Wiviott SD, Heerspink HJL, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 34233928 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  50. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
    McMurray JJV, Wheeler DC, Stefánsson BV, et al. · JACC Heart Fail · 2021 · Derived
    PubMed: PMID 34446370 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  51. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
    McMurray JJV, Wheeler DC, Stefánsson BV, et al. · Circulation · 2021 · Derived
    PubMed: PMID 33186054 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  52. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2.
    Mathieu C, Dandona P, Birkenfeld AL, et al. · Diabetes Obes Metab · 2021 · Derived
    PubMed: PMID 32691513 · NCT02268214 (DEPICT 1) · Diabetes Mellitus, Type 1
  53. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study.
    Ku EJ, Lee DH, Jeon HJ, et al. · Diabetes Res Clin Pract · 2021 · Derived
    PubMed: PMID 34740742 · NCT03748810
  54. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N, Hirsch C, Chai KL, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34473343 · NCT04393246 · COVID-19
  55. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Kosiborod MN, Esterline R, Furtado RHM, et al. · Lancet Diabetes Endocrinol · 2021 · Derived
    PubMed: PMID 34302745 · NCT04350593 (DARE-19) · COVID-19
  56. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T, Mizuno A, Takaoka Y, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34693515 · NCT02397421 (REFORM) · Diabetes Mellitus
  57. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
    Jhund PS, Solomon SD, Docherty KF, et al. · Circulation · 2021 · Derived
    PubMed: PMID 33040613 · NCT03036124 (DAPA-HF) · Heart Failure
  58. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF.
    Jhund PS, Ponikowski P, Docherty KF, et al. · Circulation · 2021 · Derived
    PubMed: PMID 33832352 · NCT03036124 (DAPA-HF) · Heart Failure
  59. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
    Jackson AM, Dewan P, Anand IS, et al. · Circulation · 2021 · Derived
    PubMed: PMID 32673497 · NCT03036124 (DAPA-HF) · Heart Failure
  60. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
    Jabbour SA, Frías JP, Ahmed A, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 32816874 · NCT02229396 · Diabetes Mellitus
  61. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF.
    Inzucchi SE, Docherty KF, Køber L, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 33355302 · NCT03036124 (DAPA-HF) · Heart Failure
  62. Towards precision medicine in diabetes? A critical review of glucotypes.
    Hulman A, Foreman YD, Brouwers MCGJ, et al. · PLoS Biol · 2021 · Derived
    PubMed: PMID 33705389 · NCT02695810 · Obesity
  63. Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin.
    Hu Y, Ding B, Shen Y, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 33536253 · NCT03982238 · Diabetes Mellitus, Type 2
  64. Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.
    Ghanim H, Abuaysheh S, Hejna J, et al. · J Clin Endocrinol Metab · 2021 · Derived
    PubMed: PMID 32044999 · NCT02433678 · Diabetes Mellitus, Type 2
  65. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
    Frias JP, Gonzalez-Galvez G, Johnsson E, et al. · Diabetes Obes Metab · 2021 · Derived
    PubMed: PMID 32052516 · NCT02419612 · Diabetes Mellitus
  66. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.
    Franklin JM, Patorno E, Desai RJ, et al. · Circulation · 2021 · Derived
    PubMed: PMID 33327727 · NCT04215523 · Diabetes Mellitus
  67. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
    Elkind-Hirsch KE, Chappell N, Seidemann E, et al. · J Clin Endocrinol Metab · 2021 · Derived
    PubMed: PMID 34097062 · NCT02635386 · Obesity
  68. Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial.
    Eickhoff MK, Olsen FJ, Frimodt-Møller M, et al. · J Diabetes Complications · 2021 · Derived
    PubMed: PMID 32340841 · NCT02914691 (DapKid) · Diabetes Mellitus, Type 2
  69. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.
    Docherty KF, Jhund PS, Bengtsson O, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 33082245 · NCT03036124 (DAPA-HF) · Heart Failure
  70. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
    Docherty KF, Jhund PS, Anand I, et al. · Circulation · 2021 · Derived
    PubMed: PMID 32883108 · NCT03036124 (DAPA-HF) · Heart Failure
  71. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.
    Dewan P, Solomon SD, Jhund PS, et al. · Eur J Heart Fail · 2021 · Derived
    PubMed: PMID 32539224 · NCT03036124 (DAPA-HF) · Heart Failure
  72. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF.
    Dewan P, Docherty KF, Bengtsson O, et al. · Eur J Heart Fail · 2021 · Derived
    PubMed: PMID 33368858 · NCT03036124 (DAPA-HF) · Heart Failure
  73. Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy.
    Daniele G, Solis-Herrera C, Dardano A, et al. · Diabetologia · 2021 · Derived
    PubMed: PMID 32827269 · NCT03168295 · Diabetes Mellitus, Type 2
  74. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
    Curtain JP, Docherty KF, Jhund PS, et al. · Eur Heart J · 2021 · Derived
    PubMed: PMID 34448003 · NCT03036124 (DAPA-HF) · Heart Failure
  75. Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.
    Cherney DZI, Dagogo-Jack S, McGuire DK, et al. · Clin Cardiol · 2021 · Derived
    PubMed: PMID 34129237 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  76. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
    Cahn A, Raz I, Leiter LA, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 33653824 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  77. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
    Brown AJM, Gandy S, McCrimmon R, et al. · Eur Heart J · 2021 · Derived
    PubMed: PMID 32578850 · NCT02956811 (DAPA-LVH) · Diabetes Mellitus, Type 2
  78. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
    Bonaca MP, Wiviott SD, Zelniker TA, et al. · Circulation · 2021 · Derived
    PubMed: PMID 32795086 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  79. Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.
    Bletsa E, Filippas-Dekouan S, Kostara C, et al. · J Clin Endocrinol Metab · 2021 · Derived
    PubMed: PMID 33592103 · NCT02798757 · Diabetes Mellitus
  80. Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes.
    Aberle J, Menzen M, Schmid SM, et al. · Sci Rep · 2021 · Derived
    PubMed: PMID 33372185 · NCT00673231 · Diabetes Mellitus, Type 2
  81. Aestivation motifs explain hypertension and muscle mass loss in mice with psoriatic skin barrier defect.
    Wild J, Jung R, Knopp T, et al. · Acta Physiol (Oxf) · 2021 · Background
    PubMed: PMID 33590724 · NCT05884866 (DapaBalci-Leap) · Renal Insufficiency, Chronic
  82. An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is).
    Wen S, Nguyen T, Gong M, et al. · Diabetes Metab Syndr Obes · 2021 · Background
    PubMed: PMID 34234493 · NCT05262257
  83. Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK.
    Tsai KL, Hsieh PL, Chou WC, et al. · Cell Biosci · 2021 · Background
    PubMed: PMID 33637129 · NCT05217654 · Reperfusion Injury
  84. Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt.
    Tomah S, Hamdy O, Abuelmagd MM, et al. · BMJ Open Gastroenterol · 2021 · Background
    PubMed: PMID 34610926 · NCT07020377 · Diabetes Mellitus, Type 2
  85. Peripheral venous pressure accurately predicts central venous pressure in the adult Fontan circulation.
    Tan W, Small A, Gallotti R, et al. · Int J Cardiol · 2021 · Background
    PubMed: PMID 33189798 · NCT05741658 (FonDap) · Heart Failure
  86. Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients.
    Song CC, Brown A, Winstead R, et al. · Endocrinol Diabetes Metab · 2021 · Background
    PubMed: PMID 33855198 · NCT07555106 (DAPA-GRAFT)
  87. Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK.
    Shrikrishnapalasuriyar N, Shaikh A, Ruslan AM, et al. · Diabetes Metab Syndr · 2021 · Background
    PubMed: PMID 32247210 · NCT06364930 · Hepatitis B, Chronic
  88. The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy.
    Sha W, Wen S, Chen L, et al. · J Diabetes Res · 2021 · Background
    PubMed: PMID 33274239 · NCT05310916 · Diabetic Retinopathy
  89. Modes of late mortality in patients with a Fontan circulation.
    Poh C, Hornung T, Celermajer DS, et al. · Heart · 2021 · Background
    PubMed: PMID 32098807 · NCT07482943 · Heart Failure
  90. Management of diabetes and hyperglycaemia in the hospital.
    Pasquel FJ, Lansang MC, Dhatariya K, et al. · Lancet Diabetes Endocrinol · 2021 · Background
    PubMed: PMID 33515493 · NCT05457933 · Coronary Artery Disease
  91. A systematic review of cognitive event-related potentials in mild cognitive impairment and Alzheimer's disease.
    Paitel ER, Samii MR, Nielson KA, et al. · Behav Brain Res · 2021 · Background
    PubMed: PMID 32941881 · NCT05262257
  92. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.
    Packer M · Diabetes Obes Metab · 2021 · Background
    PubMed: PMID 31916329 · NCT05741658 (FonDap) · Heart Failure
  93. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M, Anker SD, Butler J, et al. · J Am Coll Cardiol · 2021 · Background
    PubMed: PMID 33736819 · NCT07482943 · Heart Failure
  94. Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021.
    Nicolau JC, Feitosa Filho GS, Petriz JL, et al. · Arq Bras Cardiol · 2021 · Background
    PubMed: PMID 34320090 · NCT06286878 · Diabetes Mellitus
  95. A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
    Mulder S, Hammarstedt A, Nagaraj SB, et al. · Diabetes Obes Metab · 2021 · Background
    PubMed: PMID 32115853 · NCT05719714 · Heart Failure
  96. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.
    Marton A, Kaneko T, Kovalik JP, et al. · Nat Rev Nephrol · 2021 · Background
    PubMed: PMID 33005037 · NCT05884866 (DapaBalci-Leap) · Renal Insufficiency, Chronic
  97. Empagliflozin suppresses inflammation and protects against acute septic renal injury.
    Maayah ZH, Ferdaoussi M, Takahara S, et al. · Inflammopharmacology · 2021 · Background
    PubMed: PMID 32564182 · NCT07174687 · Eye Diseases
  98. Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials.
    Linden K, Mailey J, Kearney A, et al. · Adv Ther · 2021 · Background
    PubMed: PMID 32361851 · NCT04385589 · Heart Failure
  99. Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation-Induced Myocardial Dysfunction.
    Lin YW, Chen CY, Shih JY, et al. · J Am Heart Assoc · 2021 · Background
    PubMed: PMID 33749310 · NCT05618223 (Dapa-Rhemis) · Heart Failure
  100. SGLT2 promotes cardiac fibrosis following myocardial infarction and is regulated by miR-141.
    Li G, Zhao C, Fang S, et al. · Exp Ther Med · 2021 · Background
    PubMed: PMID 34007324 · NCT05618223 (Dapa-Rhemis) · Heart Failure
  101. Costs and consequences of acute kidney injury after cardiac surgery: A cohort study.
    Lau D, Pannu N, James MT, et al. · J Thorac Cardiovasc Surg · 2021 · Background
    PubMed: PMID 32299694 · NCT05590143 (MERCURI-2) · Acute Kidney Injury
  102. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
    Koyani CN, Plastira I, Sourij H, et al. · Pharmacol Res · 2021 · Background
    PubMed: PMID 32434052 · NCT05741658 (FonDap) · Heart Failure
  103. Adaptive physiological water conservation explains hypertension and muscle catabolism in experimental chronic renal failure.
    Kovarik JJ, Morisawa N, Wild J, et al. · Acta Physiol (Oxf) · 2021 · Background
    PubMed: PMID 33590667 · NCT05884866 (DapaBalci-Leap) · Renal Insufficiency, Chronic
  104. The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats.
    Korkmaz-Icöz S, Kocer C, Sayour AA, et al. · Int J Mol Sci · 2021 · Background
    PubMed: PMID 34360539 · NCT05217654 · Reperfusion Injury
  105. Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence.
    Khemais-Benkhiat S, Belcastro E, Idris-Khodja N, et al. · J Cell Mol Med · 2021 · Background
    PubMed: PMID 30929316 · NCT05217654 · Reperfusion Injury
  106. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E, Palladini G, Minnema MC, et al. · N Engl J Med · 2021 · Background
    PubMed: PMID 34192431 · NCT06297681
  107. Chronic kidney disease.
    Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. · Lancet · 2021 · Background
    PubMed: PMID 34175022 · NCT06982079 · Renal Insufficiency, Chronic
  108. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.
    Inker LA, Eneanya ND, Coresh J, et al. · N Engl J Med · 2021 · Background
    PubMed: PMID 34554658 · NCT06982079 · Renal Insufficiency, Chronic
  109. Value of Sodium-Glucose Co-Transporter 2 Inhibitor Versus Traditional Medication in Microalbuminuric Diabetic Patients.
    Hussein N, Abdelrahman F, Khedr A, et al. · Curr Diabetes Rev · 2021 · Background
    PubMed: PMID 33176660 · NCT05966818 · Proteinuria
  110. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
    Herrington WG, Savarese G, Haynes R, et al. · Eur J Heart Fail · 2021 · Background
    PubMed: PMID 34184823 · NCT05719714 · Heart Failure
  111. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
    Heerspink HJL, Sjöström CD, Jongs N, et al. · Eur Heart J · 2021 · Background
    PubMed: PMID 33792669 · NCT06982079 · Renal Insufficiency, Chronic
  112. Cardiac biomarkers of heart failure in chronic kidney disease.
    Han X, Zhang S, Chen Z, et al. · Clin Chim Acta · 2021 · Background
    PubMed: PMID 32710942 · NCT06759077 · Kidney Diseases
  113. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
    Griffin M, Rao VS, Ivey-Miranda J, et al. · Circulation · 2021 · Background
    PubMed: PMID 32410463 · NCT05741658 (FonDap) · Heart Failure
  114. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    GBD 2019 Diseases and Injuries Collaborators · Lancet · 2021 · Background
    PubMed: PMID 33069326 · NCT06000462 (DAPA-ANDO) · Obesity
  115. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
    Gaborit B, Ancel P, Abdullah AE, et al. · Cardiovasc Diabetol · 2021 · Background
    PubMed: PMID 33648515 · NCT05194592 · Ventricular Remodeling
  116. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
    Elsisi GH, Anwar MM, Khattab M, et al. · J Med Econ · 2021 · Background
    PubMed: PMID 32364032 · NCT04385589 · Heart Failure
  117. Correction.
    J Am Coll Cardiol · 2021 · Background
    PubMed: PMID 32943171 · NCT05194592 · Ventricular Remodeling
  118. Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure.
    Chirinos JA, Zhao L, Jia Y, et al. · Circulation · 2021 · Background
    PubMed: PMID 32237898 · NCT06812429 (EFSII) · Inflammation
  119. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
    Chertow GM, Vart P, Jongs N, et al. · J Am Soc Nephrol · 2021 · Background
    PubMed: PMID 34272327 · NCT06982079 · Renal Insufficiency, Chronic
  120. Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients.
    Chang WT, Lin YW, Ho CH, et al. · Arch Toxicol · 2021 · Background
    PubMed: PMID 33211168 · NCT06427226 · Breast Neoplasms
  121. Development of a Novel Adult Congenital Heart Disease-Specific Patient-Reported Outcome Metric.
    Cedars AM, Ko JM, John AS, et al. · J Am Heart Assoc · 2021 · Background
    PubMed: PMID 32419592 · NCT05741658 (FonDap) · Heart Failure
  122. Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity.
    Carretero Gómez J, Ena J, Seguí Ripoll JM, et al. · Curr Med Res Opin · 2021 · Background
    PubMed: PMID 34357836 · NCT06364930 · Hepatitis B, Chronic
  123. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
    Cappetta D, De Angelis A, Ciuffreda LP, et al. · Pharmacol Res · 2021 · Background
    PubMed: PMID 32360273 · NCT04385589 · Heart Failure
  124. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial.
    Butt JH, Nicolau JC, Verma S, et al. · Eur J Heart Fail · 2021 · Background
    PubMed: PMID 33594755 · NCT06286878 · Diabetes Mellitus
  125. Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.
    Berezin AE, Berezin AA · Dis Markers · 2021 · Background
    PubMed: PMID 32626540 · NCT05335629 · Diabetes Mellitus, Type 2
  126. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
    Baker ML, Perazella MA · J Nephrol · 2021 · Background
    PubMed: PMID 32067179 · NCT05335629 · Diabetes Mellitus, Type 2
  127. Costs of viral hepatitis B in the Republic of Korea, 2002-2015.
    Baik D, Kim BW, Oh JK, et al. · J Viral Hepat · 2021 · Background
    PubMed: PMID 31638305 · NCT06364930 · Hepatitis B, Chronic
  128. Age-Related Macular Degeneration.
    Apte RS · N Engl J Med · 2021 · Background
    PubMed: PMID 34347954 · NCT07174687 · Eye Diseases
  129. Heart failure from heart muscle disease in childhood: a 5-10 year follow-up study in the UK and Ireland.
    Andrews RE, Fenton MJ, Dominguez T, et al. · ESC Heart Fail · 2021 · Background
    PubMed: PMID 27812385 · NCT06012266 · Heart Failure
  130. Prevalence of risk factors of non-communicable diseases in the Sultanate of Oman: STEPS survey 2017.
    Al-Mawali A, Jayapal SK, Morsi M, et al. · PLoS One · 2021 · Background
    PubMed: PMID 34710161 · NCT06000462 (DAPA-ANDO) · Obesity
  131. Medical management of pediatric heart failure.
    Ahmed H, VanderPluym C · Cardiovasc Diagn Ther · 2021 · Background
    PubMed: PMID 33708503 · NCT06012266 · Heart Failure

2020 (86 papers)

  1. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, et al. · Lancet · 2020 · Trial result
    PubMed: PMID 32877652 · NCT05424315 (DACAMI) · Heart Failure
  2. Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia.
    Uemura MT, Maki T, Ihara M, et al. · Front Aging Neurosci · 2020 · Trial result
    PubMed: PMID 32317958 · NCT05565976 (DECIST) · Cognitive Dysfunction
  3. Early Cognitive Impairment after Minor Stroke: Associated Factors and Functional Outcome.
    Suda S, Nishimura T, Ishiwata A, et al. · J Stroke Cerebrovasc Dis · 2020 · Trial result
    PubMed: PMID 32178931 · NCT05565976 (DECIST) · Cognitive Dysfunction
  4. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
    Shi L, Zhu D, Wang S, et al. · Am J Hypertens · 2020 · Trial result
    PubMed: PMID 30689697 · NCT05424315 (DACAMI) · Heart Failure
  5. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ · Nat Rev Endocrinol · 2020 · Trial result
    PubMed: PMID 32855502 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  6. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
    Packer M, Anker SD, Butler J, et al. · N Engl J Med · 2020 · Trial result
    PubMed: PMID 32865377 · NCT05424315 (DACAMI) · Heart Failure
  7. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O, Wiviott SD, Cahn A, et al. · Lancet Diabetes Endocrinol · 2020 · Trial result
    PubMed: PMID 31196815 · NCT06398977
  8. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
    Mazer CD, Hare GMT, Connelly PW, et al. · Circulation · 2020 · Trial result
    PubMed: PMID 31707794 · NCT07516847 (DAPA-MDS1) · Anemia
  9. SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function.
    Maejima Y · Front Cardiovasc Med · 2020 · Trial result
    PubMed: PMID 31970162 · NCT04780438 · Atrial Fibrillation
  10. Rationale and Strategies for Preserving Residual Kidney Function in Dialysis Patients.
    Li T, Wilcox CS, Lipkowitz MS, et al. · Am J Nephrol · 2020 · Trial result
    PubMed: PMID 31630148 · NCT06398977
  11. Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel.
    Iadecola C, Duering M, Hachinski V, et al. · J Am Coll Cardiol · 2020 · Trial result
    PubMed: PMID 31248555 · NCT05565976 (DECIST) · Cognitive Dysfunction
  12. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
    Iacobellis G, Gra-Menendez S · Obesity (Silver Spring) · 2020 · Trial result
    PubMed: PMID 32352644 · NCT05565976 (DECIST) · Cognitive Dysfunction
  13. Dapagliflozin in Patients with Chronic Kidney Disease.
    Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. · N Engl J Med · 2020 · Trial result
    PubMed: PMID 32970396 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  14. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL, Stefansson BV, Chertow GM, et al. · Nephrol Dial Transplant · 2020 · Trial result
    PubMed: PMID 32030417 · NCT06890143 · Proteinuria
  15. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
    Chowdhury B, Luu AZ, Luu VZ, et al. · Biochem Biophys Res Commun · 2020 · Trial result
    PubMed: PMID 31980166 · NCT06668389 (STEPS) · Heart Defects, Congenital
  16. Bile Acids as Metabolic Regulators and Nutrient Sensors.
    Chiang JYL, Ferrell JM · Annu Rev Nutr · 2020 · Trial result
    PubMed: PMID 31018107 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  17. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI, Dekkers CCJ, Barbour SJ, et al. · Lancet Diabetes Endocrinol · 2020 · Trial result
    PubMed: PMID 32559474 · NCT05565976 (DECIST) · Cognitive Dysfunction
  18. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    Bakris GL, Agarwal R, Anker SD, et al. · N Engl J Med · 2020 · Trial result
    PubMed: PMID 33264825 · NCT07351864 (FIN-SGLT2-HF) · Heart Failure
  19. Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Asad ZUA, Yousif A, Khan MS, et al. · Circ Arrhythm Electrophysiol · 2020 · Trial result
    PubMed: PMID 31431051 · NCT04780438 · Atrial Fibrillation
  20. Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects.
    Andreadou I, Efentakis P, Balafas E, et al. · Front Physiol · 2020 · Trial result
    PubMed: PMID 29311992 · NCT04780438 · Atrial Fibrillation
  21. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC, Stefansson BV, Batiushin M, et al. · Nephrol Dial Transplant · 2020 · Derived
    PubMed: PMID 32862232 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  22. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
    Vilsbøll T, Ekholm E, Johnsson E, et al. · Diabetes Care · 2020 · Derived
    PubMed: PMID 31167892 · NCT02551874 · Diabetes Mellitus, Type 2
  23. Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects.
    Tang W, Engman H, Zhu Y, et al. · Clin Ther · 2020 · Derived
    PubMed: PMID 31266654 · NCT03169959 · Diabetes Mellitus, Type 2
  24. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
    Sternlicht HK, Bakris GL · Lancet Diabetes Endocrinol · 2020 · Derived
    PubMed: PMID 32559465 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  25. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C, Stefánsson B, Reyner D, et al. · Lancet Diabetes Endocrinol · 2020 · Derived
    PubMed: PMID 30992195 · NCT02547935 · Diabetes Mellitus, Type 2
  26. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
    Petrie MC, Verma S, Docherty KF, et al. · JAMA · 2020 · Derived
    PubMed: PMID 32219386 · NCT03036124 (DAPA-HF) · Heart Failure
  27. Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
    Parkinson J, Tang W, Åstrand M, et al. · Diabetes Obes Metab · 2020 · Derived
    PubMed: PMID 30756462 · NCT02460978 (DEPICT 2) · Diabetes Mellitus, Type 1
  28. Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training.
    Newman AA, Grimm NC, Wilburn JR, et al. · J Clin Endocrinol Metab · 2020 · Derived
    PubMed: PMID 30597042 · NCT02371187 · Motor Activity
  29. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME, Kosiborod M · Diabetes Obes Metab · 2020 · Derived
    PubMed: PMID 31081589 · NCT03036124 (DAPA-HF) · Heart Failure
  30. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.
    McMurray JJV, DeMets DL, Inzucchi SE, et al. · Eur J Heart Fail · 2020 · Derived
    PubMed: PMID 31309699 · NCT03036124 (DAPA-HF) · Heart Failure
  31. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
    Martinez FA, Serenelli M, Nicolau JC, et al. · Circulation · 2020 · Derived
    PubMed: PMID 31736328 · NCT03036124 (DAPA-HF) · Heart Failure
  32. muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial.
    Lu IN, Kulkarni S, Fisk M, et al. · Trials · 2020 · Derived
    PubMed: PMID 32736592 · NCT04393246 · COVID-19
  33. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A, Honka MJ, Kullberg J, et al. · Diabetes Care · 2020 · Derived
    PubMed: PMID 30885955 · NCT02426541 (DERISC) · Diabetes Mellitus, Type 2
  34. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
    Kosiborod MN, Jhund PS, Docherty KF, et al. · Circulation · 2020 · Derived
    PubMed: PMID 31736335 · NCT03036124 (DAPA-HF) · Heart Failure
  35. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET, Silverman MG, Mosenzon O, et al. · Circulation · 2020 · Derived
    PubMed: PMID 30882238 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  36. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.
    Guja C, Frías JP, Suchower L, et al. · Diabetes Ther · 2020 · Derived
    PubMed: PMID 32306296 · NCT02229396 · Diabetes Mellitus
  37. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
    Groop PH, Dandona P, Phillip M, et al. · Lancet Diabetes Endocrinol · 2020 · Derived
    PubMed: PMID 32946821 · NCT02460978 (DEPICT 2) · Diabetes Mellitus, Type 1
  38. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE, Foresto RD, Ribeiro AB, et al. · Rev Assoc Med Bras (1992) · 2020 · Derived
    PubMed: PMID 31939531 · NCT03036150 (Dapa-CKD) · Renal Insufficiency, Chronic
  39. Metformin monotherapy for adults with type 2 diabetes mellitus.
    Gnesin F, Thuesen ACB, Kähler LKA, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 32501595 · NCT03982381 (SMARTEST) · Diabetes Mellitus, Type 2
  40. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM, Bonaca MP, Raz I, et al. · Circulation · 2020 · Derived
    PubMed: PMID 30882239 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  41. Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial.
    Ferreira-Hermosillo A, Molina-Ayala MA, Molina-Guerrero D, et al. · Trials · 2020 · Derived
    PubMed: PMID 32059692 · NCT03968224 · Diabetes Mellitus, Type 2
  42. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
    Cahn A, Mosenzon O, Wiviott SD, et al. · Diabetes Care · 2020 · Derived
    PubMed: PMID 31843945 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  43. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
    Bonora BM, Vigili de Kreutzenberg S, Avogaro A, et al. · Cardiovasc Diabetol · 2020 · Derived
    PubMed: PMID 31412874 · NCT02327039 (DAPA-HDL) · Diabetes Mellitus, Type 2
  44. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD, Wiviott SD, Scirica BM, et al. · Circulation · 2020 · Derived
    PubMed: PMID 31474116 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  45. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.
    Bailey CJ, Del Prato S, Wei C, et al. · Diabetes Obes Metab · 2020 · Derived
    PubMed: PMID 31364269 · NCT01606007 · Diabetes Mellitus, Type 2
  46. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
    Alatrach M, Laichuthai N, Martinez R, et al. · Diabetes · 2020 · Derived
    PubMed: PMID 31915153 · NCT02592421 · Diabetes Mellitus, Type 2
  47. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA, Wiviott SD, Raz I, et al. · Circulation · 2020 · Background
    PubMed: PMID 30786725 · NCT06398977
  48. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
    Zelniker TA, Braunwald E · J Am Coll Cardiol · 2020 · Background
    PubMed: PMID 32000955 · NCT06012266 · Heart Failure
  49. Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.
    Yu H, Woo VC · Diabetes Metab Syndr Obes · 2020 · Background
    PubMed: PMID 28769579 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  50. Interleukin-6 and Diabetic Retinopathy: A Systematic Review and Meta-Analysis.
    Yao Y, Li R, Du J, et al. · Curr Eye Res · 2020 · Background
    PubMed: PMID 30644770 · NCT05310916 · Diabetic Retinopathy
  51. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies.
    Xue M, Xu W, Ou YN, et al. · Ageing Res Rev · 2020 · Background
    PubMed: PMID 31430566 · NCT05262257
  52. Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors.
    Wojcik C, Warden BA · Curr Cardiol Rep · 2020 · Background
    PubMed: PMID 31522263 · NCT05335629 · Diabetes Mellitus, Type 2
  53. Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer's Disease and Ischemia-Related Brain Injury.
    Wiciński M, Wódkiewicz E, Górski K, et al. · Pharmaceuticals (Basel) · 2020 · Background
    PubMed: PMID 33187206 · NCT05262257
  54. Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis.
    Wang A, Yang K, Wang T, et al. · Diabetes Metab Res Rev · 2020 · Background
    PubMed: PMID 31050384 · NCT06612086 · Hypertension, Pulmonary
  55. Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits.
    Verma S · Am J Cardiol · 2020 · Background
    PubMed: PMID 31741439 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  56. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.
    Sarin SK, Kumar M, Eslam M, et al. · Lancet Gastroenterol Hepatol · 2020 · Background
    PubMed: PMID 31852635 · NCT06364930 · Hepatitis B, Chronic
  57. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
    Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. · J Am Coll Cardiol · 2020 · Background
    PubMed: PMID 30999996 · NCT05335629 · Diabetes Mellitus, Type 2
  58. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.
    Sano M, Goto S · Circulation · 2020 · Background
    PubMed: PMID 31009585 · NCT07025629 (DAPA-ICU) · Heart Failure
  59. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
    Oshima M, Neuen BL, Jardine MJ, et al. · Lancet Diabetes Endocrinol · 2020 · Background
    PubMed: PMID 33065060 · NCT07344922 · Renal Insufficiency, Chronic
  60. SGLT2i: beyond the glucose-lowering effect.
    Ni L, Yuan C, Chen G, et al. · Cardiovasc Diabetol · 2020 · Background
    PubMed: PMID 32590982 · NCT06421870 · Renal Insufficiency, Chronic
  61. Renal effects of SGLT2 inhibitors: an update.
    Nespoux J, Vallon V · Curr Opin Nephrol Hypertens · 2020 · Background
    PubMed: PMID 31815757 · NCT06421870 · Renal Insufficiency, Chronic
  62. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME, Windsor SL, Tang F, et al. · Circulation · 2020 · Background
    PubMed: PMID 31524498 · NCT02653482 (DEFINE-HF) · Heart Failure
  63. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
    Menne J, Dumann E, Haller H, et al. · PLoS Med · 2020 · Background
    PubMed: PMID 31815931 · NCT05590143 (MERCURI-2) · Acute Kidney Injury
  64. Phthalates Exposure as Determinant of Albuminuria in Subjects With Type 2 Diabetes: A Cross-Sectional Study.
    Mengozzi A, Carli F, Biancalana E, et al. · J Clin Endocrinol Metab · 2020 · Background
    PubMed: PMID 30462244 · NCT04242758 (PURITY) · Glucose Metabolism Disorders
  65. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
    McMurray JJV, DeMets DL, Inzucchi SE, et al. · Eur J Heart Fail · 2020 · Background
    PubMed: PMID 30895697 · NCT07482943 · Heart Failure
  66. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway.
    Lu Q, Liu J, Li X, et al. · Mol Cell Endocrinol · 2020 · Background
    PubMed: PMID 31759100 · NCT05217654 · Reperfusion Injury
  67. Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials.
    Likhitsup A, Lok AS · Clin Liver Dis · 2020 · Background
    PubMed: PMID 31266616 · NCT06364930 · Hepatitis B, Chronic
  68. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
    Levey AS, Gansevoort RT, Coresh J, et al. · Am J Kidney Dis · 2020 · Background
    PubMed: PMID 31473020 · NCT06982079 · Renal Insufficiency, Chronic
  69. Cardiovascular Consequences of Acute Kidney Injury.
    Legrand M, Rossignol P · N Engl J Med · 2020 · Background
    PubMed: PMID 32492305 · NCT07025629 (DAPA-ICU) · Heart Failure
  70. SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects.
    Lam CSP, Chandramouli C, Ahooja V, et al. · J Am Heart Assoc · 2020 · Background
    PubMed: PMID 31607208 · NCT05335629 · Diabetes Mellitus, Type 2
  71. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
    Lai LL, Vethakkan SR, Nik Mustapha NR, et al. · Dig Dis Sci · 2020 · Background
    PubMed: PMID 30684076 · NCT06364930 · Hepatitis B, Chronic
  72. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
    Kim SR, Lee SG, Kim SH, et al. · Nat Commun · 2020 · Background
    PubMed: PMID 32358544 · NCT05194592 · Ventricular Remodeling
  73. Empagliflozin Ameliorates Type 2 Diabetes-Induced Ultrastructural Remodeling of the Neurovascular Unit and Neuroglia in the Female db/db Mouse.
    Hayden MR, Grant DG, Aroor AR, et al. · Brain Sci · 2020 · Background
    PubMed: PMID 30866531 · NCT05262257
  74. Biological markers and cardiac remodelling following the myocardial infarction.
    Gruzdeva O, Dyleva Y, Uchasova E, et al. · Aging (Albany NY) · 2020 · Background
    PubMed: PMID 31182683 · NCT05335629 · Diabetes Mellitus, Type 2
  75. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials.
    Gilbert RE, Thorpe KE · Diabetes Obes Metab · 2020 · Background
    PubMed: PMID 31050116 · NCT05590143 (MERCURI-2) · Acute Kidney Injury
  76. Changes in urinary excretion of phthalates, phthalate substitutes, bisphenols and other polychlorinated and phenolic substances in young Danish men; 2009-2017.
    Frederiksen H, Nielsen O, Koch HM, et al. · Int J Hyg Environ Health · 2020 · Background
    PubMed: PMID 31669154 · NCT04242758 (PURITY) · Glucose Metabolism Disorders
  77. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
    Figtree GA, Rådholm K, Barrett TD, et al. · Circulation · 2020 · Background
    PubMed: PMID 30882240 · NCT05741658 (FonDap) · Heart Failure
  78. Incidence and Outcome of Subclinical Acute Kidney Injury Using penKid in Critically Ill Patients.
    Dépret F, Hollinger A, Cariou A, et al. · Am J Respir Crit Care Med · 2020 · Background
    PubMed: PMID 32516543 · NCT07025629 (DAPA-ICU) · Heart Failure
  79. Current State of Pediatric Heart Failure.
    Das BB · Children (Basel) · 2020 · Background
    PubMed: PMID 29958420 · NCT06012266 · Heart Failure
  80. Change in admission blood glucose from chronic glycemic status in acute heart failure hospitalization and 30-day outcomes: A retrospective analysis.
    Cox ZL, Lai P, Lewis CM, et al. · Int J Cardiol · 2020 · Background
    PubMed: PMID 31395364 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  81. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry.
    Chioncel O, Mebazaa A, Maggioni AP, et al. · Eur J Heart Fail · 2020 · Background
    PubMed: PMID 31127678 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  82. Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus.
    Chen YY, Wu TT, Ho CY, et al. · Int J Mol Sci · 2020 · Background
    PubMed: PMID 31491943 · NCT05310916 · Diabetic Retinopathy
  83. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis.
    Barton BB, Segger F, Fischer K, et al. · Expert Opin Drug Saf · 2020 · Background
    PubMed: PMID 31952459 · NCT07342764 · Psychotic Disorders
  84. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019.
    American Diabetes Association · Diabetes Care · 2020 · Background
    PubMed: PMID 30559235 · NCT03968224 · Diabetes Mellitus, Type 2
  85. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019.
    American Diabetes Association · Diabetes Care · 2020 · Background
    PubMed: PMID 30559228 · NCT03968224 · Diabetes Mellitus, Type 2
  86. National trends in Fontan operation and in-hospital outcomes in the USA.
    Akintoye E, Miranda WR, Veldtman GR, et al. · Heart · 2020 · Background
    PubMed: PMID 30377261 · NCT05741658 (FonDap) · Heart Failure

2019 (88 papers)

  1. [Short-term intensive combined therapy with metformin, sagliptin and dapagliflozin for newly diagnosed type 2 diabetes: efficacy, weight control and safety].
    Xu Y, Wu P, Wen W, et al. · Nan Fang Yi Ke Da Xue Xue Bao · 2019 · Trial result
    PubMed: PMID 31852646 · NCT07033585 (GD-T2D) · Diabetes Mellitus, Type 2
  2. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    Wiviott SD, Raz I, Bonaca MP, et al. · N Engl J Med · 2019 · Trial result
    PubMed: PMID 30415602 · NCT04780438 · Atrial Fibrillation
  3. The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity.
    Wan N, Rahman A, Hitomi H, et al. · Front Endocrinol (Lausanne) · 2019 · Trial result
    PubMed: PMID 30093883 · NCT04780438 · Atrial Fibrillation
  4. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.
    Verma S, McMurray JJV · Diabetologia · 2019 · Trial result
    PubMed: PMID 30132036 · NCT04780438 · Atrial Fibrillation
  5. Vascular cognitive impairment.
    van der Flier WM, Skoog I, Schneider JA, et al. · Nat Rev Dis Primers · 2019 · Trial result
    PubMed: PMID 29446769 · NCT05565976 (DECIST) · Cognitive Dysfunction
  6. Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.
    Rajasekeran H, Reich HN, Hladunewich MA, et al. · Am J Physiol Renal Physiol · 2019 · Trial result
    PubMed: PMID 29141939 · NCT06890143 · Proteinuria
  7. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V, Jardine MJ, Neal B, et al. · N Engl J Med · 2019 · Trial result
    PubMed: PMID 30990260 · NCT04717986 (DAPA-AMI) · Heart Failure
  8. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V, de Zeeuw D, Mahaffey KW, et al. · Lancet Diabetes Endocrinol · 2019 · Trial result
    PubMed: PMID 29937267 · NCT06890143 · Proteinuria
  9. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.
    Packer DL, Mark DB, Robb RA, et al. · JAMA · 2019 · Trial result
    PubMed: PMID 30874766 · NCT04780438 · Atrial Fibrillation
  10. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    McMurray JJV, Solomon SD, Inzucchi SE, et al. · N Engl J Med · 2019 · Trial result
    PubMed: PMID 31535829 · NCT06668389 (STEPS) · Heart Defects, Congenital
  11. Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite?
    Malone JI, Hansen BC · Pediatr Diabetes · 2019 · Trial result
    PubMed: PMID 30311716 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  12. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC, Shiou YL, Jhuo SJ, et al. · Cardiovasc Diabetol · 2019 · Trial result
    PubMed: PMID 30935417 · NCT05424315 (DACAMI) · Heart Failure
  13. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
    Karg MV, Bosch A, Kannenkeril D, et al. · Cardiovasc Diabetol · 2019 · Trial result
    PubMed: PMID 29301520 · NCT02383238 (Dapa) · Diabetes Mellitus, Type 2
  14. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial.
    Kadowaki T, Nangaku M, Hantel S, et al. · J Diabetes Investig · 2019 · Trial result
    PubMed: PMID 30412655 · NCT06890143 · Proteinuria
  15. Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease.
    Hegyi P, Maléth J, Walters JR, et al. · Physiol Rev · 2019 · Trial result
    PubMed: PMID 30067158 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  16. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects.
    Garofalo C, Borrelli S, Liberti ME, et al. · Medicina (Kaunas) · 2019 · Trial result
    PubMed: PMID 31212638 · NCT04806633 · Acute Kidney Injury
  17. A Review of Tetralogy of Fallot and Postoperative Management.
    Forman J, Beech R, Slugantz L, et al. · Crit Care Nurs Clin North Am · 2019 · Trial result
    PubMed: PMID 31351553 · NCT06668389 (STEPS) · Heart Defects, Congenital
  18. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability.
    Díaz-Rodríguez E, Agra RM, Fernández ÁL, et al. · Cardiovasc Res · 2019 · Trial result
    PubMed: PMID 29016744 · NCT05565976 (DECIST) · Cognitive Dysfunction
  19. Dapagliflozin: A Review in Type 2 Diabetes.
    Dhillon S · Drugs · 2019 · Trial result
    PubMed: PMID 31236801 · NCT05565976 (DECIST) · Cognitive Dysfunction
  20. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
    Dekkers CCJ, Petrykiv S, Laverman GD, et al. · Diabetes Obes Metab · 2019 · Trial result
    PubMed: PMID 29573529 · NCT05565976 (DECIST) · Cognitive Dysfunction
  21. Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy of Fallot.
    Bokma JP, Winter MM, van Dijk AP, et al. · Circulation · 2019 · Trial result
    PubMed: PMID 29222139 · NCT06668389 (STEPS) · Heart Defects, Congenital
  22. Systolic Blood Pressure on Admission and Mortality in Patients Hospitalized With Acute Heart Failure: Observations From the Gulf Acute Heart Failure Registry.
    Al-Lawati JA, Sulaiman KJ, Al-Zakwani I, et al. · Angiology · 2019 · Trial result
    PubMed: PMID 27814267 · NCT03658031 · Diabetes Mellitus, Type 2
  23. Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325-331.
    Abdul-Ghani M, Migahid O, Megahed A, et al. · Diabetes Care · 2019 · Trial result
    PubMed: PMID 28615237 · NCT03658031 · Diabetes Mellitus, Type 2
  24. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Wiviott SD, Raz I, Bonaca MP, et al. · Am Heart J · 2019 · Derived
    PubMed: PMID 29898853 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  25. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
    Wittbrodt ET, Eudicone JM, Bell KF, et al. · Am J Manag Care · 2019 · Derived
    PubMed: PMID 29693360 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  26. Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.
    Wilcox CS, Shen W, Boulton DW, et al. · J Am Heart Assoc · 2019 · Derived
    PubMed: PMID 29440005 · NCT00930865 · Diabetes Mellitus, Type 2
  27. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
    Scott R, Morgan J, Zimmer Z, et al. · Diabetes Obes Metab · 2019 · Derived
    PubMed: PMID 30019498 · NCT02532855 · Diabetes Mellitus, Type 2
  28. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
    Müller-Wieland D, Kellerer M, Cypryk K, et al. · Diabetes Obes Metab · 2019 · Derived
    PubMed: PMID 29947099 · NCT02471404 · Diabetes Mellitus, Type 2
  29. Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
    Lundkvist P, Pereira MJ, Kamble PG, et al. · J Clin Endocrinol Metab · 2019 · Derived
    PubMed: PMID 30137410 · NCT02765204 · Diabetes Mellitus, Type 2
  30. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ, Lee DH, Jeon HJ, et al. · Diabetes Res Clin Pract · 2019 · Derived
    PubMed: PMID 30954510 · NCT03748810
  31. Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects.
    Khomitskaya Y, Tikhonova N, Gudkov K, et al. · Clin Ther · 2019 · Derived
    PubMed: PMID 29548719 · NCT02722239 · Diabetes Mellitus, Type 2
  32. Early vascular parameters in the micro- and macrocirculation in type 2 diabetes.
    Kannenkeril D, Bosch A, Harazny J, et al. · Cardiovasc Diabetol · 2019 · Derived
    PubMed: PMID 30231923 · NCT02383238 (Dapa) · Diabetes Mellitus, Type 2
  33. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
    Fioretto P, Del Prato S, Buse JB, et al. · Diabetes Obes Metab · 2019 · Derived
    PubMed: PMID 29888547 · NCT02413398 (DERIVE) · Diabetes Mellitus, Type 2
  34. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW, Lundkvist P, Jansson PA, et al. · Diabetologia · 2019 · Derived
    PubMed: PMID 29971527 · NCT02279407 (EFFECTII) · Non-alcoholic Fatty Liver Disease
  35. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
    Dandona P, Mathieu C, Phillip M, et al. · Diabetes Care · 2019 · Derived
    PubMed: PMID 30352894 · NCT02268214 (DEPICT 1) · Diabetes Mellitus, Type 1
  36. Serum Vascular Endothelial Growth Factor Levels Correlate with Severity of Retinopathy in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Zhou Z, Ju H, Sun M, et al. · Dis Markers · 2019 · Background
    PubMed: PMID 31019585 · NCT05310916 · Diabetic Retinopathy
  37. New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease.
    Zhong KL, Chen F, Hong H, et al. · Metab Brain Dis · 2019 · Background
    PubMed: PMID 29626315 · NCT05262257
  38. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.
    Zheng Y, Ley SH, Hu FB, et al. · Nat Rev Endocrinol · 2019 · Background
    PubMed: PMID 29219149 · NCT05310916 · Diabetic Retinopathy
  39. HbA1c, diabetes and cognitive decline: the English Longitudinal Study of Ageing.
    Zheng F, Yan L, Yang Z, et al. · Diabetologia · 2019 · Background
    PubMed: PMID 29368156 · NCT05262257
  40. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Zelniker TA, Wiviott SD, Raz I, et al. · Lancet · 2019 · Background
    PubMed: PMID 30424892 · NCT07025629 (DAPA-ICU) · Heart Failure
  41. Coronary lesion progression as assessed by fractional flow reserve (FFR) and angiography.
    Xaplanteris P, Ntalianis A, De Bruyne B, et al. · EuroIntervention · 2019 · Background
    PubMed: PMID 29769166 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  42. Continuous monitoring after atrial fibrillation ablation: the LINQ AF study.
    Wechselberger S, Kronborg M, Huo Y, et al. · Europace · 2019 · Background
    PubMed: PMID 29688326 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  43. Associations of Plasma Amino Acid and Acylcarnitine Profiles with Incident Reduced Glomerular Filtration Rate.
    Wang F, Sun L, Sun Q, et al. · Clin J Am Soc Nephrol · 2019 · Background
    PubMed: PMID 29519950 · NCT05719714 · Heart Failure
  44. Nephrotic Syndrome.
    Wang CS, Greenbaum LA · Pediatr Clin North Am · 2019 · Background
    PubMed: PMID 30454752 · NCT05966818 · Proteinuria
  45. The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium.
    Tseng CCS, Huibers MMH, van Kuik J, et al. · J Cardiovasc Transl Res · 2019 · Background
    PubMed: PMID 29285671 · NCT05335629 · Diabetes Mellitus, Type 2
  46. Fourth Universal Definition of Myocardial Infarction (2018).
    Thygesen K, Alpert JS, Jaffe AS, et al. · J Am Coll Cardiol · 2019 · Background
    PubMed: PMID 30153967 · NCT06286878 · Diabetes Mellitus
  47. Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.
    Stolk E, Ludwig K, Rand K, et al. · Value Health · 2019 · Background
    PubMed: PMID 30661630 · NCT05590143 (MERCURI-2) · Acute Kidney Injury
  48. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
    Schork A, Saynisch J, Vosseler A, et al. · Cardiovasc Diabetol · 2019 · Background
    PubMed: PMID 30953516 · NCT03968224 · Diabetes Mellitus, Type 2
  49. An update on the safety of SGLT2 inhibitors.
    Scheen AJ · Expert Opin Drug Saf · 2019 · Background
    PubMed: PMID 30933547 · NCT03968224 · Diabetes Mellitus, Type 2
  50. The effect of dapagliflozin treatment on epicardial adipose tissue volume.
    Sato T, Aizawa Y, Yuasa S, et al. · Cardiovasc Diabetol · 2019 · Background
    PubMed: PMID 29301516 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  51. US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States.
    Saran R, Robinson B, Abbott KC, et al. · Am J Kidney Dis · 2019 · Background
    PubMed: PMID 29477157 · NCT05719714 · Heart Failure
  52. SGLT2 inhibition and glucagon secretion in humans.
    Saponaro C, Pattou F, Bonner C, et al. · Diabetes Metab · 2019 · Background
    PubMed: PMID 30017776 · NCT03968224 · Diabetes Mellitus, Type 2
  53. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
    Rådholm K, Figtree G, Perkovic V, et al. · Circulation · 2019 · Background
    PubMed: PMID 29526832 · NCT05741658 (FonDap) · Heart Failure
  54. Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation.
    Pluymaekers NAHA, Dudink EAMP, Luermans JGLM, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 30883054 · NCT06759909 · Atrial Fibrillation
  55. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Parving H-H, Lambers-Heerspink H, de Zeeuw D, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 28106974 · NCT06398977
  56. Drug repurposing in kidney disease.
    Panchapakesan U, Pollock C · Kidney Int · 2019 · Background
    PubMed: PMID 29628139 · NCT06421870 · Renal Insufficiency, Chronic
  57. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M, Anker SD, Butler J, et al. · JAMA Cardiol · 2019 · Background
    PubMed: PMID 28768320 · NCT05741658 (FonDap) · Heart Failure
  58. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
    Mullens W, Verbrugge FH, Nijst P, et al. · Eur J Heart Fail · 2019 · Background
    PubMed: PMID 30238574 · NCT06535529
  59. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW, Neal B, Perkovic V, et al. · Circulation · 2019 · Background
    PubMed: PMID 29133604 · NCT05719714 · Heart Failure
  60. Cardiac fibrosis: new insights into the pathogenesis.
    Ma ZG, Yuan YP, Wu HM, et al. · Int J Biol Sci · 2019 · Background
    PubMed: PMID 30416379 · NCT05335629 · Diabetes Mellitus, Type 2
  61. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C, Zhang J, Xue M, et al. · Cardiovasc Diabetol · 2019 · Background
    PubMed: PMID 30710997 · NCT05335629 · Diabetes Mellitus, Type 2
  62. Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications.
    Kumar N, Garg A, Bhatt DL, et al. · Can J Physiol Pharmacol · 2019 · Background
    PubMed: PMID 30265814 · NCT05719714 · Heart Failure
  63. The Role for Protein Restriction in Addition to Renin-Angiotensin-Aldosterone System Inhibitors in the Management of CKD.
    Koppe L, Fouque D · Am J Kidney Dis · 2019 · Background
    PubMed: PMID 30149957 · NCT06890143 · Proteinuria
  64. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Kelly MS, Lewis J, Huntsberry AM, et al. · Postgrad Med · 2019 · Background
    PubMed: PMID 30449220 · NCT03968224 · Diabetes Mellitus, Type 2
  65. Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Kappel BA, Lehrke M, Schütt K, et al. · Circulation · 2019 · Background
    PubMed: PMID 28874423 · NCT05719714 · Heart Failure
  66. Management of Heart Failure in Advancing CKD: Core Curriculum 2018.
    House AA · Am J Kidney Dis · 2019 · Background
    PubMed: PMID 29478868 · NCT05719714 · Heart Failure
  67. Catheter Ablation for Cardiac Arrhythmias: Utilization and In-Hospital Complications, 2000 to 2013.
    Hosseini SM, Rozen G, Saleh A, et al. · JACC Clin Electrophysiol · 2019 · Background
    PubMed: PMID 29759619 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  68. The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review.
    Hess PL, Healey JS, Granger CB, et al. · JAMA Cardiol · 2019 · Background
    PubMed: PMID 28097334 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  69. Ventricular Torsion in Young Patients With Single-Ventricle Anatomy.
    Grattan M, Mertens L, Grosse-Wortmann L, et al. · J Am Soc Echocardiogr · 2019 · Background
    PubMed: PMID 30340887 · NCT07482943 · Heart Failure
  70. Metabolomics Research in Chronic Kidney Disease.
    Grams ME, Shafi T, Rhee EP, et al. · J Am Soc Nephrol · 2019 · Background
    PubMed: PMID 29724883 · NCT05719714 · Heart Failure
  71. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
    Garber AJ, Abrahamson MJ, Barzilay JI, et al. · Endocr Pract · 2019 · Background
    PubMed: PMID 30742570 · NCT03968224 · Diabetes Mellitus, Type 2
  72. Contemporary Procedural Complications, Hospitalizations, and Emergency Visits After Catheter Ablation for Atrial Fibrillation.
    Freeman JV, Tabada GH, Reynolds K, et al. · Am J Cardiol · 2019 · Background
    PubMed: PMID 29331355 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  73. Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
    Fink HA, Jutkowitz E, McCarten JR, et al. · Ann Intern Med · 2019 · Background
    PubMed: PMID 29255847 · NCT05262257
  74. Clinical Outcomes in Adolescents and Adults After the Fontan Procedure.
    Dennis M, Zannino D, du Plessis K, et al. · J Am Coll Cardiol · 2019 · Background
    PubMed: PMID 29495980 · NCT07482943 · Heart Failure
  75. Cardiovascular disease in dialysis patients.
    Cozzolino M, Mangano M, Stucchi A, et al. · Nephrol Dial Transplant · 2019 · Background
    PubMed: PMID 30281132 · NCT05719714 · Heart Failure
  76. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis.
    Chong J, Soufan O, Li C, et al. · Nucleic Acids Res · 2019 · Background
    PubMed: PMID 29762782 · NCT05719714 · Heart Failure
  77. Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF-κB pathway.
    Chen X, Li X, Zhang W, et al. · Metabolism · 2019 · Background
    PubMed: PMID 29526538 · NCT05217654 · Reperfusion Injury
  78. Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association.
    Chen LY, Chung MK, Allen LA, et al. · Circulation · 2019 · Background
    PubMed: PMID 29661944 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  79. Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan.
    Chen DQ, Cao G, Chen H, et al. · Nat Commun · 2019 · Background
    PubMed: PMID 30931940 · NCT05719714 · Heart Failure
  80. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
    Cavender MA, Norhammar A, Birkeland KI, et al. · J Am Coll Cardiol · 2019 · Background
    PubMed: PMID 29852973 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  81. Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center.
    Calapkulu M, Cander S, Gul OO, et al. · Diabetes Metab Syndr · 2019 · Background
    PubMed: PMID 30641713 · NCT03968224 · Diabetes Mellitus, Type 2
  82. SGLT2 Inhibitors and Mechanisms of Hypertension.
    Briasoulis A, Al Dhaybi O, Bakris GL, et al. · Curr Cardiol Rep · 2019 · Background
    PubMed: PMID 29349558 · NCT03968224 · Diabetes Mellitus, Type 2
  83. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    Bray F, Ferlay J, Soerjomataram I, et al. · CA Cancer J Clin · 2019 · Background
    PubMed: PMID 30207593 · NCT06364930 · Hepatitis B, Chronic
  84. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease.
    Bonnet F, Scheen AJ · Diabetes Metab · 2019 · Background
    PubMed: PMID 30266577 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  85. Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial.
    Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. · JAMA · 2019 · Background
    PubMed: PMID 30874754 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  86. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association.
    Benjamin EJ, Virani SS, Callaway CW, et al. · Circulation · 2019 · Background
    PubMed: PMID 29386200 · NCT05719714 · Heart Failure
  87. Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.
    Aylsworth A, Dean Z, VanNorman C, et al. · Ann Pharmacother · 2019 · Background
    PubMed: PMID 24951310 · NCT02887677 · Diabetes Mellitus
  88. Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System.
    Ansary TM, Nakano D, Nishiyama A, et al. · Int J Mol Sci · 2019 · Background
    PubMed: PMID 30717173 · NCT04792190 (DAPA-AF) · Atrial Fibrillation

2018 (53 papers)

  1. Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease.
    Sumida K, Molnar MZ, Potukuchi PK, et al. · Clin J Am Soc Nephrol · 2018 · Trial result
    PubMed: PMID 28893924 · NCT06890143 · Proteinuria
  2. Risks Associated with SGLT2 Inhibitors: An Overview.
    Singh M, Kumar A · Curr Drug Saf · 2018 · Trial result
    PubMed: PMID 29485006 · NCT05141552 (SDHF)
  3. Chronic kidney disease.
    Romagnani P, Remuzzi G, Glassock R, et al. · Nat Rev Dis Primers · 2018 · Trial result
    PubMed: PMID 29168475 · NCT06890143 · Proteinuria
  4. Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction.
    Pérez Del Villar C, Savvatis K, López B, et al. · Cardiovasc Res · 2018 · Trial result
    PubMed: PMID 28402411 · NCT04739215 (CARDIA-STIFF) · Diabetes Mellitus, Type 2
  5. Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study.
    Núñez J, Palau P, Domínguez E, et al. · Clin Cardiol · 2018 · Trial result
    PubMed: PMID 29663436 · NCT06668389 (STEPS) · Heart Defects, Congenital
  6. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS, Krishan S, Mishra SK, et al. · Diabetes Care · 2018 · Trial result
    PubMed: PMID 29895557 · NCT05042505 (Dapa-LiT) · Diabetes Mellitus
  7. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
    Jabbour S, Seufert J, Scheen A, et al. · Diabetes Obes Metab · 2018 · Trial result
    PubMed: PMID 28950419 · NCT05565976 (DECIST) · Cognitive Dysfunction
  8. MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?
    Esterline RL, Vaag A, Oscarsson J, et al. · Eur J Endocrinol · 2018 · Trial result
    PubMed: PMID 29371333 · NCT05565976 (DECIST) · Cognitive Dysfunction
  9. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.
    Dekkers CCJ, Gansevoort RT, Heerspink HJL, et al. · Curr Diab Rep · 2018 · Trial result
    PubMed: PMID 29589183 · NCT06890143 · Proteinuria
  10. Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.
    Abdul-Ghani M, Migahid O, Megahed A, et al. · Diabetes Obes Metab · 2018 · Trial result
    PubMed: PMID 29227578 · NCT03658031 · Diabetes Mellitus, Type 2
  11. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
    Rosenstock J, Mathieu C, Chen H, et al. · Arch Endocrinol Metab · 2018 · Derived
    PubMed: PMID 30304106 · NCT01606007 · Diabetes Mellitus, Type 2
  12. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
    Mathieu C, Dandona P, Gillard P, et al. · Diabetes Care · 2018 · Derived
    PubMed: PMID 30026335 · NCT02460978 (DEPICT 2) · Diabetes Mellitus, Type 1
  13. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
    Jabbour SA, Frías JP, Hardy E, et al. · Diabetes Care · 2018 · Derived
    PubMed: PMID 30082326 · NCT02229396 · Diabetes Mellitus
  14. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, et al. · Lancet Diabetes Endocrinol · 2018 · Derived
    PubMed: PMID 27651331 · NCT02229396 · Diabetes Mellitus
  15. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
    Fioretto P, Stefansson BV, Johnsson E, et al. · Diabetologia · 2018 · Derived
    PubMed: PMID 27306615 · NCT00663260 · Diabetes Mellitus, Type 2
  16. Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
    Færch K, Amadid H, Nielsen LB, et al. · BMJ Open · 2018 · Derived
    PubMed: PMID 28592573 · NCT02695810 · Obesity
  17. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
    Dandona P, Mathieu C, Phillip M, et al. · Lancet Diabetes Endocrinol · 2018 · Derived
    PubMed: PMID 28919061 · NCT02268214 (DEPICT 1) · Diabetes Mellitus, Type 1
  18. Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.
    Brown AJM, Lang C, McCrimmon R, et al. · BMC Cardiovasc Disord · 2018 · Derived
    PubMed: PMID 28835229 · NCT02956811 (DAPA-LVH) · Diabetes Mellitus, Type 2
  19. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.
    Zhou H, Wang S, Zhu P, et al. · Redox Biol · 2018 · Background
    PubMed: PMID 29306791 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  20. Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease.
    Zewinger S, Kleber ME, Rohrer L, et al. · Eur Heart J · 2018 · Background
    PubMed: PMID 28379378 · NCT05719714 · Heart Failure
  21. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y, Bajaj M, Yang HC, et al. · Cardiovasc Drugs Ther · 2018 · Background
    PubMed: PMID 28447181 · NCT05618223 (Dapa-Rhemis) · Heart Failure
  22. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve.
    Xaplanteris P, Fournier S, Pijls NHJ, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29785878 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  23. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH, Foote C, Blomster J, et al. · Lancet Diabetes Endocrinol · 2018 · Background
    PubMed: PMID 27009625 · NCT07020377 · Diabetes Mellitus, Type 2
  24. Diabetic retinopathy.
    Wong TY, Cheung CM, Larsen M, et al. · Nat Rev Dis Primers · 2018 · Background
    PubMed: PMID 27159554 · NCT05310916 · Diabetic Retinopathy
  25. Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up.
    Wilding J, Bailey C, Rigney U, et al. · Prim Care Diabetes · 2018 · Background
    PubMed: PMID 28583425 · NCT05418946 (PRECARE) · Diabetes Mellitus, Type 2
  26. Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study.
    Weisshaar S, Litschauer B, Kerbel T, et al. · Int J Cardiol · 2018 · Background
    PubMed: PMID 29288055 · NCT05217654 · Reperfusion Injury
  27. Ticagrelor mitigates ischaemia-reperfusion induced vascular endothelial dysfunction in healthy young males - a randomized, single-blinded study.
    Weisshaar S, Litschauer B, Eipeldauer M, et al. · Br J Clin Pharmacol · 2018 · Background
    PubMed: PMID 28715608 · NCT05217654 · Reperfusion Injury
  28. Alterations in white matter volume and integrity in obesity and type 2 diabetes.
    van Bloemendaal L, Ijzerman RG, Ten Kulve JS, et al. · Metab Brain Dis · 2018 · Background
    PubMed: PMID 26815786 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  29. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
    Solini A, Giannini L, Seghieri M, et al. · Cardiovasc Diabetol · 2018 · Background
    PubMed: PMID 29061124 · NCT07174687 · Eye Diseases
  30. Circulating miR-130a, miR-27b, and miR-210 in Patients With Peripheral Artery Disease and Their Potential Relationship With Oxidative Stress.
    Signorelli SS, Volsi GL, Pitruzzella A, et al. · Angiology · 2018 · Background
    PubMed: PMID 26980776 · NCT03377335 · Diabetes Mellitus, Type 2
  31. Association between oxidative stress and atrial fibrillation.
    Samman Tahhan A, Sandesara PB, Hayek SS, et al. · Heart Rhythm · 2018 · Background
    PubMed: PMID 28757307 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  32. [Methodological design of the National Health and Nutrition Survey 2016].
    Romero-Martínez M, Shamah-Levy T, Cuevas-Nasu L, et al. · Salud Publica Mex · 2018 · Background
    PubMed: PMID 28902317 · NCT03968224 · Diabetes Mellitus, Type 2
  33. Serum concentrations of asymmetric and symmetric dimethylarginine are associated with mortality in acute heart failure patients.
    Potočnjak I, Radulović B, Degoricija V, et al. · Int J Cardiol · 2018 · Background
    PubMed: PMID 29550017 · NCT05719714 · Heart Failure
  34. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
    Persson F, Nyström T, Jørgensen ME, et al. · Diabetes Obes Metab · 2018 · Background
    PubMed: PMID 28771923 · NCT06398977
  35. Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation.
    Pandey A, Kim S, Moore C, et al. · JACC Heart Fail · 2018 · Background
    PubMed: PMID 28034376 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  36. Validation of days at home as an outcome measure after surgery: a prospective cohort study in Australia.
    Myles PS, Shulman MA, Heritier S, et al. · BMJ Open · 2018 · Background
    PubMed: PMID 28821518 · NCT05590143 (MERCURI-2) · Acute Kidney Injury
  37. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
    Monami M, Nreu B, Zannoni S, et al. · Diabetes Res Clin Pract · 2018 · Background
    PubMed: PMID 28570924 · NCT03968224 · Diabetes Mellitus, Type 2
  38. Soluble ST2 in Heart Failure.
    McCarthy CP, Januzzi JL · Heart Fail Clin · 2018 · Background
    PubMed: PMID 29153199 · NCT05335629 · Diabetes Mellitus, Type 2
  39. New markers of urinary tract infection.
    Masajtis-Zagajewska A, Nowicki M · Clin Chim Acta · 2018 · Background
    PubMed: PMID 28622967 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  40. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P, Pereira MJ, Katsogiannos P, et al. · Diabetes Obes Metab · 2018 · Background
    PubMed: PMID 28345814 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  41. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Liu J, Li L, Li S, et al. · Sci Rep · 2018 · Background
    PubMed: PMID 28588220 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  42. The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels.
    Li H, Shin SE, Seo MS, et al. · Life Sci · 2018 · Background
    PubMed: PMID 29409796 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  43. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.
    Kosiborod M, Gause-Nilsson I, Xu J, et al. · J Diabetes Complications · 2018 · Background
    PubMed: PMID 28284707 · NCT07174687 · Eye Diseases
  44. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
    Kohler S, Zeller C, Iliev H, et al. · Adv Ther · 2018 · Background
    PubMed: PMID 28631216 · NCT06612086 · Hypertension, Pulmonary
  45. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
    GBD 2016 Risk Factors Collaborators · Lancet · 2018 · Background
    PubMed: PMID 28919119 · NCT06364930 · Hepatitis B, Chronic
  46. Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study.
    Gayat E, Cariou A, Deye N, et al. · Crit Care · 2018 · Background
    PubMed: PMID 29347987 · NCT07025629 (DAPA-ICU) · Heart Failure
  47. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories.
    Foreman KJ, Marquez N, Dolgert A, et al. · Lancet · 2018 · Background
    PubMed: PMID 30340847 · NCT06982079 · Renal Insufficiency, Chronic
  48. World Health Organization disability assessment schedule 2.0: An international systematic review.
    Federici S, Bracalenti M, Meloni F, et al. · Disabil Rehabil · 2018 · Background
    PubMed: PMID 27820966 · NCT05590143 (MERCURI-2) · Acute Kidney Injury
  49. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
    Del Prato S, Rosenstock J, Garcia-Sanchez R, et al. · Diabetes Obes Metab · 2018 · Background
    PubMed: PMID 29446523 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  50. The associations between phthalate exposure and insulin resistance, β-cell function and blood glucose control in a population-based sample.
    Dales RE, Kauri LM, Cakmak S, et al. · Sci Total Environ · 2018 · Background
    PubMed: PMID 28898934 · NCT04242758 (PURITY) · Glucose Metabolism Disorders
  51. Evaluation of the relationship between ventricular end-diastolic pressure and echocardiographic measures of diastolic function in adults with a Fontan circulation.
    Cordina R, Ministeri M, Babu-Narayan SV, et al. · Int J Cardiol · 2018 · Background
    PubMed: PMID 29472024 · NCT07482943 · Heart Failure
  52. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI, Jørgensen ME, Carstensen B, et al. · Lancet Diabetes Endocrinol · 2018 · Background
    PubMed: PMID 28781064 · NCT06398977
  53. Cardiovascular events after ICU discharge in patients with new-onset atrial fibrillation: A report from the FROG-ICU study.
    Arrigo M, Feliot E, Gayat E, et al. · Int J Cardiol · 2018 · Background
    PubMed: PMID 30045823 · NCT07025629 (DAPA-ICU) · Heart Failure

2017 (63 papers)

  1. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V, Thomson SC · Diabetologia · 2017 · Trial result
    PubMed: PMID 27878313 · NCT06890143 · Proteinuria
  2. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
    Tirucherai GS, LaCreta F, Ismat FA, et al. · Diabetes Obes Metab · 2017 · Trial result
    PubMed: PMID 27291448 · NCT06890143 · Proteinuria
  3. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    Neal B, Perkovic V, Mahaffey KW, et al. · N Engl J Med · 2017 · Trial result
    PubMed: PMID 28605608 · NCT05424315 (DACAMI) · Heart Failure
  4. Post-stroke dementia - a comprehensive review.
    Mijajlović MD, Pavlović A, Brainin M, et al. · BMC Med · 2017 · Trial result
    PubMed: PMID 28095900 · NCT05565976 (DECIST) · Cognitive Dysfunction
  5. Contrast-Induced Acute Kidney Injury.
    McCullough PA, Choi JP, Feghali GA, et al. · J Am Coll Cardiol · 2017 · Trial result
    PubMed: PMID 27659469 · NCT04806633 · Acute Kidney Injury
  6. Proteinuria in Children: Evaluation and Differential Diagnosis.
    Leung AK, Wong AH, Barg SS, et al. · Am Fam Physician · 2017 · Trial result
    PubMed: PMID 28290633 · NCT06890143 · Proteinuria
  7. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
    Heerspink HJ, Desai M, Jardine M, et al. · J Am Soc Nephrol · 2017 · Trial result
    PubMed: PMID 27539604 · NCT06890143 · Proteinuria
  8. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P, Zambon A, Rossato M, et al. · Diabetes Care · 2017 · Trial result
    PubMed: PMID 27440829 · NCT04806633 · Acute Kidney Injury
  9. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
    Daniele G, Xiong J, Solis-Herrera C, et al. · Diabetes Care · 2017 · Trial result
    PubMed: PMID 27561923 · NCT01439854 (DAPA MITO) · Insulin Resistance
  10. Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes.
    Al-Jobori H, Daniele G, Cersosimo E, et al. · Diabetes · 2017 · Trial result
    PubMed: PMID 28428225 · NCT03658031 · Diabetes Mellitus, Type 2
  11. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
    Abdul-Ghani M, Migahid O, Megahed A, et al. · Diabetes Care · 2017 · Trial result
    PubMed: PMID 28096223 · NCT03658031 · Diabetes Mellitus, Type 2
  12. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA, Mansfield TA, Cain VA, et al. · Lancet Diabetes Endocrinol · 2017 · Derived
    PubMed: PMID 26620248 · NCT01195662 · Diabetes Mellitus, Type 2
  13. Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study.
    Vakkalagadda B, Lubin S, Reynolds L, et al. · Clin Ther · 2017 · Derived
    PubMed: PMID 27491280 · NCT01662999 · Diabetes Mellitus, Type 2
  14. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.
    Singh JS, Fathi A, Vickneson K, et al. · Cardiovasc Diabetol · 2017 · Derived
    PubMed: PMID 27422625 · NCT02397421 (REFORM) · Diabetes Mellitus
  15. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
    Ott C, Jumar A, Striepe K, et al. · Cardiovasc Diabetol · 2017 · Derived
    PubMed: PMID 28231831 · NCT02383238 (Dapa) · Diabetes Mellitus, Type 2
  16. Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
    Mellander A, Billger M, Johnsson E, et al. · Clin Drug Investig · 2017 · Derived
    PubMed: PMID 27461213 · NCT00357370 · Diabetes Mellitus, Type 2
  17. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
    Leiter LA, Cefalu WT, de Bruin TW, et al. · Diabetes Obes Metab · 2017 · Derived
    PubMed: PMID 27009868 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  18. Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
    Kuhadiya ND, Ghanim H, Mehta A, et al. · J Clin Endocrinol Metab · 2017 · Derived
    PubMed: PMID 27490915 · NCT02518945 · Diabetes Mellitus, Type 1
  19. The effect of dapagliflozin on renal function in patients with type 2 diabetes.
    Kohan DE, Fioretto P, Johnsson K, et al. · J Nephrol · 2017 · Derived
    PubMed: PMID 26894924 · NCT00528372 · Diabetes Mellitus, Type 2
  20. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
    Fadini GP, Bonora BM, Zatti G, et al. · Cardiovasc Diabetol · 2017 · Derived
    PubMed: PMID 28376855 · NCT02327039 (DAPA-HDL) · Diabetes Mellitus, Type 2
  21. Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.
    Wilding JP, Rajeev SP, DeFronzo RA, et al. · Diabetes Care · 2017 · Background
    PubMed: PMID 27440828 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  22. Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress.
    Veeraveedu PT, Sanada S, Okuda K, et al. · Biochem Pharmacol · 2017 · Background
    PubMed: PMID 28450225 · NCT05335629 · Diabetes Mellitus, Type 2
  23. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
    van Bommel EJM, Muskiet MHA, Tonneijck L, et al. · Clin J Am Soc Nephrol · 2017 · Background
    PubMed: PMID 28254770 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  24. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
    Ter Maaten JM, Valente MA, Damman K, et al. · Circ Heart Fail · 2017 · Background
    PubMed: PMID 27266853 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  25. Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption.
    Ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. · J Endocrinol · 2017 · Background
    PubMed: PMID 26769912 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  26. Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients.
    Ten Kulve JS, van Bloemendaal L, Balesar R, et al. · J Clin Endocrinol Metab · 2017 · Background
    PubMed: PMID 26672638 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  27. Methods, accuracy and clinical implications of atrial fibrillation detection by cardiac implantable electronic devices.
    Solari D, Bertero E, Miceli R, et al. · Int J Cardiol · 2017 · Background
    PubMed: PMID 28143653 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  28. Identification of Major Adverse Kidney Events Within the Electronic Health Record.
    Semler MW, Rice TW, Shaw AD, et al. · J Med Syst · 2017 · Background
    PubMed: PMID 27234478 · NCT05590143 (MERCURI-2) · Acute Kidney Injury
  29. The Fontan epidemic: Population projections from the Australia and New Zealand Fontan Registry.
    Schilling C, Dalziel K, Nunn R, et al. · Int J Cardiol · 2017 · Background
    PubMed: PMID 27257850 · NCT07482943 · Heart Failure
  30. HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium.
    Ruiz M, Okada H, Dahlbäck B, et al. · Lipids Health Dis · 2017 · Background
    PubMed: PMID 28179022 · NCT07174687 · Eye Diseases
  31. Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease.
    Ruiz-Hurtado G, Ruilope LM, de la Sierra A, et al. · Diabetes Care · 2017 · Background
    PubMed: PMID 27515965 · NCT03887416
  32. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
    Rizzo M, Rizvi AA, Patti AM, et al. · Cardiovasc Diabetol · 2017 · Background
    PubMed: PMID 27912784 · NCT03377335 · Diabetes Mellitus, Type 2
  33. Utility of galectin-3 in predicting post-infarct remodeling after acute myocardial infarction based on extracellular volume fraction mapping.
    Perea RJ, Morales-Ruiz M, Ortiz-Perez JT, et al. · Int J Cardiol · 2017 · Background
    PubMed: PMID 27544605 · NCT06619600 (DAPA-STEMI) · Diabetes Mellitus
  34. Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance.
    Palazzuoli A, Testani JM, Ruocco G, et al. · Int J Cardiol · 2017 · Background
    PubMed: PMID 27657476 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  35. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure.
    Packer M, O'Connor C, McMurray JJV, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28402745 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  36. Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.
    Okamoto A, Yokokawa H, Sanada H, et al. · Drugs R D · 2017 · Background
    PubMed: PMID 27333994 · NCT03968224 · Diabetes Mellitus, Type 2
  37. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    Neal B, Perkovic V, Matthews DR, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 29166232 · NCT05719714 · Heart Failure
  38. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
    Muskiet MHA, Tonneijck L, Smits MM, et al. · Nat Rev Nephrol · 2017 · Background
    PubMed: PMID 28869249 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  39. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
    Mudaliar S, Alloju S, Henry RR, et al. · Diabetes Care · 2017 · Background
    PubMed: PMID 27289124 · NCT05719714 · Heart Failure
  40. Wounds that heal and wounds that don't - The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis.
    Millar NL, O'Donnell C, McInnes IB, et al. · Semin Cell Dev Biol · 2017 · Background
    PubMed: PMID 27521518 · NCT05335629 · Diabetes Mellitus, Type 2
  41. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
    Li D, Wang T, Shen S, et al. · Diabetes Obes Metab · 2017 · Background
    PubMed: PMID 27862830 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  42. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.
    Lee TM, Chang NC, Lin SZ, et al. · Free Radic Biol Med · 2017 · Background
    PubMed: PMID 28132924 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  43. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M, Cavender MA, Fu AZ, et al. · Circulation · 2017 · Background
    PubMed: PMID 28522450 · NCT06286878 · Diabetes Mellitus
  44. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.
    Konstam MA, Kiernan M, Chandler A, et al. · J Am Coll Cardiol · 2017 · Background
    PubMed: PMID 28302292 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  45. High salt intake reprioritizes osmolyte and energy metabolism for body fluid conservation.
    Kitada K, Daub S, Zhang Y, et al. · J Clin Invest · 2017 · Background
    PubMed: PMID 28414295 · NCT05884866 (DapaBalci-Leap) · Renal Insufficiency, Chronic
  46. An overview of renal metabolomics.
    Kalim S, Rhee EP · Kidney Int · 2017 · Background
    PubMed: PMID 27692817 · NCT05719714 · Heart Failure
  47. Emergency Department, Hospital Inpatient, and Mortality Burden of Atrial Fibrillation in the United States, 2006 to 2014.
    Jackson SL, Tong X, Yin X, et al. · Am J Cardiol · 2017 · Background
    PubMed: PMID 28964382 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  48. Metabolomics for clinical use and research in chronic kidney disease.
    Hocher B, Adamski J · Nat Rev Nephrol · 2017 · Background
    PubMed: PMID 28262773 · NCT05719714 · Heart Failure
  49. Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension.
    Hiltunen TP, Rimpelä JM, Mohney RP, et al. · PLoS One · 2017 · Background
    PubMed: PMID 29121091 · NCT05719714 · Heart Failure
  50. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
    Fralick M, Schneeweiss S, Patorno E, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28591538 · NCT05217654 · Reperfusion Injury
  51. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
    Fioretto P, Mansfield TA, Ptaszynska A, et al. · Drugs Aging · 2017 · Background
    PubMed: PMID 27357173 · NCT07174687 · Eye Diseases
  52. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
    Ferrannini E, Mark M, Mayoux E, et al. · Diabetes Care · 2017 · Background
    PubMed: PMID 27289126 · NCT03887416
  53. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
    Ferrannini E, Baldi S, Frascerra S, et al. · Diabetes · 2017 · Background
    PubMed: PMID 26861783 · NCT05719714 · Heart Failure
  54. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
    Felker GM, Mentz RJ, Cole RT, et al. · J Am Coll Cardiol · 2017 · Background
    PubMed: PMID 27654854 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  55. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry.
    Echouffo-Tcheugui JB, Xu H, DeVore AD, et al. · Am Heart J · 2017 · Background
    PubMed: PMID 27914505 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  56. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
    DeFronzo RA, Norton L, Abdul-Ghani M, et al. · Nat Rev Nephrol · 2017 · Background
    PubMed: PMID 27941935 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  57. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.
    de Silva VA, Suraweera C, Ratnatunga SS, et al. · BMC Psychiatry · 2017 · Background
    PubMed: PMID 27716110 · NCT07342764 · Psychotic Disorders
  58. [Cardiovascular risk study in patients with renin-angiotensin system blockade by means of the proteone of circulating extracellular vesicles].
    de la Cuesta F, Baldan-Martin M, Mourino-Alvarez L, et al. · Hipertens Riesgo Vasc · 2017 · Background
    PubMed: PMID 26826536 · NCT03887416
  59. Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1.
    Christensen PM, Liu CH, Swendeman SL, et al. · FASEB J · 2017 · Background
    PubMed: PMID 26956418 · NCT07174687 · Eye Diseases
  60. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.
    Chang YK, Choi H, Jeong JY, et al. · PLoS One · 2017 · Background
    PubMed: PMID 27391020 · NCT07025629 (DAPA-ICU) · Heart Failure
  61. Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β-Thalassemia.
    Bellanti F, Di Iorio VL, Danhof M, et al. · J Clin Pharmacol · 2017 · Background
    PubMed: PMID 26785826 · NCT06012266 · Heart Failure
  62. Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression: New Predictors of Renal Damage and De Novo Albuminuria Indicators.
    Baldan-Martin M, Mourino-Alvarez L, Gonzalez-Calero L, et al. · Hypertension · 2017 · Background
    PubMed: PMID 27217411 · NCT03887416
  63. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
    Abdul-Ghani M, Del Prato S, Chilton R, et al. · Diabetes Care · 2017 · Background
    PubMed: PMID 27208375 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2

2016 (60 papers)

  1. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
    Terasaki M, Hiromura M, Mori Y, et al. · PLoS One · 2016 · Trial result
    PubMed: PMID 26606676 · NCT05998525 · Diabetes Mellitus, Type 2
  2. Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE).
    Sulaiman K, Panduranga P, Al-Zakwani I, et al. · Eur J Heart Fail · 2016 · Trial result
    PubMed: PMID 25739882 · NCT03658031 · Diabetes Mellitus, Type 2
  3. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Sarafidis PA, Tsapas A · N Engl J Med · 2016 · Trial result
    PubMed: PMID 26981941 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  4. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T, Isogawa A, Toda N, et al. · Clin Drug Investig · 2016 · Trial result
    PubMed: PMID 26914659 · NCT05459701 · Diabetes Mellitus, Type 2
  5. Peak oxygen uptake, ventilatory efficiency and QRS-duration predict event free survival in patients late after surgical repair of tetralogy of Fallot.
    Müller J, Hager A, Diller GP, et al. · Int J Cardiol · 2016 · Trial result
    PubMed: PMID 26114442 · NCT06668389 (STEPS) · Heart Defects, Congenital
  6. Non-invasive quantification of hepatic steatosis in living, related liver donors using dual-echo Dixon imaging and single-voxel proton spectroscopy.
    Krishan S, Jain D, Bathina Y, et al. · Clin Radiol · 2016 · Trial result
    PubMed: PMID 26555703 · NCT05042505 (Dapa-LiT) · Diabetes Mellitus
  7. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation.
    Ishibashi Y, Matsui T, Yamagishi S, et al. · Horm Metab Res · 2016 · Trial result
    PubMed: PMID 26158396 · NCT04806633 · Acute Kidney Injury
  8. Coronary artery calcium scanning: past, present, and future.
    Hecht HS · JACC Cardiovasc Imaging · 2016 · Trial result
    PubMed: PMID 25937196 · NCT05998525 · Diabetes Mellitus, Type 2
  9. Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Chang M, Liu X, Cui D, et al. · Clin Ther · 2016 · Trial result
    PubMed: PMID 26048185 · NCT01535677 · Diabetes Mellitus, Type 2
  10. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus.
    Abdul-Ghani MA, Norton L, DeFronzo RA, et al. · Am J Physiol Renal Physiol · 2016 · Trial result
    PubMed: PMID 26354881 · NCT04240171 · Diabetes Mellitus, Type 2
  11. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects.
    Tang W, Reele S, Hamer-Maansson JE, et al. · Diabetes Obes Metab · 2016 · Derived
    PubMed: PMID 25511685 · NCT01072578 · Diabetes Mellitus
  12. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
    Matthaei S, Catrinoiu D, Celiński A, et al. · Diabetes Care · 2016 · Derived
    PubMed: PMID 26324329 · NCT01619059 · Diabetes Mellitus, Type 2
  13. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C, Ranetti AE, Li D, et al. · Diabetes Care · 2016 · Derived
    PubMed: PMID 26246458 · NCT01646320 · Diabetes Mellitus, Type 2
  14. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
    Cefalu WT, Leiter LA, de Bruin TW, et al. · Diabetes Care · 2016 · Derived
    PubMed: PMID 25852208 · NCT01031680 · Diabetes Mellitus, Type 2
  15. Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
    Bloch MJ · J Am Soc Hypertens · 2016 · Derived
    PubMed: PMID 27408945 · NCT01730534 (DECLARE-TIMI58) · Diabetes Mellitus, Type 2
  16. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B, Lachin JM, Inzucchi SE, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 26981940 · NCT05719714 · Heart Failure
  17. Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial.
    Zimmermann FM, Ferrara A, Johnson NP, et al. · Eur Heart J · 2016 · Background
    PubMed: PMID 26400825 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  18. European Guidelines for Obesity Management in Adults.
    Yumuk V, Tsigos C, Fried M, et al. · Obes Facts · 2016 · Background
    PubMed: PMID 26641646 · NCT06000462 (DAPA-ANDO) · Obesity
  19. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
    Weber MA, Mansfield TA, Alessi F, et al. · Blood Press · 2016 · Background
    PubMed: PMID 26623980 · NCT02887677 · Diabetes Mellitus
  20. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C, Inzucchi SE, Lachin JM, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27299675 · NCT03887416
  21. Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease.
    Vlotides G, Mertens PR · Nephrol Dial Transplant · 2016 · Background
    PubMed: PMID 25230708 · NCT02887677 · Diabetes Mellitus
  22. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.
    van Bloemendaal L, Veltman DJ, Ten Kulve JS, et al. · Diabetes Obes Metab · 2016 · Background
    PubMed: PMID 26094857 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  23. Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation.
    van Bloemendaal L, Veltman DJ, ten Kulve JS, et al. · Obesity (Silver Spring) · 2016 · Background
    PubMed: PMID 26331843 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  24. Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response.
    Vaduganathan M, Kumar V, Voors AA, et al. · Expert Rev Cardiovasc Ther · 2016 · Background
    PubMed: PMID 26357970 · NCT04778787 · Heart Failure
  25. Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome.
    Tziomalos K, Athyros VG, Karagiannis A, et al. · Curr Pharm Des · 2016 · Background
    PubMed: PMID 24745924 · NCT02887677 · Diabetes Mellitus
  26. Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs.
    Tziomalos K, Athyros VG, Karagiannis A, et al. · Curr Vasc Pharmacol · 2016 · Background
    PubMed: PMID 26864445 · NCT03377335 · Diabetes Mellitus, Type 2
  27. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.
    ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. · Diabetologia · 2016 · Background
    PubMed: PMID 26385462 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  28. Development and Function of Effector Regulatory T Cells.
    Teh PP, Vasanthakumar A, Kallies A, et al. · Prog Mol Biol Transl Sci · 2016 · Background
    PubMed: PMID 26615096 · NCT05335629 · Diabetes Mellitus, Type 2
  29. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
    Sun YN, Zhou Y, Chen X, et al. · BMJ Open · 2016 · Background
    PubMed: PMID 24710132 · NCT02887677 · Diabetes Mellitus
  30. Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.
    Seman L, Macha S, Nehmiz G, et al. · Clin Pharmacol Drug Dev · 2016 · Background
    PubMed: PMID 27121669 · NCT05217654 · Reperfusion Injury
  31. Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression.
    Ruiz-Hurtado G, Condezo-Hoyos L, Pulido-Olmo H, et al. · J Hypertens · 2016 · Background
    PubMed: PMID 25033166 · NCT03887416
  32. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.
    Rosenstock J, Ferrannini E · Diabetes Care · 2016 · Background
    PubMed: PMID 26294774 · NCT03968224 · Diabetes Mellitus, Type 2
  33. Metabolomics and renal disease.
    Rhee EP · Curr Opin Nephrol Hypertens · 2016 · Background
    PubMed: PMID 26050125 · NCT05719714 · Heart Failure
  34. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
    Rajeev SP, Cuthbertson DJ, Wilding JP, et al. · Diabetes Obes Metab · 2016 · Background
    PubMed: PMID 26403227 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  35. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
    Rajasekeran H, Lytvyn Y, Cherney DZ, et al. · Kidney Int · 2016 · Background
    PubMed: PMID 26880444 · NCT03887416
  36. Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria.
    Pulido-Olmo H, García-Prieto CF, Álvarez-Llamas G, et al. · Clin Sci (Lond) · 2016 · Background
    PubMed: PMID 26733721 · NCT03887416
  37. Repurposing metformin: an old drug with new tricks in its binding pockets.
    Pryor R, Cabreiro F · Biochem J · 2016 · Background
    PubMed: PMID 26475449 · NCT03968224 · Diabetes Mellitus, Type 2
  38. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
    Peters AL, Buschur EO, Buse JB, et al. · Diabetes Care · 2016 · Background
    PubMed: PMID 26078479 · NCT05310916 · Diabetic Retinopathy
  39. Effects of oral hypoglycemic agents on platelet function.
    Papazafiropoulou A, Papanas N, Pappas S, et al. · J Diabetes Complications · 2016 · Background
    PubMed: PMID 26026848 · NCT06286878 · Diabetes Mellitus
  40. A contemporary approach to body mass regulation mechanisms.
    Nowak A, Czkwianianc E · Prz Gastroenterol · 2016 · Background
    PubMed: PMID 27350833 · NCT03968224 · Diabetes Mellitus, Type 2
  41. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.
    Muskiet MH, Tonneijck L, Smits MM, et al. · Lancet Diabetes Endocrinol · 2016 · Background
    PubMed: PMID 25943756 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  42. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.
    Michel MC, Mayoux E, Vallon V, et al. · Naunyn Schmiedebergs Arch Pharmacol · 2016 · Background
    PubMed: PMID 26108304 · NCT06000462 (DAPA-ANDO) · Obesity
  43. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Marso SP, Daniels GH, Brown-Frandsen K, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27295427 · NCT06286878 · Diabetes Mellitus
  44. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY, Zhang N, Chen R, et al. · J Diabetes Complications · 2016 · Background
    PubMed: PMID 26365905 · NCT06000462 (DAPA-ANDO) · Obesity
  45. Effect of canagliflozin on liver function tests in patients with type 2 diabetes.
    Leiter LA, Forst T, Polidori D, et al. · Diabetes Metab · 2016 · Background
    PubMed: PMID 26575250 · NCT06364930 · Hepatitis B, Chronic
  46. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation.
    Kuck KH, Brugada J, Fürnkranz A, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27042964 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  47. Is Metformin-Induced Vitamin B12 Deficiency Responsible for Cognitive Decline in Type 2 Diabetes?
    Khattar D, Khaliq F, Vaney N, et al. · Indian J Psychol Med · 2016 · Background
    PubMed: PMID 27570337 · NCT05262257
  48. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
    Imprialos KP, Sarafidis PA, Karagiannis AI, et al. · J Hypertens · 2016 · Background
    PubMed: PMID 26372321 · NCT03887416
  49. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ, Perkins BA, Fitchett DH, et al. · Circulation · 2016 · Background
    PubMed: PMID 27470878 · NCT06286878 · Diabetes Mellitus
  50. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
    Fioretto P, Giaccari A, Sesti G, et al. · Cardiovasc Diabetol · 2016 · Background
    PubMed: PMID 26474563 · NCT03968224 · Diabetes Mellitus, Type 2
  51. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
    Ferrannini G, Hach T, Crowe S, et al. · Diabetes Care · 2016 · Background
    PubMed: PMID 26180105 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  52. Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness.
    Faerch K, Hulmán A, Solomon TP, et al. · Curr Diabetes Rev · 2016 · Background
    PubMed: PMID 25877695 · NCT02695810 · Obesity
  53. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
    Erondu N, Desai M, Ways K, et al. · Diabetes Care · 2016 · Background
    PubMed: PMID 26203064 · NCT03968224 · Diabetes Mellitus, Type 2
  54. The kidney in heart failure: an update.
    Damman K, Testani JM · Eur Heart J · 2016 · Background
    PubMed: PMID 25838436 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  55. Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice.
    Chiba Y, Yamada T, Tsukita S, et al. · PLoS One · 2016 · Background
    PubMed: PMID 26963613 · NCT05459701 · Diabetes Mellitus, Type 2
  56. Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension.
    Cengiz M, Yavuzer S, Kılıçkıran Avcı B, et al. · Clin Exp Hypertens · 2016 · Background
    PubMed: PMID 26114349 · NCT03377335 · Diabetes Mellitus, Type 2
  57. Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database.
    Boye KS, Curtis SE, Lage MJ, et al. · Patient Prefer Adherence · 2016 · Background
    PubMed: PMID 27574406 · NCT06327815 · Diabetes Mellitus, Type 2
  58. Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma.
    Barbagallo I, Parenti R, Zappalà A, et al. · Acta Histochem · 2016 · Background
    PubMed: PMID 26493719 · NCT03377335 · Diabetes Mellitus, Type 2
  59. Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics.
    Baldan-Martin M, de la Cuesta F, Alvarez-Llamas G, et al. · Int J Cardiol · 2016 · Background
    PubMed: PMID 26119064 · NCT03887416
  60. Diabetes and Alzheimer's disease crosstalk.
    Baglietto-Vargas D, Shi J, Yaeger DM, et al. · Neurosci Biobehav Rev · 2016 · Background
    PubMed: PMID 26969101 · NCT05262257

2015 (68 papers)

  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B, Wanner C, Lachin JM, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 26378978 · NCT04717986 (DAPA-AMI) · Heart Failure
  2. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
    Rosenstock J, Hansen L, Zee P, et al. · Diabetes Care · 2015 · Trial result
    PubMed: PMID 25352655 · NCT01606007 · Diabetes Mellitus, Type 2
  3. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.
    Ravani P, Rossi R, Bonanni A, et al. · J Am Soc Nephrol · 2015 · Trial result
    PubMed: PMID 25592855 · NCT06890143 · Proteinuria
  4. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
    Oliva RV, Bakris GL · J Am Soc Hypertens · 2015 · Trial result
    PubMed: PMID 24631482 · NCT03658031 · Diabetes Mellitus, Type 2
  5. Loop Diuretics in Clinical Practice.
    Oh SW, Han SY · Electrolyte Blood Press · 2015 · Trial result
    PubMed: PMID 26240596 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  6. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M, Nardini C, Mannucci E, et al. · Diabetes Obes Metab · 2015 · Trial result
    PubMed: PMID 24320621 · NCT04240171 · Diabetes Mellitus, Type 2
  7. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA, Hardy E, Sugg J, et al. · Diabetes Care · 2015 · Trial result
    PubMed: PMID 24144654 · NCT00984867 · Diabetes Mellitus, Type 2
  8. [Not Available].
    Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) sobre el manejo del infarto agudo de miocardio con elevación del segmento ST (IAMCEST) · Rev Esp Cardiol · 2015 · Trial result
    PubMed: PMID 23040488 · NCT04717986 (DAPA-AMI) · Heart Failure
  9. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA, Kuritzky L · Postgrad Med · 2015 · Trial result
    PubMed: PMID 25414933 · NCT04240171 · Diabetes Mellitus, Type 2
  10. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
    Bailey CJ, Morales Villegas EC, Woo V, et al. · Diabet Med · 2015 · Trial result
    PubMed: PMID 25381876 · NCT00528372 · Diabetes Mellitus, Type 2
  11. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis, risk factors, outcome, prevention and treatment.
    Aurelio A, Durante A · Cardiology · 2015 · Trial result
    PubMed: PMID 24557146 · NCT04806633 · Acute Kidney Injury
  12. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.
    Abdul-Ghani MA, Puckett C, Triplitt C, et al. · Diabetes Obes Metab · 2015 · Trial result
    PubMed: PMID 25425451 · NCT03658031 · Diabetes Mellitus, Type 2
  13. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP, Woo V, Rohwedder K, et al. · Diabetes Obes Metab · 2015 · Derived
    PubMed: PMID 23911013 · NCT00673231 · Diabetes Mellitus, Type 2
  14. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S, Bowering K, Rohwedder K, et al. · Diabetes Care · 2015 · Derived
    PubMed: PMID 25592197 · NCT01392677 · Diabetes Mellitus, Type 2
  15. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR, Rosenstock J, Edelman S, et al. · Diabetes Care · 2015 · Derived
    PubMed: PMID 25271207 · NCT01498185 · Diabetes Mellitus, Type 1
  16. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Bolinder J, Ljunggren Ö, Johansson L, et al. · Diabetes Obes Metab · 2015 · Derived
    PubMed: PMID 23906445 · NCT00855166 · Diabetes Mellitus, Type 2
  17. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
    Zamani P, Rawat D, Shiva-Kumar P, et al. · Circulation · 2015 · Background
    PubMed: PMID 25533966 · NCT05719714 · Heart Failure
  18. Novel approaches to drug discovery for the treatment of type 2 diabetes.
    Xu X, Wang G, Zhou T, et al. · Expert Opin Drug Discov · 2015 · Background
    PubMed: PMID 25054271 · NCT02887677 · Diabetes Mellitus
  19. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF.
    Voors AA, Davison BA, Teerlink JR, et al. · Eur J Heart Fail · 2015 · Background
    PubMed: PMID 25287144 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  20. Approaches to catheter ablation for persistent atrial fibrillation.
    Verma A, Jiang CY, Betts TR, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 25946280 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  21. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.
    van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. · Diabetes · 2015 · Background
    PubMed: PMID 25071023 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  22. Worsening of renal function during 1 year after hospital discharge is a strong and independent predictor of all-cause mortality in acute decompensated heart failure.
    Ueda T, Kawakami R, Sugawara Y, et al. · J Am Heart Assoc · 2015 · Background
    PubMed: PMID 25370599 · NCT05719714 · Heart Failure
  23. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
    Tikkanen I, Narko K, Zeller C, et al. · Diabetes Care · 2015 · Background
    PubMed: PMID 25271206 · NCT05194592 · Ventricular Remodeling
  24. Atrial fibrillation and heart failure: update 2015.
    Thihalolipavan S, Morin DP · Prog Cardiovasc Dis · 2015 · Background
    PubMed: PMID 26192885 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  25. Diuretic response in acute heart failure-an analysis from ASCEND-HF.
    ter Maaten JM, Dunning AM, Valente MA, et al. · Am Heart J · 2015 · Background
    PubMed: PMID 26299229 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  26. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM, Altunbas HA, Balci MK, et al. · Diabetes Metab Res Rev · 2015 · Background
    PubMed: PMID 24989141 · NCT02887677 · Diabetes Mellitus
  27. Diagnosis and management of acute coronary syndrome: an evidence-based update.
    Smith JN, Negrelli JM, Manek MB, et al. · J Am Board Fam Med · 2015 · Background
    PubMed: PMID 25748771 · NCT05335629 · Diabetes Mellitus, Type 2
  28. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
    Schumm-Draeger PM, Burgess L, Korányi L, et al. · Diabetes Obes Metab · 2015 · Background
    PubMed: PMID 25200570 · NCT01217892 · Diabetes Mellitus, Type 2
  29. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ · Drugs · 2015 · Background
    PubMed: PMID 25488697 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  30. Evaluation of a novel brachial cuff-based oscillometric method for estimating central systolic pressure in hemodialysis patients.
    Sarafidis PA, Georgianos PI, Karpetas A, et al. · Am J Nephrol · 2015 · Background
    PubMed: PMID 25322847 · NCT02887677 · Diabetes Mellitus
  31. Preoperative weight loss in super-obese patients: study of the rate of weight loss and its effects on surgical morbidity.
    Santo MA, Riccioppo D, Pajecki D, et al. · Clinics (Sao Paulo) · 2015 · Background
    PubMed: PMID 25627995 · NCT03968224 · Diabetes Mellitus, Type 2
  32. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.
    Rizzo M, Abate N, Chandalia M, et al. · J Clin Endocrinol Metab · 2015 · Background
    PubMed: PMID 25393640 · NCT03377335 · Diabetes Mellitus, Type 2
  33. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.
    Prasad-Reddy L, Isaacs D · Drugs Context · 2015 · Background
    PubMed: PMID 26213556 · NCT03419624 · Diabetes Mellitus, Type 2
  34. Beneficial effects of phlorizin on diabetic nephropathy in diabetic db/db mice.
    Pei F, Li BY, Zhang Z, et al. · J Diabetes Complications · 2015 · Background
    PubMed: PMID 24927646 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  35. Diabetes drugs and neurological disorders: new views and therapeutic possibilities.
    Patrone C, Eriksson O, Lindholm D, et al. · Lancet Diabetes Endocrinol · 2015 · Background
    PubMed: PMID 24622756 · NCT05262257
  36. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring.
    Parati G, Stergiou G, O'Brien E, et al. · J Hypertens · 2015 · Background
    PubMed: PMID 24886823 · NCT03887416
  37. Serum apolipoprotein B-48 concentration is associated with a reduced estimated glomerular filtration rate and increased proteinuria.
    Okubo M, Hanada H, Matsui M, et al. · J Atheroscler Thromb · 2015 · Background
    PubMed: PMID 24882621 · NCT02577159 (DAPHNIS) · Diabetes Mellitus, Type 2
  38. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management.
    Nitzan O, Elias M, Chazan B, et al. · Diabetes Metab Syndr Obes · 2015 · Background
    PubMed: PMID 25759592 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  39. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA, Del Prato S, Durán-García S, et al. · Diabetes Obes Metab · 2015 · Background
    PubMed: PMID 24919526 · NCT03968224 · Diabetes Mellitus, Type 2
  40. Weight gain and antipsychotics: a drug safety review.
    Musil R, Obermeier M, Russ P, et al. · Expert Opin Drug Saf · 2015 · Background
    PubMed: PMID 25400109 · NCT07342764 · Psychotic Disorders
  41. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
    Lin B, Koibuchi N, Hasegawa Y, et al. · Cardiovasc Diabetol · 2015 · Background
    PubMed: PMID 25344694 · NCT05262257
  42. Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus.
    Liakos A, Karagiannis T, Bekiari E, et al. · Ther Adv Endocrinol Metab · 2015 · Background
    PubMed: PMID 25941564 · NCT03968224 · Diabetes Mellitus, Type 2
  43. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).
    Lala A, McNulty SE, Mentz RJ, et al. · Circ Heart Fail · 2015 · Background
    PubMed: PMID 26041600 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  44. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
    Kolh P, Windecker S, Alfonso F, et al. · Eur J Cardiothorac Surg · 2015 · Background
    PubMed: PMID 25173601 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  45. The nonglycemic actions of dipeptidyl peptidase-4 inhibitors.
    Kim NH, Yu T, Lee DH, et al. · Biomed Res Int · 2015 · Background
    PubMed: PMID 25140306 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  46. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
    Kaku K, Kiyosue A, Inoue S, et al. · Diabetes Obes Metab · 2015 · Background
    PubMed: PMID 24909293 · NCT01294423 · Diabetes Mellitus, Type 2
  47. New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering?
    Jayawardene D, Ward GM, O'Neal DN, et al. · Heart Lung Circ · 2015 · Background
    PubMed: PMID 24996388 · NCT03968224 · Diabetes Mellitus, Type 2
  48. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
    January CT, Wann LS, Alpert JS, et al. · J Am Coll Cardiol · 2015 · Background
    PubMed: PMID 24685669 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  49. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
    Inzucchi SE, Zinman B, Wanner C, et al. · Diab Vasc Dis Res · 2015 · Background
    PubMed: PMID 25589482 · NCT06286878 · Diabetes Mellitus
  50. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
    Inzucchi SE, Bergenstal RM, Buse JB, et al. · Diabetes Care · 2015 · Background
    PubMed: PMID 25538310 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  51. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
    Hirakawa Y, Arima H, Zoungas S, et al. · Diabetes Care · 2015 · Background
    PubMed: PMID 24812434 · NCT02879409 · Diabetes Mellitus, Type 2
  52. Fractional flow reserve and the index of microvascular resistance in patients with acute coronary syndromes.
    Hennigan B, Layland J, Fearon WF, et al. · EuroIntervention · 2015 · Background
    PubMed: PMID 25256535 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  53. Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion.
    Hattersley AT, Thorens B · N Engl J Med · 2015 · Background
    PubMed: PMID 26332554 · NCT03968224 · Diabetes Mellitus, Type 2
  54. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
    Green JB, Bethel MA, Armstrong PW, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26052984 · NCT06286878 · Diabetes Mellitus
  55. Molecular pathology of emerging coronavirus infections.
    Gralinski LE, Baric RS · J Pathol · 2015 · Background
    PubMed: PMID 25270030 · NCT04393246 · COVID-19
  56. Prevalence of white-coat and masked hypertension in national and international registries.
    Gorostidi M, Vinyoles E, Banegas JR, et al. · Hypertens Res · 2015 · Background
    PubMed: PMID 25319601 · NCT02887677 · Diabetes Mellitus
  57. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
    Gallo LA, Wright EM, Vallon V, et al. · Diab Vasc Dis Res · 2015 · Background
    PubMed: PMID 25616707 · NCT06000462 (DAPA-ANDO) · Obesity
  58. Inflammation, oxidative stress, and obesity.
    Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, et al. · Int J Mol Sci · 2015 · Background
    PubMed: PMID 21686173 · NCT03968224 · Diabetes Mellitus, Type 2
  59. Cardiovascular risk stratification and management in pre-diabetes.
    Færch K, Vistisen D, Johansen NB, et al. · Curr Diab Rep · 2015 · Background
    PubMed: PMID 24743942 · NCT02695810 · Obesity
  60. Loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy.
    Cox ZL, Lenihan DJ · J Card Fail · 2015 · Background
    PubMed: PMID 24879974 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  61. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis.
    Cooper C, Sommerlad A, Lyketsos CG, et al. · Am J Psychiatry · 2015 · Background
    PubMed: PMID 25698435 · NCT05262257
  62. Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients.
    Cersosimo E, Solis-Herrera C, Triplitt C, et al. · J Bras Nefrol · 2015 · Background
    PubMed: PMID 24676619 · NCT06421870 · Renal Insufficiency, Chronic
  63. Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure.
    Broch K, Andreassen AK, Ueland T, et al. · Int J Cardiol · 2015 · Background
    PubMed: PMID 25464491 · NCT05335629 · Diabetes Mellitus, Type 2
  64. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
    Bonner C, Kerr-Conte J, Gmyr V, et al. · Nat Med · 2015 · Background
    PubMed: PMID 25894829 · NCT03968224 · Diabetes Mellitus, Type 2
  65. [Prevalence of obesity in Mexican adults 2000-2012].
    Barquera S, Campos-Nonato I, Hernández-Barrera L, et al. · Salud Publica Mex · 2015 · Background
    PubMed: PMID 24626691 · NCT03968224 · Diabetes Mellitus, Type 2
  66. Clinical significance of markers of collagen metabolism in rheumatic mitral valve disease.
    Banerjee T, Mukherjee S, Ghosh S, et al. · PLoS One · 2015 · Background
    PubMed: PMID 24603967 · NCT05618223 (Dapa-Rhemis) · Heart Failure
  67. Corneal confocal microscopy shows an improvement in small-fiber neuropathy in subjects with type 1 diabetes on continuous subcutaneous insulin infusion compared with multiple daily injection.
    Azmi S, Ferdousi M, Petropoulos IN, et al. · Diabetes Care · 2015 · Background
    PubMed: PMID 25538321 · NCT02879409 · Diabetes Mellitus, Type 2
  68. Pharmacological management of obesity: an endocrine Society clinical practice guideline.
    Apovian CM, Aronne LJ, Bessesen DH, et al. · J Clin Endocrinol Metab · 2015 · Background
    PubMed: PMID 25590212 · NCT03968224 · Diabetes Mellitus, Type 2

2014 (57 papers)

  1. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A, Kurosaki E, Yokono M, et al. · Eur J Pharmacol · 2014 · Trial result
    PubMed: PMID 23707905 · NCT05459701 · Diabetes Mellitus, Type 2
  2. [Ultrasound measurement of carotid stenosis: recommendations from the Spanish Society of Neurosonology].
    Serena J, Irimia P, Calleja S, et al. · Neurologia · 2014 · Trial result
    PubMed: PMID 23040716 · NCT05565976 (DECIST) · Cognitive Dysfunction
  3. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J, Seman LJ, Jelaska A, et al. · Diabetes Obes Metab · 2014 · Trial result
    PubMed: PMID 23906374 · NCT05042505 (Dapa-LiT) · Diabetes Mellitus
  4. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
    Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. · Diabetes Obes Metab · 2014 · Trial result
    PubMed: PMID 23668478 · NCT03658031 · Diabetes Mellitus, Type 2
  5. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
    Kasichayanula S, Liu X, Pe Benito M, et al. · Br J Clin Pharmacol · 2014 · Trial result
    PubMed: PMID 23210765 · NCT00554450 · Diabetes Mellitus, Type 2
  6. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.
    Kalra S · Diabetes Ther · 2014 · Trial result
    PubMed: PMID 25424969 · NCT05424315 (DACAMI) · Heart Failure
  7. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
    Ferrannini E, Seman L, Seewaldt-Becker E, et al. · Diabetes Obes Metab · 2014 · Trial result
    PubMed: PMID 23398530 · NCT05042505 (Dapa-LiT) · Diabetes Mellitus
  8. Diastolic chamber properties of the left ventricle assessed by global fitting of pressure-volume data: improving the gold standard of diastolic function.
    Bermejo J, Yotti R, Pérez del Villar C, et al. · J Appl Physiol (1985) · 2014 · Trial result
    PubMed: PMID 23743396 · NCT04739215 (CARDIA-STIFF) · Diabetes Mellitus, Type 2
  9. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
    van Haalen HG, Pompen M, Bergenheim K, et al. · Clin Drug Investig · 2014 · Derived
    PubMed: PMID 24243529 · NCT00673231 · Diabetes Mellitus, Type 2
  10. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
    Kohan DE, Fioretto P, Tang W, et al. · Kidney Int · 2014 · Derived
    PubMed: PMID 24067431 · NCT00663260 · Diabetes Mellitus, Type 2
  11. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
    Zhang Q, Dou J, Lu J, et al. · Diabetes Res Clin Pract · 2014 · Background
    PubMed: PMID 25015317 · NCT03968224 · Diabetes Mellitus, Type 2
  12. Long-term drug treatment for obesity: a systematic and clinical review.
    Yanovski SZ, Yanovski JA · JAMA · 2014 · Background
    PubMed: PMID 24231879 · NCT03968224 · Diabetes Mellitus, Type 2
  13. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
    Yang L, Li H, Li H, et al. · Clin Ther · 2014 · Background
    PubMed: PMID 23910664 · NCT02113241 · Insulin Resistance
  14. Treat-to-target trials in diabetes.
    Wangnoo SK, Sethi B, Sahay RK, et al. · Indian J Endocrinol Metab · 2014 · Background
    PubMed: PMID 24741511 · NCT03419624 · Diabetes Mellitus, Type 2
  15. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.
    van Bloemendaal L, Ten Kulve JS, la Fleur SE, et al. · J Endocrinol · 2014 · Background
    PubMed: PMID 24323912 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  16. Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
    Valente MA, Voors AA, Damman K, et al. · Eur Heart J · 2014 · Background
    PubMed: PMID 24585267 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  17. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure.
    Testani JM, Brisco MA, Turner JM, et al. · Circ Heart Fail · 2014 · Background
    PubMed: PMID 24379278 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  18. Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice.
    Tatarkiewicz K, Polizzi C, Villescaz C, et al. · Diabetes Obes Metab · 2014 · Background
    PubMed: PMID 24251534 · NCT03419624 · Diabetes Mellitus, Type 2
  19. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?
    Stanton RC · Circulation · 2014 · Background
    PubMed: PMID 24334174 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  20. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
    Sjöstrand M, Iqbal N, Lu J, et al. · Diabetes Res Clin Pract · 2014 · Background
    PubMed: PMID 24947443 · NCT02613897 · Diabetes Mellitus, Type 2
  21. Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: results from the INFUSE-AMI study.
    Sanidas EA, Brener SJ, Maehara A, et al. · Catheter Cardiovasc Interv · 2014 · Background
    PubMed: PMID 24030863 · NCT06286878 · Diabetes Mellitus
  22. SGLT-2 inhibitors and their potential in the treatment of diabetes.
    Rosenwasser RF, Sultan S, Sutton D, et al. · Diabetes Metab Syndr Obes · 2014 · Background
    PubMed: PMID 24348059 · NCT02887677 · Diabetes Mellitus
  23. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
    Rosenstock J, Jelaska A, Frappin G, et al. · Diabetes Care · 2014 · Background
    PubMed: PMID 24929430 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  24. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.
    Rizzo M, Chandalia M, Patti AM, et al. · Cardiovasc Diabetol · 2014 · Background
    PubMed: PMID 24559258 · NCT03377335 · Diabetes Mellitus, Type 2
  25. Approaching pre-diabetes.
    Perreault L, Færch K · J Diabetes Complications · 2014 · Background
    PubMed: PMID 24342268 · NCT02695810 · Obesity
  26. Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients.
    Peng H, Zhong M, Zhao W, et al. · PLoS One · 2014 · Background
    PubMed: PMID 24349318 · NCT03377335 · Diabetes Mellitus, Type 2
  27. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning.
    Patel NJ, Deshmukh A, Pant S, et al. · Circulation · 2014 · Background
    PubMed: PMID 24842943 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  28. Non-invasive 24 hour ambulatory monitoring of aortic wave reflection and arterial stiffness by a novel oscillometric device: the first feasibility and reproducibility study.
    Papaioannou TG, Argyris A, Protogerou AD, et al. · Int J Cardiol · 2014 · Background
    PubMed: PMID 24063914 · NCT02887677 · Diabetes Mellitus
  29. A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy.
    Orme M, Fenici P, Lomon ID, et al. · Diabetol Metab Syndr · 2014 · Background
    PubMed: PMID 25006351 · NCT03968224 · Diabetes Mellitus, Type 2
  30. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
    Merovci A, Solis-Herrera C, Daniele G, et al. · J Clin Invest · 2014 · Background
    PubMed: PMID 24463448 · NCT02613897 · Diabetes Mellitus, Type 2
  31. Are levels of NT-proBNP and SDMA useful to determine diastolic dysfunction in chronic kidney disease and renal transplant patients?
    Memon L, Spasojevic-Kalimanovska V, Stanojevic NB, et al. · J Clin Lab Anal · 2014 · Background
    PubMed: PMID 24218128 · NCT05719714 · Heart Failure
  32. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?
    Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, et al. · World J Diabetes · 2014 · Background
    PubMed: PMID 25126392 · NCT02887677 · Diabetes Mellitus
  33. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
    Mancia G, Fagard R, Narkiewicz K, et al. · Eur Heart J · 2014 · Background
    PubMed: PMID 23771844 · NCT03887416
  34. Prevention of vitamin D insufficiency in Switzerland: a never-ending story.
    Lava SA, Simonetti GD, Bianchetti AA, et al. · Int J Pharm · 2014 · Background
    PubMed: PMID 24216246 · NCT06012266 · Heart Failure
  35. Unrecognized diabetes and myocardial necrosis: predictors of hyperglycemia in myocardial infarction.
    Ladeira RT, Baracioli LM, Faulin TE, et al. · Arq Bras Cardiol · 2014 · Background
    PubMed: PMID 23598457 · NCT06286878 · Diabetes Mellitus
  36. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
    Kilov G, Leow S, Thomas M, et al. · Aust Fam Physician · 2014 · Background
    PubMed: PMID 24130972 · NCT02113241 · Insulin Resistance
  37. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
    Kasichayanula S, Liu X, Lacreta F, et al. · Clin Pharmacokinet · 2014 · Background
    PubMed: PMID 24105299 · NCT02113241 · Insulin Resistance
  38. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.
    Kaku K, Maegawa H, Tanizawa Y, et al. · Diabetes Ther · 2014 · Background
    PubMed: PMID 25341477 · NCT02577159 (DAPHNIS) · Diabetes Mellitus, Type 2
  39. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L, Ma J, Li H, et al. · Clin Ther · 2014 · Background
    PubMed: PMID 24378206 · NCT02577159 (DAPHNIS) · Diabetes Mellitus, Type 2
  40. Geographic atrophy: clinical features and potential therapeutic approaches.
    Holz FG, Strauss EC, Schmitz-Valckenberg S, et al. · Ophthalmology · 2014 · Background
    PubMed: PMID 24433969 · NCT07174687 · Eye Diseases
  41. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
    Heise T, Seewaldt-Becker E, Macha S, et al. · Diabetes Obes Metab · 2014 · Background
    PubMed: PMID 23356556 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  42. Complications of catheter ablation of atrial fibrillation: a systematic review.
    Gupta A, Perera T, Ganesan A, et al. · Circ Arrhythm Electrophysiol · 2014 · Background
    PubMed: PMID 24243785 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  43. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
    Ferrannini E, Muscelli E, Frascerra S, et al. · J Clin Invest · 2014 · Background
    PubMed: PMID 24463454 · NCT03968224 · Diabetes Mellitus, Type 2
  44. Prognostic value of the Index of Microcirculatory Resistance measured after primary percutaneous coronary intervention.
    Fearon WF, Low AF, Yong AS, et al. · Circulation · 2014 · Background
    PubMed: PMID 23681066 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  45. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures.
    Deshmukh A, Patel NJ, Pant S, et al. · Circulation · 2014 · Background
    PubMed: PMID 24061087 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  46. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.
    DeFronzo RA, Hompesch M, Kasichayanula S, et al. · Diabetes Care · 2014 · Background
    PubMed: PMID 23735727 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  47. Fractional flow reserve-guided PCI for stable coronary artery disease.
    De Bruyne B, Fearon WF, Pijls NH, et al. · N Engl J Med · 2014 · Background
    PubMed: PMID 25176289 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  48. Quantitative assessment of the coronary microvasculature: new tools for the black box.
    De Bruyne B, Barbato E · Circulation · 2014 · Background
    PubMed: PMID 23681065 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  49. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
    Cherney DZ, Perkins BA, Soleymanlou N, et al. · Circulation · 2014 · Background
    PubMed: PMID 24334175 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  50. [The current state of obesity in Mexico].
    Barrera-Cruz A, Rodríguez-González A, Molina-Ayala MA, et al. · Rev Med Inst Mex Seguro Soc · 2014 · Background
    PubMed: PMID 23883458 · NCT03968224 · Diabetes Mellitus, Type 2
  51. [Practice clinical guideline. Prevention, diagnosis and treatment of overweight and obesity].
    Barrera-Cruz A, Avila-Jiménez L, Cano-Pérez E, et al. · Rev Med Inst Mex Seguro Soc · 2014 · Background
    PubMed: PMID 23883468 · NCT03968224 · Diabetes Mellitus, Type 2
  52. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.
    Baker WL, Smyth LR, Riche DM, et al. · J Am Soc Hypertens · 2014 · Background
    PubMed: PMID 24602971 · NCT06000462 (DAPA-ANDO) · Obesity
  53. Clinical profile of urinary tract infections in diabetics and non-diabetics.
    Aswani SM, Chandrashekar U, Shivashankara K, et al. · Australas Med J · 2014 · Background
    PubMed: PMID 24567764 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  54. Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'.
    Andrassy KM · Kidney Int · 2014 · Background
    PubMed: PMID 23989362 · NCT03887416
  55. Dapagliflozin efficacy and safety: a perspective review.
    Anderson SL · Ther Adv Drug Saf · 2014 · Background
    PubMed: PMID 25436106 · NCT03419624 · Diabetes Mellitus, Type 2
  56. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
    Albarrán OG, Ampudia-Blasco FJ · Med Clin (Barc) · 2014 · Background
    PubMed: PMID 24444523 · NCT02887677 · Diabetes Mellitus
  57. Dapagliflozin for the treatment of type 2 diabetes.
    Abdul-Ghani MA, DeFronzo RA · Expert Opin Pharmacother · 2014 · Background
    PubMed: PMID 23800130 · NCT02211742 (DapaT1DM)

2013 (41 papers)

  1. Impact of diabetes on cardiovascular disease: an update.
    Matheus AS, Tannus LR, Cobas RA, et al. · Int J Hypertens · 2013 · Trial result
    PubMed: PMID 23533715 · NCT04717986 (DAPA-AMI) · Heart Failure
  2. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction.
    Kasner M, Westermann D, Lopez B, et al. · J Am Coll Cardiol · 2013 · Trial result
    PubMed: PMID 21329845 · NCT04739215 (CARDIA-STIFF) · Diabetes Mellitus, Type 2
  3. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.
    Heidenreich PA, Albert NM, Allen LA, et al. · Circ Heart Fail · 2013 · Trial result
    PubMed: PMID 23616602 · NCT05759000 · Heart Failure
  4. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
    Ganesan AN, Shipp NJ, Brooks AG, et al. · J Am Heart Assoc · 2013 · Trial result
    PubMed: PMID 23537812 · NCT04780438 · Atrial Fibrillation
  5. Bile acid metabolism and signaling.
    Chiang JY · Compr Physiol · 2013 · Trial result
    PubMed: PMID 23897684 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  6. Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of Fallot).
    Babu-Narayan SV, Uebing A, Davlouros PA, et al. · Int J Cardiol · 2013 · Trial result
    PubMed: PMID 20970202 · NCT06668389 (STEPS) · Heart Defects, Congenital
  7. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
    Armstrong PW, Gershlick AH, Goldstein P, et al. · N Engl J Med · 2013 · Trial result
    PubMed: PMID 23473396 · NCT04717986 (DAPA-AMI) · Heart Failure
  8. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
    Wilding JP, Woo V, Soler NG, et al. · Dtsch Med Wochenschr · 2013 · Derived
    PubMed: PMID 23529568 · NCT00673231 · Diabetes Mellitus, Type 2
  9. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
    Strojek K, Yoon KH, Hruba V, et al. · Dtsch Med Wochenschr · 2013 · Derived
    PubMed: PMID 23529567 · NCT00680745 · Diabetes Mellitus, Type 2
  10. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
    Nauck M, del Prato S, Meier JJ, et al. · Dtsch Med Wochenschr · 2013 · Derived
    PubMed: PMID 23529570 · NCT00660907 · Diabetes Mellitus, Type 2
  11. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
    Ljunggren Ö, Bolinder J, Johansson L, et al. · Diabetes Obes Metab · 2013 · Derived
    PubMed: PMID 22651373 · NCT00855166 · Diabetes Mellitus, Type 2
  12. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
    Bailey CJ, Gross JL, Hennicken D, et al. · BMC Med · 2013 · Derived
    PubMed: PMID 23425012 · NCT00528879 · Diabetes Mellitus, Type 2
  13. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
    White WB, Cannon CP, Heller SR, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23992602 · NCT06286878 · Diabetes Mellitus
  14. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Vasilakou D, Karagiannis T, Athanasiadou E, et al. · Ann Intern Med · 2013 · Background
    PubMed: PMID 24026259 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  15. Time delay of baroreflex control and oscillatory pattern of sympathetic activity in patients with metabolic syndrome and obstructive sleep apnea.
    Toschi-Dias E, Trombetta IC, Dias da Silva VJ, et al. · Am J Physiol Heart Circ Physiol · 2013 · Background
    PubMed: PMID 23355343 · NCT06286878 · Diabetes Mellitus
  16. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
    Teerlink JR, Cotter G, Davison BA, et al. · Lancet · 2013 · Background
    PubMed: PMID 23141816 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  17. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
    Seaquist ER, Anderson J, Childs B, et al. · Diabetes Care · 2013 · Background
    PubMed: PMID 23589542 · NCT02613897 · Diabetes Mellitus, Type 2
  18. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
    Scirica BM, Bhatt DL, Braunwald E, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23992601 · NCT06286878 · Diabetes Mellitus
  19. Glomerular hyperfiltration and renal disease progression in type 2 diabetes.
    Ruggenenti P, Porrini EL, Gaspari F, et al. · Diabetes Care · 2013 · Background
    PubMed: PMID 22773704 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  20. FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels.
    Queipo-Ortuño MI, Escoté X, Ceperuelo-Mallafré V, et al. · PLoS One · 2013 · Background
    PubMed: PMID 23139800 · NCT03968224 · Diabetes Mellitus, Type 2
  21. Dapagliflozin: a review of its use in type 2 diabetes mellitus.
    Plosker GL · Drugs · 2013 · Background
    PubMed: PMID 23170914 · NCT02211742 (DapaT1DM)
  22. The role of the immune system in obesity and insulin resistance.
    Patel PS, Buras ED, Balasubramanyam A, et al. · J Obes · 2013 · Background
    PubMed: PMID 23577240 · NCT03968224 · Diabetes Mellitus, Type 2
  23. Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.
    Panee J · Cytokine · 2013 · Background
    PubMed: PMID 22766373 · NCT03968224 · Diabetes Mellitus, Type 2
  24. Anti-diabetic compounds and their patent information: an update.
    Pandey R, Kumar N, Yadav M, et al. · Recent Pat Inflamm Allergy Drug Discov · 2013 · Background
    PubMed: PMID 23016523 · NCT02887677 · Diabetes Mellitus
  25. Evaluation of Aspirin and Clopidogrel resistance in patients with Acute Coronary Syndrome by using Adenosine Diposphate Test and Aspirin Test.
    O I, M O, A AS, et al. · Pak J Med Sci · 2013 · Background
    PubMed: PMID 24353516 · NCT06286878 · Diabetes Mellitus
  26. Thyroid function influences serum apolipoprotein B-48 levels in patients with thyroid disease.
    Mugii S, Hanada H, Okubo M, et al. · J Atheroscler Thromb · 2013 · Background
    PubMed: PMID 22786447 · NCT02577159 (DAPHNIS) · Diabetes Mellitus, Type 2
  27. Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort.
    Mebazaa A, Gayat E, Lassus J, et al. · J Am Coll Cardiol · 2013 · Background
    PubMed: PMID 23333145 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  28. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
    Lui SL, Yung S, Yim A, et al. · Am J Kidney Dis · 2013 · Background
    PubMed: PMID 22835900 · NCT06398977
  29. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
    Lim SS, Vos T, Flaxman AD, et al. · Lancet · 2013 · Background
    PubMed: PMID 23245609 · NCT03887416
  30. The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults.
    Lewis DA, Brown R, Williams J, et al. · Front Cell Infect Microbiol · 2013 · Background
    PubMed: PMID 23967406 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  31. Implementation of guidelines for the management of arterial hypertension. The impulsion study.
    Karagiannis A, Hatzitolios AI, Athyros VG, et al. · Open Cardiovasc Med J · 2013 · Background
    PubMed: PMID 19557149 · NCT02887677 · Diabetes Mellitus
  32. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
    Kaku K, Inoue S, Matsuoka O, et al. · Diabetes Obes Metab · 2013 · Background
    PubMed: PMID 23194084 · NCT02113241 · Insulin Resistance
  33. Dissociation of Bcl-2-Beclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes.
    He C, Zhu H, Li H, et al. · Diabetes · 2013 · Background
    PubMed: PMID 23223177 · NCT05217654 · Reperfusion Injury
  34. Oscillometric estimation of aortic pulse wave velocity: comparison with intra-aortic catheter measurements.
    Hametner B, Wassertheurer S, Kropf J, et al. · Blood Press Monit · 2013 · Background
    PubMed: PMID 23571229 · NCT02887677 · Diabetes Mellitus
  35. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B, Monnier L, Serusclat P, et al. · Diabetes Metab · 2013 · Background
    PubMed: PMID 22809630 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  36. Effects of bariatric surgery on adipokine-induced inflammation and insulin resistance.
    Goktas Z, Moustaid-Moussa N, Shen CL, et al. · Front Endocrinol (Lausanne) · 2013 · Background
    PubMed: PMID 23772224 · NCT03968224 · Diabetes Mellitus, Type 2
  37. Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of age-related eye disease study report no. 26.
    Feuer WJ, Yehoshua Z, Gregori G, et al. · JAMA Ophthalmol · 2013 · Background
    PubMed: PMID 23307222 · NCT07174687 · Eye Diseases
  38. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population.
    Colilla S, Crow A, Petkun W, et al. · Am J Cardiol · 2013 · Background
    PubMed: PMID 23831166 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  39. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.
    Chen HH, Anstrom KJ, Givertz MM, et al. · JAMA · 2013 · Background
    PubMed: PMID 24247300 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  40. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP).
    Bergenstal RM, Ahmann AJ, Bailey T, et al. · Diabetes Technol Ther · 2013 · Background
    PubMed: PMID 23448694 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  41. Achievement of goals in U.S. Diabetes Care, 1999-2010.
    Ali MK, Bullard KM, Gregg EW, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23863067 · NCT02613897 · Diabetes Mellitus, Type 2

2012 (60 papers)

  1. Prevalence of chronic kidney disease in China: a cross-sectional survey.
    Zhang L, Wang F, Wang L, et al. · Lancet · 2012 · Trial result
    PubMed: PMID 22386035 · NCT06890143 · Proteinuria
  2. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.
    Permutt Z, Le TA, Peterson MR, et al. · Aliment Pharmacol Ther · 2012 · Trial result
    PubMed: PMID 22554256 · NCT05042505 (Dapa-LiT) · Diabetes Mellitus
  3. Troponin I release after intravenous treatment with high furosemide doses plus hypertonic saline solution in decompensated heart failure trial (Tra-HSS-Fur).
    Parrinello G, Di Pasquale P, Torres D, et al. · Am Heart J · 2012 · Trial result
    PubMed: PMID 22980301 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  4. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
    Nauck MA, Del Prato S, Meier JJ, et al. · Diabetes Care · 2012 · Trial result
    PubMed: PMID 21816980 · NCT00660907 · Diabetes Mellitus, Type 2
  5. Relationship between location and size of myocardial infarction and their reciprocal influences on post-infarction left ventricular remodelling.
    Masci PG, Ganame J, Francone M, et al. · Eur Heart J · 2012 · Trial result
    PubMed: PMID 21398642 · NCT05424315 (DACAMI) · Heart Failure
  6. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.
    Le TA, Chen J, Changchien C, et al. · Hepatology · 2012 · Trial result
    PubMed: PMID 22431131 · NCT05042505 (Dapa-LiT) · Diabetes Mellitus
  7. Who has higher readmission rates for heart failure, and why? Implications for efforts to improve care using financial incentives.
    Joynt KE, Jha AK · Circ Cardiovasc Qual Outcomes · 2012 · Trial result
    PubMed: PMID 21156879 · NCT05759000 · Heart Failure
  8. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
    Henry RR, Murray AV, Marmolejo MH, et al. · Int J Clin Pract · 2012 · Trial result
    PubMed: PMID 22413962 · NCT00643851 · Diabetes Mellitus, Type 2
  9. Urine volume and change in estimated GFR in a community-based cohort study.
    Clark WF, Sontrop JM, Macnab JJ, et al. · Clin J Am Soc Nephrol · 2012 · Trial result
    PubMed: PMID 21885793 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  10. Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure.
    Chun S, Tu JV, Wijeysundera HC, et al. · Circ Heart Fail · 2012 · Trial result
    PubMed: PMID 22556322 · NCT05759000 · Heart Failure
  11. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
    Wilding JP, Woo V, Soler NG, et al. · Ann Intern Med · 2012 · Derived
    PubMed: PMID 22431673 · NCT00673231 · Diabetes Mellitus, Type 2
  12. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
    Rosenstock J, Vico M, Wei L, et al. · Diabetes Care · 2012 · Derived
    PubMed: PMID 22446170 · NCT00683878 · Diabetes Mellitus, Type 2
  13. Antiarrhythmic drug therapy for atrial fibrillation.
    Zimetbaum P · Circulation · 2012 · Background
    PubMed: PMID 22249528 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  14. Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model.
    van der Wal WM, Noordzij M, Dekker FW, et al. · Nephrol Dial Transplant · 2012 · Background
    PubMed: PMID 21317411 · NCT06398977
  15. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat.
    Thomson SC, Rieg T, Miracle C, et al. · Am J Physiol Regul Integr Comp Physiol · 2012 · Background
    PubMed: PMID 21940401 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  16. HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2.
    Sugawara A, Kawai K, Motohashi S, et al. · Diabetologia · 2012 · Background
    PubMed: PMID 22580991 · NCT02879409 · Diabetes Mellitus, Type 2
  17. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.
    Schepers E, Barreto DV, Liabeuf S, et al. · Clin J Am Soc Nephrol · 2012 · Background
    PubMed: PMID 21817129 · NCT05719714 · Heart Failure
  18. Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis.
    Salamone F, Galvano F, Marino Gammazza A, et al. · Dig Liver Dis · 2012 · Background
    PubMed: PMID 22197629 · NCT03377335 · Diabetes Mellitus, Type 2
  19. Current challenges in the clinical management of hypertension.
    Ruilope LM · Nat Rev Cardiol · 2012 · Background
    PubMed: PMID 22027655 · NCT03887416
  20. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study.
    Rossano JW, Kim JJ, Decker JA, et al. · J Card Fail · 2012 · Background
    PubMed: PMID 22633303 · NCT06012266 · Heart Failure
  21. Effect of gastrointestinal surgical manipulation on metabolic syndrome: a focus on metabolic surgery.
    Rizzello M, De Angelis F, Campanile FC, et al. · Gastroenterol Res Pract · 2012 · Background
    PubMed: PMID 23133447 · NCT03968224 · Diabetes Mellitus, Type 2
  22. Feasibility and reproducibility of noninvasive 24-h ambulatory aortic blood pressure monitoring with a brachial cuff-based oscillometric device.
    Protogerou AD, Argyris A, Nasothimiou E, et al. · Am J Hypertens · 2012 · Background
    PubMed: PMID 22673021 · NCT02887677 · Diabetes Mellitus
  23. Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans.
    Park KW, Park JJ, Jeon KH, et al. · Cardiovasc Ther · 2012 · Background
    PubMed: PMID 21129165 · NCT06286878 · Diabetes Mellitus
  24. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR, Swallow R, Dugi KA, et al. · Diabet Med · 2012 · Background
    PubMed: PMID 21781152 · NCT02613897 · Diabetes Mellitus, Type 2
  25. In patients with acute myocardial infarction, the impact of hyperglycemia as a risk factor for mortality is not homogeneous across age-groups.
    Nicolau JC, Serrano CV, Giraldez RR, et al. · Diabetes Care · 2012 · Background
    PubMed: PMID 22028280 · NCT06286878 · Diabetes Mellitus
  26. The index of microcirculatory resistance predicts myocardial infarction related to percutaneous coronary intervention.
    Ng MK, Yong AS, Ho M, et al. · Circ Cardiovasc Interv · 2012 · Background
    PubMed: PMID 22874078 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  27. Endothelial dysfunction in type 2 diabetes.
    Natali A, Ferrannini E · Diabetologia · 2012 · Background
    PubMed: PMID 22261897 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  28. Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels.
    Nakatani K, Sugimoto T, Masuda D, et al. · Atherosclerosis · 2012 · Background
    PubMed: PMID 21641598 · NCT02577159 (DAPHNIS) · Diabetes Mellitus, Type 2
  29. fMRI reactivity to high-calorie food pictures predicts short- and long-term outcome in a weight-loss program.
    Murdaugh DL, Cox JE, Cook EW, et al. · Neuroimage · 2012 · Background
    PubMed: PMID 22332246 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  30. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence.
    Masuda D, Sugimoto T, Tsujii K, et al. · Eur J Clin Invest · 2012 · Background
    PubMed: PMID 22587365 · NCT02577159 (DAPHNIS) · Diabetes Mellitus, Type 2
  31. Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia.
    Masuda D, Sakai N, Sugimoto T, et al. · J Atheroscler Thromb · 2012 · Background
    PubMed: PMID 21946533 · NCT02577159 (DAPHNIS) · Diabetes Mellitus, Type 2
  32. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis.
    Lomonaco R, Ortiz-Lopez C, Orsak B, et al. · Hepatology · 2012 · Background
    PubMed: PMID 21674556 · NCT07020377 · Diabetes Mellitus, Type 2
  33. Circulating levels of phthalate metabolites are associated with prevalent diabetes in the elderly.
    Lind PM, Zethelius B, Lind L, et al. · Diabetes Care · 2012 · Background
    PubMed: PMID 22498808 · NCT04242758 (PURITY) · Glucose Metabolism Disorders
  34. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
    Lin SD, Wang JS, Hsu SR, et al. · J Diabetes Complications · 2012 · Background
    PubMed: PMID 21813293 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  35. Does glucose variability influence the relationship between mean plasma glucose and HbA1c levels in type 1 and type 2 diabetic patients?
    Kuenen JC, Borg R, Kuik DJ, et al. · Diabetes Care · 2012 · Background
    PubMed: PMID 21700921 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  36. Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics.
    Koumaras C, Tzimou M, Stavrinou E, et al. · Am J Cardiovasc Drugs · 2012 · Background
    PubMed: PMID 22540323 · NCT02887677 · Diabetes Mellitus
  37. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk.
    Katsiki N, Koumaras C, Athyros VG, et al. · Angiology · 2012 · Background
    PubMed: PMID 22144689 · NCT02887677 · Diabetes Mellitus
  38. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T, Paschos P, Paletas K, et al. · BMJ · 2012 · Background
    PubMed: PMID 22411919 · NCT02887677 · Diabetes Mellitus
  39. Immunity as a link between obesity and insulin resistance.
    Kalupahana NS, Moustaid-Moussa N, Claycombe KJ, et al. · Mol Aspects Med · 2012 · Background
    PubMed: PMID 22040698 · NCT03968224 · Diabetes Mellitus, Type 2
  40. Is discordance of coronary flow reserve and fractional flow reserve due to methodology or clinically relevant coronary pathophysiology?
    Johnson NP, Kirkeeide RL, Gould KL, et al. · JACC Cardiovasc Imaging · 2012 · Background
    PubMed: PMID 22340827 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  41. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Inzucchi SE, Bergenstal RM, Buse JB, et al. · Diabetes Care · 2012 · Background
    PubMed: PMID 22517736 · NCT02887677 · Diabetes Mellitus
  42. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Inzucchi SE, Bergenstal RM, Buse JB, et al. · Diabetologia · 2012 · Background
    PubMed: PMID 22526604 · NCT03419624 · Diabetes Mellitus, Type 2
  43. Drug-induced hypoglycaemia in type 2 diabetes.
    Inkster B, Zammitt NN, Frier BM, et al. · Expert Opin Drug Saf · 2012 · Background
    PubMed: PMID 22690846 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  44. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups.
    Hill NR, Oliver NS, Choudhary P, et al. · Diabetes Technol Ther · 2012 · Background
    PubMed: PMID 21714681 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  45. Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism.
    Hanada H, Mugii S, Okubo M, et al. · Clin Chim Acta · 2012 · Background
    PubMed: PMID 21958700 · NCT02577159 (DAPHNIS) · Diabetes Mellitus, Type 2
  46. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis.
    Han S, Iglay K, Davies MJ, et al. · Curr Med Res Opin · 2012 · Background
    PubMed: PMID 22494018 · NCT06327815 · Diabetes Mellitus, Type 2
  47. Obesity and severe obesity forecasts through 2030.
    Finkelstein EA, Khavjou OA, Thompson H, et al. · Am J Prev Med · 2012 · Background
    PubMed: PMID 22608371 · NCT03419624 · Diabetes Mellitus, Type 2
  48. Ischemia and reperfusion--from mechanism to translation.
    Eltzschig HK, Eckle T · Nat Med · 2012 · Background
    PubMed: PMID 22064429 · NCT05217654 · Reperfusion Injury
  49. Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL.
    Elsøe S, Ahnström J, Christoffersen C, et al. · Atherosclerosis · 2012 · Background
    PubMed: PMID 22204862 · NCT07174687 · Eye Diseases
  50. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
    Devenny JJ, Godonis HE, Harvey SJ, et al. · Obesity (Silver Spring) · 2012 · Background
    PubMed: PMID 22402735 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  51. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
    DeFronzo RA, Davidson JA, Del Prato S, et al. · Diabetes Obes Metab · 2012 · Background
    PubMed: PMID 21955459 · NCT06421870 · Renal Insufficiency, Chronic
  52. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry.
    Chiang CE, Naditch-Brûlé L, Murin J, et al. · Circ Arrhythm Electrophysiol · 2012 · Background
    PubMed: PMID 22787011 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  53. Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes.
    Chao EC · Core Evid · 2012 · Background
    PubMed: PMID 22701099 · NCT02113241 · Insulin Resistance
  54. Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression.
    Cerezo C, Ruilope LM, Segura J, et al. · J Hypertens · 2012 · Background
    PubMed: PMID 22080225 · NCT03887416
  55. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
    Bolognese L, Falsini G, Schwenke C, et al. · Am J Cardiol · 2012 · Background
    PubMed: PMID 21943940 · NCT05335629 · Diabetes Mellitus, Type 2
  56. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
    Bolinder J, Ljunggren Ö, Kullberg J, et al. · J Clin Endocrinol Metab · 2012 · Background
    PubMed: PMID 22238392 · NCT03968224 · Diabetes Mellitus, Type 2
  57. Tissue Doppler time intervals and derived indices in hypoplastic left heart syndrome.
    Bellsham-Revell HR, Tibby SM, Bell AJ, et al. · Eur Heart J Cardiovasc Imaging · 2012 · Background
    PubMed: PMID 22157969 · NCT07482943 · Heart Failure
  58. Circulating carboxy-terminal propeptide of type I procollagen is increased in rheumatic heart disease.
    Banerjee T, Mukherjee S, Biswas M, et al. · Int J Cardiol · 2012 · Background
    PubMed: PMID 22305814 · NCT05618223 (Dapa-Rhemis) · Heart Failure
  59. Treating diabetes today with gliclazide MR: a matter of numbers.
    Avogaro A · Diabetes Obes Metab · 2012 · Background
    PubMed: PMID 22118706 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  60. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.
    Abdul-Ghani MA, Norton L, DeFronzo RA, et al. · Curr Diab Rep · 2012 · Background
    PubMed: PMID 22528597 · NCT02887677 · Diabetes Mellitus

2011 (40 papers)

  1. Quantification of liver fat with magnetic resonance imaging.
    Reeder SB, Sirlin CB · Magn Reson Imaging Clin N Am · 2011 · Trial result
    PubMed: PMID 21094444 · NCT05042505 (Dapa-LiT) · Diabetes Mellitus
  2. Changes in estimating echocardiography pulmonary capillary wedge pressure after hypersaline plus furosemide versus furosemide alone in decompensated heart failure.
    Parrinello G, Paterna S, Di Pasquale P, et al. · J Card Fail · 2011 · Trial result
    PubMed: PMID 21440872 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  3. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
    Kasichayanula S, Chang M, Hasegawa M, et al. · Diabetes Obes Metab · 2011 · Trial result
    PubMed: PMID 21226818 · NCT00538174 (MAD) · Diabetes Mellitus, Type 2
  4. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.
    Hummel CS, Lu C, Loo DD, et al. · Am J Physiol Cell Physiol · 2011 · Trial result
    PubMed: PMID 20980548 · NCT05424315 (DACAMI) · Heart Failure
  5. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
    Ferrannini E, Ramos SJ, Salsali A, et al. · Diabetes Care · 2011 · Trial result
    PubMed: PMID 20566676 · NCT00528372 · Diabetes Mellitus, Type 2
  6. What are the costs of heart failure?
    Braunschweig F, Cowie MR, Auricchio A, et al. · Europace · 2011 · Trial result
    PubMed: PMID 21518742 · NCT05759000 · Heart Failure
  7. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
    Strojek K, Yoon KH, Hruba V, et al. · Diabetes Obes Metab · 2011 · Derived
    PubMed: PMID 21672123 · NCT00680745 · Diabetes Mellitus, Type 2
  8. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
    Zhang L, Feng Y, List J, et al. · Diabetes Obes Metab · 2011 · Background
    PubMed: PMID 20518806 · NCT02113241 · Insulin Resistance
  9. Biology of human sodium glucose transporters.
    Wright EM, Loo DD, Hirayama BA, et al. · Physiol Rev · 2011 · Background
    PubMed: PMID 21527736 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  10. Validation of a brachial cuff-based method for estimating central systolic blood pressure.
    Weber T, Wassertheurer S, Rammer M, et al. · Hypertension · 2011 · Background
    PubMed: PMID 21911710 · NCT02887677 · Diabetes Mellitus
  11. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis.
    Vlachopoulos C, Aznaouridis K, O'Rourke MF, et al. · Eur Heart J · 2011 · Background
    PubMed: PMID 20197424 · NCT02887677 · Diabetes Mellitus
  12. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Taskinen MR, Rosenstock J, Tamminen I, et al. · Diabetes Obes Metab · 2011 · Background
    PubMed: PMID 21114605 · NCT02613897 · Diabetes Mellitus, Type 2
  13. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes.
    Renko M, Tapanainen P, Tossavainen P, et al. · Diabetes Care · 2011 · Background
    PubMed: PMID 20937688 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  14. Closer to noninvasive out-of-office aortic blood pressure assessment: a time to think and act.
    Protogerou AD, Smulyan H, Safar ME, et al. · Hypertension · 2011 · Background
    PubMed: PMID 21911711 · NCT02887677 · Diabetes Mellitus
  15. Effect of nesiritide in patients with acute decompensated heart failure.
    O'Connor CM, Starling RC, Hernandez AF, et al. · N Engl J Med · 2011 · Background
    PubMed: PMID 21732835 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  16. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.
    Mikhailidis DP, Elisaf M, Rizzo M, et al. · Curr Vasc Pharmacol · 2011 · Background
    PubMed: PMID 21595628 · NCT03377335 · Diabetes Mellitus, Type 2
  17. Glucose handling by the kidney.
    Mather A, Pollock C · Kidney Int Suppl · 2011 · Background
    PubMed: PMID 21358696 · NCT02211742 (DapaT1DM)
  18. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.
    Lamanna C, Monami M, Marchionni N, et al. · Diabetes Obes Metab · 2011 · Background
    PubMed: PMID 21205121 · NCT06286878 · Diabetes Mellitus
  19. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.
    Kim MH, Johnston SS, Chu BC, et al. · Circ Cardiovasc Qual Outcomes · 2011 · Background
    PubMed: PMID 21540439 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  20. The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis.
    Karagiannis A, Tziomalos K, Anagnostis P, et al. · Curr Vasc Pharmacol · 2011 · Background
    PubMed: PMID 20626344 · NCT02887677 · Diabetes Mellitus
  21. The clinical significance of hyperfiltration in diabetes.
    Jerums G, Premaratne E, Panagiotopoulos S, et al. · Diabetologia · 2011 · Background
    PubMed: PMID 20496053 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  22. Globalization of diabetes: the role of diet, lifestyle, and genes.
    Hu FB · Diabetes Care · 2011 · Background
    PubMed: PMID 21617109 · NCT02887677 · Diabetes Mellitus
  23. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.
    Heidenreich PA, Trogdon JG, Khavjou OA, et al. · Circulation · 2011 · Background
    PubMed: PMID 21262990 · NCT05719714 · Heart Failure
  24. Inflammatory mechanisms in obesity.
    Gregor MF, Hotamisligil GS · Annu Rev Immunol · 2011 · Background
    PubMed: PMID 21219177 · NCT03968224 · Diabetes Mellitus, Type 2
  25. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Gomis R, Espadero RM, Jones R, et al. · Diabetes Obes Metab · 2011 · Background
    PubMed: PMID 21410628 · NCT02613897 · Diabetes Mellitus, Type 2
  26. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.
    Dicker D · Diabetes Care · 2011 · Background
    PubMed: PMID 21525468 · NCT02613897 · Diabetes Mellitus, Type 2
  27. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients.
    Di Flaviani A, Picconi F, Di Stefano P, et al. · Diabetes Care · 2011 · Background
    PubMed: PMID 21610126 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  28. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
    Del Prato S, Barnett AH, Huisman H, et al. · Diabetes Obes Metab · 2011 · Background
    PubMed: PMID 21205122 · NCT02613897 · Diabetes Mellitus, Type 2
  29. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation.
    De Jong AM, Maass AH, Oberdorf-Maass SU, et al. · Cardiovasc Res · 2011 · Background
    PubMed: PMID 21075756 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  30. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options.
    De Caterina R, Madonna R, Sourij H, et al. · Eur Heart J · 2011 · Background
    PubMed: PMID 20519242 · NCT06286878 · Diabetes Mellitus
  31. GlyCulator: a glycemic variability calculation tool for continuous glucose monitoring data.
    Czerwoniuk D, Fendler W, Walenciak L, et al. · J Diabetes Sci Technol · 2011 · Background
    PubMed: PMID 21527118 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  32. Prognostic effect of coronary flow reserve in women versus men with chest pain syndrome and normal dipyridamole stress echocardiography.
    Cortigiani L, Rigo F, Gherardi S, et al. · Am J Cardiol · 2011 · Background
    PubMed: PMID 21126613 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  33. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M.
    Christoffersen C, Obinata H, Kumaraswamy SB, et al. · Proc Natl Acad Sci U S A · 2011 · Background
    PubMed: PMID 21606363 · NCT07174687 · Eye Diseases
  34. What is the right dose for children?
    Cella M, Knibbe C, Danhof M, et al. · Br J Clin Pharmacol · 2011 · Background
    PubMed: PMID 21087295 · NCT06012266 · Heart Failure
  35. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T, Pullman J, Malloy J, et al. · J Clin Endocrinol Metab · 2011 · Background
    PubMed: PMID 21307137 · NCT03419624 · Diabetes Mellitus, Type 2
  36. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial.
    Berneis K, Rizzo M, Berthold HK, et al. · Eur Heart J · 2011 · Background
    PubMed: PMID 20525999 · NCT03377335 · Diabetes Mellitus, Type 2
  37. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.
    Bennett WL, Maruthur NM, Singh S, et al. · Ann Intern Med · 2011 · Background
    PubMed: PMID 21403054 · NCT06286878 · Diabetes Mellitus
  38. Modelling and simulation as research tools in paediatric drug development.
    Bellanti F, Della Pasqua O · Eur J Clin Pharmacol · 2011 · Background
    PubMed: PMID 21246352 · NCT06012266 · Heart Failure
  39. Coagulation and fibrinolysis in diabetes.
    Alzahrani SH, Ajjan RA · Diab Vasc Dis Res · 2011 · Background
    PubMed: PMID 20847109 · NCT06286878 · Diabetes Mellitus
  40. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
    Abdul-Ghani MA, Norton L, Defronzo RA, et al. · Endocr Rev · 2011 · Background
    PubMed: PMID 21606218 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2

2010 (25 papers)

  1. Rubbing salt into wounds: hypertonic saline to assist with volume removal in heart failure.
    Liszkowski M, Nohria A · Curr Heart Fail Rep · 2010 · Trial result
    PubMed: PMID 20607462 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  2. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission.
    Krumholz HM, Merrill AR, Schone EM, et al. · Circ Cardiovasc Qual Outcomes · 2010 · Trial result
    PubMed: PMID 20031870 · NCT05759000 · Heart Failure
  3. Prevalence of dementia disorders in the oldest-old: an autopsy study.
    Jellinger KA, Attems J · Acta Neuropathol · 2010 · Trial result
    PubMed: PMID 20204386 · NCT05565976 (DECIST) · Cognitive Dysfunction
  4. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
    Bailey CJ, Gross JL, Pieters A, et al. · Lancet · 2010 · Derived
    PubMed: PMID 20609968 · NCT00528879 · Diabetes Mellitus, Type 2
  5. Validation of the mobil-O-Graph: 24 h-blood pressure measurement device.
    Wei W, Tölle M, Zidek W, et al. · Blood Press Monit · 2010 · Background
    PubMed: PMID 20216407 · NCT02887677 · Diabetes Mellitus
  6. A new oscillometric method for pulse wave analysis: comparison with a common tonometric method.
    Wassertheurer S, Kropf J, Weber T, et al. · J Hum Hypertens · 2010 · Background
    PubMed: PMID 20237499 · NCT02887677 · Diabetes Mellitus
  7. Inflammation, a link between obesity and cardiovascular disease.
    Wang Z, Nakayama T · Mediators Inflamm · 2010 · Background
    PubMed: PMID 20847813 · NCT03968224 · Diabetes Mellitus, Type 2
  8. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes.
    Wadén J, Forsblom C, Thorn LM, et al. · Diabetes · 2010 · Background
    PubMed: PMID 19651819 · NCT02879409 · Diabetes Mellitus, Type 2
  9. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.
    Vlachopoulos C, Aznaouridis K, Stefanadis C, et al. · J Am Coll Cardiol · 2010 · Background
    PubMed: PMID 20338492 · NCT02887677 · Diabetes Mellitus
  10. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.
    Targher G, Day CP, Bonora E, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20879883 · NCT07020377 · Diabetes Mellitus, Type 2
  11. Global estimates of the prevalence of diabetes for 2010 and 2030.
    Shaw JE, Sicree RA, Zimmet PZ, et al. · Diabetes Res Clin Pract · 2010 · Background
    PubMed: PMID 19896746 · NCT02887677 · Diabetes Mellitus
  12. The diagnosis of urinary tract infection: a systematic review.
    Schmiemann G, Kniehl E, Gebhardt K, et al. · Dtsch Arztebl Int · 2010 · Background
    PubMed: PMID 20539810 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  13. Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds.
    Sarafidis PA, Georgianos PI, Lasaridis AN, et al. · Expert Opin Drug Saf · 2010 · Background
    PubMed: PMID 20095917 · NCT02887677 · Diabetes Mellitus
  14. Forty years of the Fontan operation: a failed strategy.
    Rychik J · Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu · 2010 · Background
    PubMed: PMID 20307870 · NCT05741658 (FonDap) · Heart Failure
  15. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
    Rodbard HW, Jellinger PS, Davidson JA, et al. · Endocr Pract · 2010 · Background
    PubMed: PMID 19858063 · NCT02613897 · Diabetes Mellitus, Type 2
  16. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
    Obermeier M, Yao M, Khanna A, et al. · Drug Metab Dispos · 2010 · Background
    PubMed: PMID 19996149 · NCT02113241 · Insulin Resistance
  17. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.
    Marfella R, Barbieri M, Grella R, et al. · J Diabetes Complications · 2010 · Background
    PubMed: PMID 19261490 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  18. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.
    Look AHEAD Research Group, Wing RR · Arch Intern Med · 2010 · Background
    PubMed: PMID 20876408 · NCT06000462 (DAPA-ANDO) · Obesity
  19. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study.
    Hussey EK, Dobbins RL, Stoltz RR, et al. · J Clin Pharmacol · 2010 · Background
    PubMed: PMID 20200268 · NCT03968224 · Diabetes Mellitus, Type 2
  20. Evaluation of the Mobil-O-Graph new generation ABPM device using the ESH criteria.
    Franssen PM, Imholz BP · Blood Press Monit · 2010 · Background
    PubMed: PMID 20658764 · NCT02887677 · Diabetes Mellitus
  21. Processing of food pictures: influence of hunger, gender and calorie content.
    Frank S, Laharnar N, Kullmann S, et al. · Brain Res · 2010 · Background
    PubMed: PMID 20423700 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  22. Serial cardiopulmonary exercise testing in patients with previous Fontan surgery.
    Fernandes SM, McElhinney DB, Khairy P, et al. · Pediatr Cardiol · 2010 · Background
    PubMed: PMID 19915891 · NCT07482943 · Heart Failure
  23. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
    Diamant M, Van Gaal L, Stranks S, et al. · Lancet · 2010 · Background
    PubMed: PMID 20609969 · NCT03419624 · Diabetes Mellitus, Type 2
  24. SGLT2 inhibition--a novel strategy for diabetes treatment.
    Chao EC, Henry RR · Nat Rev Drug Discov · 2010 · Background
    PubMed: PMID 20508640 · NCT02887677 · Diabetes Mellitus
  25. Cardiovascular disease in diabetes.
    Bloomgarden ZT · Diabetes Care · 2010 · Background
    PubMed: PMID 20351221 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2

2009 (24 papers)

  1. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.
    Wilding JP, Norwood P, T'joen C, et al. · Diabetes Care · 2009 · Trial result
    PubMed: PMID 19528367 · NCT00357370 · Diabetes Mellitus, Type 2
  2. Routine early angioplasty after fibrinolysis for acute myocardial infarction.
    Cantor WJ, Fitchett D, Borgundvaag B, et al. · N Engl J Med · 2009 · Trial result
    PubMed: PMID 19553646 · NCT04717986 (DAPA-AMI) · Heart Failure
  3. Pathophysiology of prediabetes.
    Abdul-Ghani MA, DeFronzo RA · Curr Diab Rep · 2009 · Trial result
    PubMed: PMID 19490820 · NCT03658031 · Diabetes Mellitus, Type 2
  4. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
    List JF, Woo V, Morales E, et al. · Diabetes Care · 2009 · Derived
    PubMed: PMID 19114612 · NCT00263276 · Diabetes Mellitus, Type 2
  5. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs.
    Zhang CL, Katoh M, Shibasaki T, et al. · Science · 2009 · Background
    PubMed: PMID 19644119 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  6. Group of signs: a new method to evaluate glycemic variability.
    Zaccardi F, Stefano PD, Busetto E, et al. · J Diabetes Sci Technol · 2009 · Background
    PubMed: PMID 19885294 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  7. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.
    Tonino PA, De Bruyne B, Pijls NH, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19144937 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  8. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy.
    Singla A, Antonino MJ, Bliden KP, et al. · Am Heart J · 2009 · Background
    PubMed: PMID 19853698 · NCT06286878 · Diabetes Mellitus
  9. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT.
    Siegelaar SE, Kilpatrick ES, Rigby AS, et al. · Diabetologia · 2009 · Background
    PubMed: PMID 19672575 · NCT02879409 · Diabetes Mellitus, Type 2
  10. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.
    Raz I, Wilson PW, Strojek K, et al. · Diabetes Care · 2009 · Background
    PubMed: PMID 19246588 · NCT02879409 · Diabetes Mellitus, Type 2
  11. Status and rationale of renoprotection studies in adolescents with type 1 diabetes.
    Marcovecchio ML, Tossavainen PH, Dunger DB, et al. · Pediatr Diabetes · 2009 · Background
    PubMed: PMID 19496962 · NCT02879409 · Diabetes Mellitus, Type 2
  12. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis.
    Magee GM, Bilous RW, Cardwell CR, et al. · Diabetologia · 2009 · Background
    PubMed: PMID 19198800 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  13. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure.
    Kosiborod M, Inzucchi SE, Spertus JA, et al. · Circulation · 2009 · Background
    PubMed: PMID 19332465 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  14. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
    Komoroski B, Vachharajani N, Feng Y, et al. · Clin Pharmacol Ther · 2009 · Background
    PubMed: PMID 19129749 · NCT03968224 · Diabetes Mellitus, Type 2
  15. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
    Komoroski B, Vachharajani N, Boulton D, et al. · Clin Pharmacol Ther · 2009 · Background
    PubMed: PMID 19129748 · NCT02613897 · Diabetes Mellitus, Type 2
  16. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes.
    Kilpatrick ES, Rigby AS, Atkin SL, et al. · Diabetes Care · 2009 · Background
    PubMed: PMID 19549736 · NCT02879409 · Diabetes Mellitus, Type 2
  17. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.
    Idris I, Donnelly R · Diabetes Obes Metab · 2009 · Background
    PubMed: PMID 19125776 · NCT03968224 · Diabetes Mellitus, Type 2
  18. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases.
    Hajer GR, van Haeften TW, Visseren FL, et al. · Eur Heart J · 2009 · Background
    PubMed: PMID 18775919 · NCT03968224 · Diabetes Mellitus, Type 2
  19. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.
    Göke B, Hershon K, Kerr D, et al. · Horm Metab Res · 2009 · Background
    PubMed: PMID 18726829 · NCT02613897 · Diabetes Mellitus, Type 2
  20. Glucose control and vascular complications in veterans with type 2 diabetes.
    Duckworth W, Abraira C, Moritz T, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19092145 · NCT02879409 · Diabetes Mellitus, Type 2
  21. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus.
    Demirtunc R, Duman D, Basar M, et al. · J Diabetes Complications · 2009 · Background
    PubMed: PMID 18358749 · NCT06286878 · Diabetes Mellitus
  22. Development of a semi-quantitative food frequency questionnaire for use in United Arab Emirates and Kuwait based on local foods.
    Dehghan M, Al Hamad N, Yusufali A, et al. · Nutr J · 2009 · Background
    PubMed: PMID 15921524 · NCT02879409 · Diabetes Mellitus, Type 2
  23. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.
    Defronzo RA · Diabetes · 2009 · Background
    PubMed: PMID 19336687 · NCT02887677 · Diabetes Mellitus
  24. Epidemiology of chronic kidney disease in heart failure.
    Ahmed A, Campbell RC · Heart Fail Clin · 2009 · Background
    PubMed: PMID 18760751 · NCT05719714 · Heart Failure

2008 (25 papers)

  1. Universal definition of myocardial infarction.
    Thygesen K, Alpert JS, White HD, et al. · Circulation · 2008 · Trial result
    PubMed: PMID 17951284 · NCT04717986 (DAPA-AMI) · Heart Failure
  2. Acute heart failure in patients with acute myocardial infarction treated with primary percutaneous coronary intervention.
    Santoro GM, Carrabba N, Migliorini A, et al. · Eur J Heart Fail · 2008 · Trial result
    PubMed: PMID 18599344 · NCT05424315 (DACAMI) · Heart Failure
  3. Proteinuria as a risk factor for the progression of chronic renal disease.
    Petrović D, Stojimirović B · Vojnosanit Pregl · 2008 · Trial result
    PubMed: PMID 18700466 · NCT06890143 · Proteinuria
  4. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases.
    Tilg H, Moschen AR · Clin Sci (Lond) · 2008 · Background
    PubMed: PMID 18194136 · NCT03968224 · Diabetes Mellitus, Type 2
  5. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension.
    Sarafidis PA, Bakris GL · J Clin Hypertens (Greenwich) · 2008 · Background
    PubMed: PMID 18256578 · NCT02887677 · Diabetes Mellitus
  6. Intra-arterial vitamin C prevents endothelial dysfunction caused by ischemia-reperfusion.
    Pleiner J, Schaller G, Mittermayer F, et al. · Atherosclerosis · 2008 · Background
    PubMed: PMID 17645881 · NCT05217654 · Reperfusion Injury
  7. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
    Nathan DM, Buse JB, Davidson MB, et al. · Diabetes Care · 2008 · Background
    PubMed: PMID 18165348 · NCT03419624 · Diabetes Mellitus, Type 2
  8. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.
    Nathan DM, Buse JB, Davidson MB, et al. · Diabetologia · 2008 · Background
    PubMed: PMID 18026926 · NCT02613897 · Diabetes Mellitus, Type 2
  9. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Meng W, Ellsworth BA, Nirschl AA, et al. · J Med Chem · 2008 · Background
    PubMed: PMID 18260618 · NCT03968224 · Diabetes Mellitus, Type 2
  10. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats.
    Malatiali S, Francis I, Barac-Nieto M, et al. · Exp Diabetes Res · 2008 · Background
    PubMed: PMID 18769499 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  11. Global burden of blood-pressure-related disease, 2001.
    Lawes CM, Vander Hoorn S, Rodgers A, et al. · Lancet · 2008 · Background
    PubMed: PMID 18456100 · NCT03887416
  12. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes.
    Kilpatrick ES, Rigby AS, Atkin SL, et al. · Diabetologia · 2008 · Background
    PubMed: PMID 18040661 · NCT02879409 · Diabetes Mellitus, Type 2
  13. Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis.
    Johansen OE · Scand J Clin Lab Invest · 2008 · Background
    PubMed: PMID 17852797 · NCT06286878 · Diabetes Mellitus
  14. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients.
    Jankowski P, Kawecka-Jaszcz K, Czarnecka D, et al. · Hypertension · 2008 · Background
    PubMed: PMID 18268136 · NCT02887677 · Diabetes Mellitus
  15. Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range.
    Jani R, Molina M, Matsuda M, et al. · Diabetes Care · 2008 · Background
    PubMed: PMID 18000182 · NCT02613897 · Diabetes Mellitus, Type 2
  16. Long-term follow-up after tight control of blood pressure in type 2 diabetes.
    Holman RR, Paul SK, Bethel MA, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18784091 · NCT02879409 · Diabetes Mellitus, Type 2
  17. Metformin as first choice in oral diabetes treatment: the UKPDS experience.
    Holman R · Journ Annu Diabetol Hotel Dieu · 2008 · Background
    PubMed: PMID 18613325 · NCT03419624 · Diabetes Mellitus, Type 2
  18. Is glycemic control improving in U.S. adults?
    Hoerger TJ, Segel JE, Gregg EW, et al. · Diabetes Care · 2008 · Background
    PubMed: PMID 17934153 · NCT02887677 · Diabetes Mellitus
  19. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin.
    García de la Torre N, Rubio MA, Bordiú E, et al. · J Clin Endocrinol Metab · 2008 · Background
    PubMed: PMID 18713823 · NCT03968224 · Diabetes Mellitus, Type 2
  20. European Union. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population.
    Eur J Health Law · 2008 · Background
    PubMed: PMID 18988606 · NCT06012266 · Heart Failure
  21. Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study.
    Corrado E, Rizzo M, Coppola G, et al. · Coron Artery Dis · 2008 · Background
    PubMed: PMID 18418229 · NCT03377335 · Diabetes Mellitus, Type 2
  22. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice.
    Christoffersen C, Jauhiainen M, Moser M, et al. · J Biol Chem · 2008 · Background
    PubMed: PMID 18006500 · NCT07174687 · Eye Diseases
  23. Pediatric antihypertensive trial failures: analysis of end points and dose range.
    Benjamin DK, Smith PB, Jadhav P, et al. · Hypertension · 2008 · Background
    PubMed: PMID 18332283 · NCT06012266 · Heart Failure
  24. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    ADVANCE Collaborative Group, Patel A, MacMahon S, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18539916 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  25. Effects of intensive glucose lowering in type 2 diabetes.
    Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18539917 · NCT02879409 · Diabetes Mellitus, Type 2

2007 (18 papers)

  1. A prospective, randomized, double-blind, placebo controlled trial of beta-blockade in patients who have undergone surgical correction of tetralogy of Fallot.
    Norozi K, Bahlmann J, Raab B, et al. · Cardiol Young · 2007 · Trial result
    PubMed: PMID 17572925 · NCT06668389 (STEPS) · Heart Defects, Congenital
  2. Predicting the 20-year diabetes incidence rate.
    Dankner R, Abdul-Ghani MA, Gerber Y, et al. · Diabetes Metab Res Rev · 2007 · Trial result
    PubMed: PMID 17315136 · NCT03658031 · Diabetes Mellitus, Type 2
  3. Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes.
    Wolf G · Nutr Rev · 2007 · Background
    PubMed: PMID 17566551 · NCT03968224 · Diabetes Mellitus, Type 2
  4. Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance.
    Steinberg GR · Cell Cycle · 2007 · Background
    PubMed: PMID 17438370 · NCT03968224 · Diabetes Mellitus, Type 2
  5. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.
    Sanada S, Hakuno D, Higgins LJ, et al. · J Clin Invest · 2007 · Background
    PubMed: PMID 17492053 · NCT05335629 · Diabetes Mellitus, Type 2
  6. Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals.
    Rothemund Y, Preuschhof C, Bohner G, et al. · Neuroimage · 2007 · Background
    PubMed: PMID 17566768 · NCT03361098 (DECREASE) · Diabetes Mellitus, Type 2
  7. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.
    Rodbard HW, Blonde L, Braithwaite SS, et al. · Endocr Pract · 2007 · Background
    PubMed: PMID 17613449 · NCT02613897 · Diabetes Mellitus, Type 2
  8. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians.
    Qaseem A, Vijan S, Snow V, et al. · Ann Intern Med · 2007 · Background
    PubMed: PMID 17876024 · NCT02613897 · Diabetes Mellitus, Type 2
  9. [Tools to measure treatment adherence].
    Nogués Solán X, Sorli Redó ML, Villar García J, et al. · An Med Interna · 2007 · Background
    PubMed: PMID 17590137 · NCT03968224 · Diabetes Mellitus, Type 2
  10. Adipose tissue interleukin-18 mRNA and plasma interleukin-18: effect of obesity and exercise.
    Leick L, Lindegaard B, Stensvold D, et al. · Obesity (Silver Spring) · 2007 · Background
    PubMed: PMID 17299108 · NCT03968224 · Diabetes Mellitus, Type 2
  11. Expert consensus document on arterial stiffness: methodological issues and clinical applications.
    Laurent S, Cockcroft J, Van Bortel L, et al. · Eur Heart J · 2007 · Background
    PubMed: PMID 17000623 · NCT02887677 · Diabetes Mellitus
  12. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA, Gheorghiade M, Burnett JC, et al. · JAMA · 2007 · Background
    PubMed: PMID 17384437 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  13. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study.
    Januzzi JL, Peacock WF, Maisel AS, et al. · J Am Coll Cardiol · 2007 · Background
    PubMed: PMID 17692745 · NCT05335629 · Diabetes Mellitus, Type 2
  14. Hypothesis: the 'metabolic memory', the new challenge of diabetes.
    Ihnat MA, Thorpe JE, Ceriello A, et al. · Diabet Med · 2007 · Background
    PubMed: PMID 17490424 · NCT02879409 · Diabetes Mellitus, Type 2
  15. The systolic to diastolic duration ratio in children with hypoplastic left heart syndrome: a novel Doppler index of right ventricular function.
    Friedberg MK, Silverman NH · J Am Soc Echocardiogr · 2007 · Background
    PubMed: PMID 17543747 · NCT07482943 · Heart Failure
  16. The effect of temperature on blood flow and deep temperature in the human forearm.
    Barcroft H, Edholm OG · J Physiol · 2007 · Background
    PubMed: PMID 16991588 · NCT05217654 · Reperfusion Injury
  17. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
    Balas B, Baig MR, Watson C, et al. · J Clin Endocrinol Metab · 2007 · Background
    PubMed: PMID 17244786 · NCT02613897 · Diabetes Mellitus, Type 2
  18. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
    Bakris G, Molitch M, Hewkin A, et al. · Diabetes Care · 2007 · Background
    PubMed: PMID 17130190 · NCT02887677 · Diabetes Mellitus

2006 (10 papers)

  1. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients.
    Chertow GM, Burdick E, Honour M, et al. · J Am Soc Nephrol · 2006 · Trial result
    PubMed: PMID 16177006 · NCT04806633 · Acute Kidney Injury
  2. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose.
    Abdul-Ghani MA, Tripathy D, DeFronzo RA, et al. · Diabetes Care · 2006 · Trial result
    PubMed: PMID 16644654 · NCT03658031 · Diabetes Mellitus, Type 2
  3. Incidence, causes, and outcomes of dilated cardiomyopathy in children.
    Towbin JA, Lowe AM, Colan SD, et al. · JAMA · 2006 · Background
    PubMed: PMID 17047217 · NCT06012266 · Heart Failure
  4. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.
    Rahmoune H, Thompson PW, Ward JM, et al. · Diabetes · 2006 · Background
    PubMed: PMID 16306358 · NCT02887677 · Diabetes Mellitus
  5. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.
    Monnier L, Mas E, Ginet C, et al. · JAMA · 2006 · Background
    PubMed: PMID 16609090 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  6. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.
    Kilpatrick ES, Rigby AS, Atkin SL, et al. · Diabetes Care · 2006 · Background
    PubMed: PMID 16801566 · NCT02879409 · Diabetes Mellitus, Type 2
  7. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
    Hillege HL, Nitsch D, Pfeffer MA, et al. · Circulation · 2006 · Background
    PubMed: PMID 16461840 · NCT05719714 · Heart Failure
  8. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents.
    Goodarzi MO, Bryer-Ash M · Diabetes Obes Metab · 2006 · Background
    PubMed: PMID 16219009 · NCT03968224 · Diabetes Mellitus, Type 2
  9. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism.
    Blüher M, Fasshauer M, Tönjes A, et al. · Exp Clin Endocrinol Diabetes · 2006 · Background
    PubMed: PMID 16235156 · NCT03968224 · Diabetes Mellitus, Type 2
  10. Cognitive P300 potential in subjects with Diabetes Mellitus.
    Alvarenga Kde F, Duarte JL, Silva DP, et al. · Braz J Otorhinolaryngol · 2006 · Background
    PubMed: PMID 16446918 · NCT05262257

2005 (12 papers)

  1. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study.
    Paterna S, Di Pasquale P, Parrinello G, et al. · J Am Coll Cardiol · 2005 · Trial result
    PubMed: PMID 15963399 · NCT06442280 (DAPA-TONIC) · Diabetes Mellitus, Type 2
  2. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis.
    Wolfrum C, Poy MN, Stoffel M, et al. · Nat Med · 2005 · Background
    PubMed: PMID 15793583 · NCT07174687 · Eye Diseases
  3. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats.
    Ueta K, Ishihara T, Matsumoto Y, et al. · Life Sci · 2005 · Background
    PubMed: PMID 15792833 · NCT03968224 · Diabetes Mellitus, Type 2
  4. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.
    Schmitz J, Owyang A, Oldham E, et al. · Immunity · 2005 · Background
    PubMed: PMID 16286016 · NCT05335629 · Diabetes Mellitus, Type 2
  5. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition.
    Klein S, Sheard NF, Pi-Sunyer X, et al. · Diabetes Care · 2005 · Background
    PubMed: PMID 15277443 · NCT02613897 · Diabetes Mellitus, Type 2
  6. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes.
    Home P · Curr Med Res Opin · 2005 · Background
    PubMed: PMID 16004665 · NCT02879409 · Diabetes Mellitus, Type 2
  7. Temporal variability of urinary phthalate metabolite levels in men of reproductive age.
    Hauser R, Meeker JD, Park S, et al. · Environ Health Perspect · 2005 · Background
    PubMed: PMID 15579421 · NCT04242758 (PURITY) · Glucose Metabolism Disorders
  8. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes.
    Drouin P, Standl E, Diamicron MR Study Group, et al. · Diabetes Obes Metab · 2005 · Background
    PubMed: PMID 15479217 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  9. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease?
    Bagby SP · J Am Soc Nephrol · 2005 · Background
    PubMed: PMID 15504931 · NCT05719714 · Heart Failure
  10. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. · Diabetes · 2005 · Background
    PubMed: PMID 16046311 · NCT06286878 · Diabetes Mellitus
  11. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).
    Adams KF, Fonarow GC, Emerman CL, et al. · Am Heart J · 2005 · Background
    PubMed: PMID 15846257 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2
  12. Epicardial stenosis severity does not affect minimal microcirculatory resistance.
    Aarnoudse W, Fearon WF, Manoharan G, et al. · Circulation · 2005 · Background
    PubMed: PMID 15466646 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2

2004 (13 papers)

  1. Follow-up report on the diagnosis of diabetes mellitus.
    Genuth S, Alberti KG, Bennett P, et al. · Diabetes Care · 2004 · Trial result
    PubMed: PMID 14578255 · NCT03658031 · Diabetes Mellitus, Type 2
  2. The sodium/glucose cotransport family SLC5.
    Wright EM, Turk E · Pflugers Arch · 2004 · Background
    PubMed: PMID 12748858 · NCT02887677 · Diabetes Mellitus
  3. Obesity is associated with macrophage accumulation in adipose tissue.
    Weisberg SP, McCann D, Desai M, et al. · J Clin Invest · 2004 · Background
    PubMed: PMID 14679176 · NCT03968224 · Diabetes Mellitus, Type 2
  4. T1/ST2--an IL-1 receptor-like modulator of immune responses.
    Trajkovic V, Sweet MJ, Xu D, et al. · Cytokine Growth Factor Rev · 2004 · Background
    PubMed: PMID 15110792 · NCT05335629 · Diabetes Mellitus, Type 2
  5. Accuracy of mode switch algorithms for detection of atrial tachyarrhythmias.
    Passman RS, Weinberg KM, Freher M, et al. · J Cardiovasc Electrophysiol · 2004 · Background
    PubMed: PMID 15250860 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  6. Role of variability in microvascular resistance on fractional flow reserve and coronary blood flow velocity reserve in intermediate coronary lesions.
    Meuwissen M, Chamuleau SA, Siebes M, et al. · Circulation · 2004 · Background
    PubMed: PMID 11208673 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  7. Surrogate markers for cardiovascular disease: structural markers.
    Mancini GB, Dahlöf B, Díez J, et al. · Circulation · 2004 · Background
    PubMed: PMID 15226248 · NCT05335629 · Diabetes Mellitus, Type 2
  8. Design and analysis of pilot studies: recommendations for good practice.
    Lancaster GA, Dodd S, Williamson PR, et al. · J Eval Clin Pract · 2004 · Background
    PubMed: PMID 15189396 · NCT02879409 · Diabetes Mellitus, Type 2
  9. Mono(2-ethyl-5-hydroxyhexyl) phthalate and mono-(2-ethyl-5-oxohexyl) phthalate as biomarkers for human exposure assessment to di-(2-ethylhexyl) phthalate.
    Kato K, Silva MJ, Reidy JA, et al. · Environ Health Perspect · 2004 · Background
    PubMed: PMID 14998748 · NCT04242758 (PURITY) · Glucose Metabolism Disorders
  10. The biological variation of sex hormone-binding globulin in type 2 diabetes: implications for sex hormone-binding globulin as a surrogate marker of insulin resistance.
    Jayagopal V, Kilpatrick ES, Jennings PE, et al. · Diabetes Care · 2004 · Background
    PubMed: PMID 14694008 · NCT02879409 · Diabetes Mellitus, Type 2
  11. Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002.
    Centers for Disease Control and Prevention (CDC) · MMWR Morb Mortal Wkly Rep · 2004 · Background
    PubMed: PMID 15549021 · NCT02613897 · Diabetes Mellitus, Type 2
  12. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.
    Browning JD, Szczepaniak LS, Dobbins R, et al. · Hepatology · 2004 · Background
    PubMed: PMID 15565570 · NCT07020377 · Diabetes Mellitus, Type 2
  13. Validation of coronary flow reserve measurements by thermodilution in clinical practice.
    Barbato E, Aarnoudse W, Aengevaeren WR, et al. · Eur Heart J · 2004 · Background
    PubMed: PMID 14972422 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2

2003 (8 papers)

  1. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.
    Wood IS, Trayhurn P · Br J Nutr · 2003 · Background
    PubMed: PMID 12568659 · NCT03968224 · Diabetes Mellitus, Type 2
  2. Tumour necrosis factor alpha: a key regulator of adipose tissue mass.
    Warne JP · J Endocrinol · 2003 · Background
    PubMed: PMID 12773114 · NCT03968224 · Diabetes Mellitus, Type 2
  3. Transient limb ischemia induces remote ischemic preconditioning in vivo.
    Liem DA, Verdouw PD, Duncker DJ, et al. · Circulation · 2003 · Background
    PubMed: PMID 12821595 · NCT05217654 · Reperfusion Injury
  4. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
    Lewington S, Clarke R, Qizilbash N, et al. · Lancet · 2003 · Background
    PubMed: PMID 12493255 · NCT03887416
  5. Beneficial effects of metformin on haemostasis and vascular function in man.
    Grant PJ · Diabetes Metab · 2003 · Background
    PubMed: PMID 14502100 · NCT06286878 · Diabetes Mellitus
  6. Novel index for invasively assessing the coronary microcirculation.
    Fearon WF, Balsam LB, Farouque HM, et al. · Circulation · 2003 · Background
    PubMed: PMID 12821539 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  7. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension.
    Clement DL, De Buyzere ML, De Bacquer DA, et al. · N Engl J Med · 2003 · Background
    PubMed: PMID 12802026 · NCT02887677 · Diabetes Mellitus
  8. Accuracy of an eight-point tactile-electrode impedance method in the assessment of total body water.
    Bedogni G, Malavolti M, Severi S, et al. · Eur J Clin Nutr · 2003 · Background
    PubMed: PMID 12428182 · NCT05741658 (FonDap) · Heart Failure

2002 (8 papers)

  1. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.
    Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group · JAMA · 2002 · Background
    PubMed: PMID 12020338 · NCT02879409 · Diabetes Mellitus, Type 2
  2. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction.
    Weinberg EO, Shimpo M, De Keulenaer GW, et al. · Circulation · 2002 · Background
    PubMed: PMID 12460879 · NCT05335629 · Diabetes Mellitus, Type 2
  3. Interleukin-6 induces cellular insulin resistance in hepatocytes.
    Senn JJ, Klover PJ, Nowak IA, et al. · Diabetes · 2002 · Background
    PubMed: PMID 12453891 · NCT03968224 · Diabetes Mellitus, Type 2
  4. Heart failure and ventricular dysfunction in patients with single or systemic right ventricles.
    Piran S, Veldtman G, Siu S, et al. · Circulation · 2002 · Background
    PubMed: PMID 11889012 · NCT07482943 · Heart Failure
  5. Metformin and carbohydrate-modified diet: a novel obesity treatment protocol: preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia.
    Mogul HR, Peterson SJ, Weinstein BI, et al. · Heart Dis · 2002 · Background
    PubMed: PMID 11975807 · NCT03968224 · Diabetes Mellitus, Type 2
  6. Gliclazide modified release.
    McGavin JK, Perry CM, Goa KL, et al. · Drugs · 2002 · Background
    PubMed: PMID 12076188 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2
  7. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes.
    Lurbe E, Redon J, Kesani A, et al. · N Engl J Med · 2002 · Background
    PubMed: PMID 12226150 · NCT03887416
  8. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding.
    Dixon JB, O'Brien PE · Diabetes Care · 2002 · Background
    PubMed: PMID 11815510 · NCT03419624 · Diabetes Mellitus, Type 2

2001 (16 papers)

  1. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
    Jafar TH, Stark PC, Schmid CH, et al. · Kidney Int · 2001 · Trial result
    PubMed: PMID 11532109 · NCT06890143 · Proteinuria
  2. Atherosclerosis. the road ahead.
    Glass CK, Witztum JL · Cell · 2001 · Trial result
    PubMed: PMID 11239408 · NCT05998525 · Diabetes Mellitus, Type 2
  3. Role of AMP-activated protein kinase in mechanism of metformin action.
    Zhou G, Myers R, Li Y, et al. · J Clin Invest · 2001 · Background
    PubMed: PMID 11602624 · NCT06286878 · Diabetes Mellitus
  4. Resistin: a new link between obesity and insulin resistance?
    Vidal-Puig A, O'Rahilly S · Clin Endocrinol (Oxf) · 2001 · Background
    PubMed: PMID 11678824 · NCT03968224 · Diabetes Mellitus, Type 2
  5. The hormone resistin links obesity to diabetes.
    Steppan CM, Bailey ST, Bhat S, et al. · Nature · 2001 · Background
    PubMed: PMID 11201732 · NCT03968224 · Diabetes Mellitus, Type 2
  6. Obesity: preventing and managing the global epidemic. Report of a WHO consultation.
    World Health Organ Tech Rep Ser · 2001 · Background
    PubMed: PMID 11234459 · NCT03968224 · Diabetes Mellitus, Type 2
  7. Prognosis of acute myocardial infarction in the thrombolytic era: medical evaluation is still valuable.
    Nicolau JC, Serrano CV, Garzon SA, et al. · Eur J Heart Fail · 2001 · Background
    PubMed: PMID 11595605 · NCT06286878 · Diabetes Mellitus
  8. Interleukin-10 and the interleukin-10 receptor.
    Moore KW, de Waal Malefyt R, Coffman RL, et al. · Annu Rev Immunol · 2001 · Background
    PubMed: PMID 11244051 · NCT03968224 · Diabetes Mellitus, Type 2
  9. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo.
    Kharbanda RK, Peters M, Walton B, et al. · Circulation · 2001 · Background
    PubMed: PMID 11273988 · NCT05217654 · Reperfusion Injury
  10. Mechanism by which metformin reduces glucose production in type 2 diabetes.
    Hundal RS, Krssak M, Dufour S, et al. · Diabetes · 2001 · Background
    PubMed: PMID 11118008 · NCT03968224 · Diabetes Mellitus, Type 2
  11. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
    Go AS, Hylek EM, Phillips KA, et al. · JAMA · 2001 · Background
    PubMed: PMID 11343485 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  12. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.
    Fernandez-Real JM, Vayreda M, Richart C, et al. · J Clin Endocrinol Metab · 2001 · Background
    PubMed: PMID 11238501 · NCT03968224 · Diabetes Mellitus, Type 2
  13. Fractional flow reserve in patients with prior myocardial infarction.
    De Bruyne B, Pijls NH, Bartunek J, et al. · Circulation · 2001 · Background
    PubMed: PMID 11447079 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  14. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "Normal" coronary angiography.
    De Bruyne B, Hersbach F, Pijls NH, et al. · Circulation · 2001 · Background
    PubMed: PMID 11705815 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  15. Baroreflex and oscillation of heart period at 0.1 Hz studied by alpha-blockade and cross-spectral analysis in healthy humans.
    Cevese A, Gulli G, Polati E, et al. · J Physiol · 2001 · Background
    PubMed: PMID 11179406 · NCT06286878 · Diabetes Mellitus
  16. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study.
    Bargman JM, Thorpe KE, Churchill DN, et al. · J Am Soc Nephrol · 2001 · Background
    PubMed: PMID 11562415 · NCT06398977

2000 (5 papers)

  1. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.
    Alpert JS, Thygesen K, Antman E, et al. · J Am Coll Cardiol · 2000 · Trial result
    PubMed: PMID 10987628 · NCT04717986 (DAPA-AMI) · Heart Failure
  2. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption.
    Vallon V, Richter K, Blantz RC, et al. · J Am Soc Nephrol · 2000 · Background
    PubMed: PMID 10589696 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  3. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.
    Taal MW, Brenner BM · Kidney Int · 2000 · Background
    PubMed: PMID 10792600 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  4. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
    Stratton IM, Adler AI, Neil HA, et al. · BMJ · 2000 · Background
    PubMed: PMID 10938048 · NCT02879409 · Diabetes Mellitus, Type 2
  5. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.
    Dries DL, Exner DV, Domanski MJ, et al. · J Am Coll Cardiol · 2000 · Background
    PubMed: PMID 10716471 · NCT05719714 · Heart Failure

1999 (8 papers)

  1. Structure and function of the Na+/glucose cotransporter.
    Wright EM, Loo DD, Panayotova-Heiermann M, et al. · Acta Physiol Scand Suppl · 1999 · Trial result
    PubMed: PMID 9789568 · NCT05424315 (DACAMI) · Heart Failure
  2. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration.
    Sunness JS, Gonzalez-Baron J, Applegate CA, et al. · Ophthalmology · 1999 · Background
    PubMed: PMID 10485549 · NCT07174687 · Eye Diseases
  3. Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus.
    Shepherd PR, Kahn BB · N Engl J Med · 1999 · Background
    PubMed: PMID 10413738 · NCT03968224 · Diabetes Mellitus, Type 2
  4. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.
    Oku A, Ueta K, Arakawa K, et al. · Diabetes · 1999 · Background
    PubMed: PMID 10480610 · NCT03968224 · Diabetes Mellitus, Type 2
  5. Laparoscopic Roux-en-Y gastric bypass for super/super obesity.
    Nguyen NT, Ho HS, Palmer LS, et al. · Obes Surg · 1999 · Background
    PubMed: PMID 10484302 · NCT03968224 · Diabetes Mellitus, Type 2
  6. Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT.
    Molyneaux LM, Constantino MI, McGill M, et al. · Diabetes Res Clin Pract · 1999 · Background
    PubMed: PMID 9886743 · NCT02879409 · Diabetes Mellitus, Type 2
  7. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells.
    Iwahana H, Yanagisawa K, Ito-Kosaka A, et al. · Eur J Biochem · 1999 · Background
    PubMed: PMID 10491084 · NCT05335629 · Diabetes Mellitus, Type 2
  8. Renal volume measurements: accuracy and repeatability of US compared with that of MR imaging.
    Bakker J, Olree M, Kaatee R, et al. · Radiology · 1999 · Background
    PubMed: PMID 10352583 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2

1998 (4 papers)

  1. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.
    Haïssaguerre M, Jaïs P, Shah DC, et al. · N Engl J Med · 1998 · Trial result
    PubMed: PMID 9725923 · NCT04780438 · Atrial Fibrillation
  2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    UK Prospective Diabetes Study Group · BMJ · 1998 · Background
    PubMed: PMID 9732337 · NCT02879409 · Diabetes Mellitus, Type 2
  3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet · 1998 · Background
    PubMed: PMID 9742976 · NCT02879409 · Diabetes Mellitus, Type 2
  4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet · 1998 · Background
    PubMed: PMID 9742977 · NCT02879409 · Diabetes Mellitus, Type 2

1997 (3 papers)

  1. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury.
    Szabó C · Shock · 1997 · Background
    PubMed: PMID 8856840 · NCT05217654 · Reperfusion Injury
  2. Histological substrate of atrial biopsies in patients with lone atrial fibrillation.
    Frustaci A, Chimenti C, Bellocci F, et al. · Circulation · 1997 · Background
    PubMed: PMID 9286947 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  3. Spectral decomposition in multichannel recordings based on multivariate parametric identification.
    Baselli G, Porta A, Rimoldi O, et al. · IEEE Trans Biomed Eng · 1997 · Background
    PubMed: PMID 9353988 · NCT06286878 · Diabetes Mellitus

1996 (4 papers)

  1. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses.
    Pijls NH, De Bruyne B, Peels K, et al. · N Engl J Med · 1996 · Background
    PubMed: PMID 8637515 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  2. Low and high frequency components of blood pressure variability.
    Pagani M, Lucini D, Rimoldi O, et al. · Ann N Y Acad Sci · 1996 · Background
    PubMed: PMID 8853630 · NCT06286878 · Diabetes Mellitus
  3. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.
    Circulation · 1996 · Background
    PubMed: PMID 8598068 · NCT06286878 · Diabetes Mellitus
  4. Current concepts of renal hemodynamics in diabetes.
    Anderson S, Vora JP · J Diabetes Complications · 1996 · Background
    PubMed: PMID 8573753 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2

1995 (7 papers)

  1. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.
    Wijffels MC, Kirchhof CJ, Dorland R, et al. · Circulation · 1995 · Background
    PubMed: PMID 7671380 · NCT04792190 (DAPA-AF) · Atrial Fibrillation
  2. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
    Stumvoll M, Nurjhan N, Perriello G, et al. · N Engl J Med · 1995 · Background
    PubMed: PMID 7623903 · NCT03968224 · Diabetes Mellitus, Type 2
  3. Testing for baseline balance in clinical trials.
    Senn S · Stat Med · 1995 · Background
    PubMed: PMID 7997705 · NCT02879409 · Diabetes Mellitus, Type 2
  4. Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow.
    Pijls NH, Van Gelder B, Van der Voort P, et al. · Circulation · 1995 · Background
    PubMed: PMID 7586302 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  5. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1.
    Kanety H, Feinstein R, Papa MZ, et al. · J Biol Chem · 1995 · Background
    PubMed: PMID 7559552 · NCT03968224 · Diabetes Mellitus, Type 2
  6. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
    DeFronzo RA, Goodman AM · N Engl J Med · 1995 · Background
    PubMed: PMID 7623902 · NCT03968224 · Diabetes Mellitus, Type 2
  7. Measuring forearm blood flow and interpreting the responses to drugs and mediators.
    Benjamin N, Calver A, Collier J, et al. · Hypertension · 1995 · Background
    PubMed: PMID 7737727 · NCT05217654 · Reperfusion Injury

1994 (3 papers)

  1. Power spectrum analysis of heart rate variability to assess the changes in sympathovagal balance during graded orthostatic tilt.
    Montano N, Ruscone TG, Porta A, et al. · Circulation · 1994 · Background
    PubMed: PMID 7923668 · NCT06286878 · Diabetes Mellitus
  2. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.
    Kanai Y, Lee WS, You G, et al. · J Clin Invest · 1994 · Background
    PubMed: PMID 8282810 · NCT06286878 · Diabetes Mellitus
  3. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography.
    De Bruyne B, Baudhuin T, Melin JA, et al. · Circulation · 1994 · Background
    PubMed: PMID 8124786 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2

1993 (7 papers)

  1. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors.
    Gaudron P, Eilles C, Kugler I, et al. · Circulation · 1993 · Trial result
    PubMed: PMID 8443896 · NCT05424315 (DACAMI) · Heart Failure
  2. Analysis of coronary angioplasty practice in the United States with an insurance-claims data base.
    Topol EJ, Ellis SG, Cosgrove DM, et al. · Circulation · 1993 · Background
    PubMed: PMID 8141866 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  3. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty.
    Pijls NH, van Son JA, Kirkeeide RL, et al. · Circulation · 1993 · Background
    PubMed: PMID 8462157 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2
  4. Baseline analysis of renal function in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group [corrected].
    Molitch ME, Steffes MW, Cleary PA, et al. · Kidney Int · 1993 · Background
    PubMed: PMID 8455366 · NCT02879409 · Diabetes Mellitus, Type 2
  5. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.
    Hotamisligil GS, Shargill NS, Spiegelman BM, et al. · Science · 1993 · Background
    PubMed: PMID 7678183 · NCT03968224 · Diabetes Mellitus, Type 2
  6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
    Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. · N Engl J Med · 1993 · Background
    PubMed: PMID 8366922 · NCT02887677 · Diabetes Mellitus
  7. Transstenotic coronary pressure gradient measurement in humans: in vitro and in vivo evaluation of a new pressure monitoring angioplasty guide wire.
    De Bruyne B, Pijls NH, Paulus WJ, et al. · J Am Coll Cardiol · 1993 · Background
    PubMed: PMID 8509531 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2

1992 (1 paper)

  1. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.
    Hermann LS, Karlsson JE, Sjöstrand A, et al. · Eur J Clin Pharmacol · 1992 · Background
    PubMed: PMID 1748145 · NCT03968224 · Diabetes Mellitus, Type 2

1991 (1 paper)

  1. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus.
    Tuttle KR, Bruton JL, Perusek MC, et al. · N Engl J Med · 1991 · Background
    PubMed: PMID 2030719 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2

1990 (5 papers)

  1. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor.
    Tominaga S · FEBS Lett · 1990 · Background
    PubMed: PMID 2532153 · NCT05335629 · Diabetes Mellitus, Type 2
  2. Renal hypertrophy, growth factors, and nephropathy in diabetes mellitus.
    Schwieger J, Fine LG · Semin Nephrol · 1990 · Background
    PubMed: PMID 2190281 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  3. Atrophic macular degeneration. Rate of spread of geographic atrophy and visual loss.
    Schatz H, McDonald HR · Ophthalmology · 1990 · Background
    PubMed: PMID 2587050 · NCT07174687 · Eye Diseases
  4. Analysis of serial measurements in medical research.
    Matthews JN, Altman DG, Campbell MJ, et al. · BMJ · 1990 · Background
    PubMed: PMID 2106931 · NCT02879409 · Diabetes Mellitus, Type 2
  5. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.
    Collins R, Peto R, MacMahon S, et al. · Lancet · 1990 · Background
    PubMed: PMID 1969567 · NCT03887416

1989 (1 paper)

  1. Evolution of geographic atrophy of the retinal pigment epithelium.
    Sarks JP, Sarks SH, Killingsworth MC, et al. · Eye (Lond) · 1989 · Background
    PubMed: PMID 2476333 · NCT07174687 · Eye Diseases

1988 (3 papers)

  1. Chronic renal failure, parathyroid hormone and fatty acids oxidation in skeletal muscle.
    Smogorzewski M, Piskorska G, Borum PR, et al. · Kidney Int · 1988 · Background
    PubMed: PMID 3361755 · NCT05719714 · Heart Failure
  2. Super obesity and gastric reduction procedures.
    Mason EE, Doherty C, Maher JW, et al. · Gastroenterol Clin North Am · 1988 · Background
    PubMed: PMID 3436656 · NCT03968224 · Diabetes Mellitus, Type 2
  3. Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis.
    Luzi L, Barrett EJ, Groop LC, et al. · Diabetes · 1988 · Background
    PubMed: PMID 3141236 · NCT03968224 · Diabetes Mellitus, Type 2

1986 (4 papers)

  1. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.
    Zatz R, Dunn BR, Meyer TW, et al. · J Clin Invest · 1986 · Background
    PubMed: PMID 3011862 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  2. Geographic atrophy of the retinal pigment epithelium.
    Maguire P, Vine AK · Am J Ophthalmol · 1986 · Background
    PubMed: PMID 3777083 · NCT07174687 · Eye Diseases
  3. Estimation of total body water by bioelectrical impedance analysis.
    Kushner RF, Schoeller DA · Am J Clin Nutr · 1986 · Background
    PubMed: PMID 3529918 · NCT05741658 (FonDap) · Heart Failure
  4. Glomerular filtration surface in type I diabetes mellitus.
    Ellis EN, Steffes MW, Goetz FC, et al. · Kidney Int · 1986 · Background
    PubMed: PMID 3712971 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2

1985 (1 paper)

  1. The disposal of an oral glucose load in healthy subjects. A quantitative study.
    Ferrannini E, Bjorkman O, Reichard GA, et al. · Diabetes · 1985 · Background
    PubMed: PMID 3891471 · NCT02613897 · Diabetes Mellitus, Type 2

1982 (1 paper)

  1. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.
    Hostetter TH, Rennke HG, Brenner BM, et al. · Am J Med · 1982 · Background
    PubMed: PMID 7036732 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2

1981 (4 papers)

  1. Geographic atrophy of the retinal pigment epithelium: diagnosis and vision rehabilitation.
    Potter JW, Thallemer JM · J Am Optom Assoc · 1981 · Background
    PubMed: PMID 7264141 · NCT07174687 · Eye Diseases
  2. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975.
    Leibowitz HM, Krueger DE, Maunder LR, et al. · Surv Ophthalmol · 1981 · Background
    PubMed: PMID 7444756 · NCT07174687 · Eye Diseases
  3. Glomerular hemodynamics in experimental diabetes mellitus.
    Hostetter TH, Troy JL, Brenner BM, et al. · Kidney Int · 1981 · Background
    PubMed: PMID 7241881 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2
  4. The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy.
    Brenner BM, Hostetter TH, Olson JL, et al. · Acta Endocrinol Suppl (Copenh) · 1981 · Background
    PubMed: PMID 6940408 · NCT02911792 (Hyper) · Diabetes Mellitus, Type 2

1974 (1 paper)

  1. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve.
    Gould KL, Lipscomb K, Hamilton GW, et al. · Am J Cardiol · 1974 · Background
    PubMed: PMID 4808557 · NCT05392959 (DAPAMICRO) · Diabetes Mellitus, Type 2

1970 (1 paper)

  1. Mean amplitude of glycemic excursions, a measure of diabetic instability.
    Service FJ, Molnar GD, Rosevear JW, et al. · Diabetes · 1970 · Background
    PubMed: PMID 5469118 · NCT02925559 (EFFORT) · Diabetes Mellitus, Type 2

1967 (1 paper)

  1. Estimation of the probability of an event as a function of several independent variables.
    Walker SH, Duncan DB · Biometrika · 1967 · Background
    PubMed: PMID 6049533 · NCT04298229 (DICTATE-AHF) · Diabetes Mellitus, Type 2

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).